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Summaiy
In most cases of human obesity serum leptin levels are elevated, 
suggesting that reduced sensitivity to endogenous leptin may contribute towards 
the increase in body weight. There are several potential areas that may be 
involved in reduced leptin sensitivity, including the blood-brain-barrier (BBB) 
transport system, changes in expression of the functional leptin receptor, OB- 
Rb, and components of the leptin receptor-mediated STAT signalling pathway 
in which members of the SOCS family, SOCS-3 and CIS, act as negative 
regulators. The aim of this thesis was to examine how the mRNA expression of 
the leptin receptor and components of the leptin receptor-mediated signalling 
pathway alters in obesity models and thereby establish to what extent such 
genes are involved in leptin sensitivity. A novel fluorogenic method of 
quantitative RT-PCR, TaqMan, was utilised to examine the changes in mRNA 
expression.
Gene expression was examined in central and peripheral tissues of 
obesity-prone AKR/J mice fed either a chow or a palatable diet for 14 weeks 
and compared to C57BL/6 lean and ob/ob mice fed a chow diet. The expression 
of OB-Ra mRNA was reduced in the hypothalamus and pituitary of AKR/J mice 
fed a palatable diet compared to those fed chow, which may implicate reduced 
OB-Ra-mediated signalling. In WAT of palatable diet-fed mice compared to 
those fed on chow, the expression of STATS and CIS mRNA was increased but 
SOCS-3 mRNA was reduced, which suggests this tissue may have increased 
sensitivity to leptin, but the increased CIS mRNA may compensate for the
xxii
increased STATS mRNA. In contrast, in the small intestine, all of the 
components of leptin receptor-mediated signalling were reduced, except for 
CIS, which suggests this tissue has low leptin sensitivity and may have reduced 
leptin signalling.
In the hypothalamus of ob/ob mice compared to leans, the expression of 
STAT3 and SOCS-3 mRNA were reduced. In the pituitary of ob/ob mice 
compared to leans, the expression of OB-Rb, STAT3, STATS and SOCS-3 
mRNA was reduced, which may be due a consequence of the leptin deficiency. 
In the pancreas, the expression of STAT3, STATS and SOCS-3 mRNA was 
increased perhaps reflecting an increase in leptin sensitivity or increased insulin 
signalling. In BAT, the increased expression of OB-Ra, OB-Rb and STAT3 
mRNA and reduced CIS mRNA appears consistent with elevated leptin 
sensitivity in this tissue although SOCS-3 mRNA was considerably elevated 
which may be due to obesity-related factors other than leptin.
In order to further expand our understanding of the regulation of leptin 
sensitivity, the expression of components of the leptin receptor-mediated 
signalling pathway were analysed in the hypothalamus of ob/ob mice 
intraperitoneally treated with leptin for 24 hours compared to 2 weeks. In 
comparing ob/ob mice to leans in this study, the expression of OB-Rb, STAT3, 
STAT5 was increased in contrast to the changes reported in the previous study. 
The treatment of ob/ob mice with leptin for 24 hours showed a significant 
reduction in the hypothalamus of SOCS-3 mRNA, but after 2 weeks of leptin 
treatment the expression of SOCS-3 mRNA was increased not only in ob/ob
X X lll
mice but also in pair-fed controls. The involvement of SOCS-3 in hypothalamic 
leptin sensitivity has previously been reported but in this study the increase after 
2 weeks of leptin treatment may be due to feeding rather than leptin.
The expression of OB-Ra and OB-Rb mRNA was also examined in ZDF 
fa/fa  rats to examine if the mutated leptin receptor has an effect on its 
expression. An increase of both OB-Ra and OB-Rb mRNA was observed in 
ZDF fa/fa  rats compared to ZDF +/? rats, which may be a compensatory change 
to the reduced leptin receptor-mediated signalling and leptin receptor cell 
surface expression in these animals.
The gene expression changes in tissues of dietary obese and genetically 
obese mice followed no consistent pattern in relation to leptin sensitivity and 
can be interpreted in a number of different ways. The changes suggest, 
however, that some tissues may be more sensitive to the effects of leptin and 
changes in sensitivity compared to others but there appears to be no clear gene 
or set of gene changes predictive amongst the genes examined of leptin 
sensitivity. Since the expression of STATs and SOCs can be regulated by a 
number of signals it is difficult to definitively distinguish the effects of leptin, 
tissue-specific effects and other obesity-related factors in these tissues.
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Chapter 1 
Introduction
1.1 Obesity as a major health disease
Obesity is widely acknowledged as a serious threat to public health and 
is considered a social stigma in many cultures. Furthermore, being overweight 
is strongly associated with the development of adverse medical conditions, such 
as hypertension, diabetes, heart disease, cancer, and thus it has a strong negative 
effect on life expectancy (Friedman, 2000; Kopelman, 2000).
Obesity has been increasing in prevalence over the last few decades, 
especially in Western countries. In the United States, for example, the 
prevalence of obesity among the adult (age 20-74) population increased from 
12.8% in 1960-62 to 22.5% in 1988-94 (Flegal et a/., 1998). A similar trend has 
been seen among children and adolescents, with the prevalence of overweight 
(6-17 years old) increasing from 5% in 1963-70 to 11% in 1988-94 (Troiano & 
Flegal, 1998). Today, more than half of all adults can be classified as 
overweight or obese (Must et al., 1999), and it has been estimated that some
300,000 deaths per year are attributable to obesity (Allison et a l, 1999). The 
direct cost of obesity-related health care in the U.S. has been estimated at $52 
billion per year, or 5.7% of total expenditures on health care; indirect costs due 
to lost productivity are thought to be of equal magnitude (Wolf & Colditz, 
1998).
1.2 Leptin
1.2.1 Early implications of a satiety factor
Over the past four decades, considerable clinical and experimental 
evidence has accumulated to support the existence of sensitive systems for 
controlling body weight in animals and humans. Kennedy proposed that the 
amount of energy stored in adipose mass represented the balance between 
ingested calories and energy expenditure (Kennedy, 1953). He hypothesised 
that the hypothalamus sensed the concentration of an unknown circulating 
factor, which provided information on the amount of body fat stores. This 
adipostatic model of body weight regulation is consistent with the observation 
that a decrease in adiposity from fasting or surgical resection causes 
hyperphagia, reduces energy expenditure and eventually restores body weight to 
the previous level (Faust et a l, 1977; Harris et a l, 1986; Harris, 1990). 
Conversely, weight gain from forced overfeeding inhibits voluntary food intake 
(Harris et a l, 1986; Harris 1990).
Hervey demonstrated the parabiosis (a long-term surgical anastomosis 
made between the muscle and/or peritoneal compartments) of two rats, one 
rendered obese by lesions in the ventromedial hypothalamus (VMH) and one 
control rat, resulted in death by starvation of the latter (Hervey, 1958). This 
suggested that increased levels of a circulating satiety factor from the obese rats 
inhibited food intake in the non-lesioned lean rats. In contrast, the obese rats 
were incapable of responding to elevated endogenous levels of the presumed 
satiety factor, because of the hypothalamic lesion.
More convincing evidence for a circulating factor that could control food 
intake was provided by the discovery of recessive mutations, obese (pb) and 
diabetes {db), both of which led to hyperphagia, reduced energy expenditure 
and early onset obesity in mice (Ingalls et a l, 1950). Coleman (Coleman, 1973; 
Coleman & Hummel, 1969) and Hausberger (Hausberger, 1959) showed that 
parabiosis of wild-type and ob/ob mice reduced the weight gain in ob/ob mice, 
whereas parabiosis of wild-type and db/db mice caused profound hypophagia in 
lean wild-type mice. These results suggested that the ob locus was necessary to 
produce the satiety factor and that the dh locus encoded a molecule required for 
response to this factor.
In 1994, Zhang et a l reported the discovery through positional cloning 
of the gene responsible for the ob phenotype (Zhang et a l, 1994). The authors 
identified two mutations at the ob locus, which led to underexpression of the 16- 
kDa protein product, termed leptin (from the Greek word leptos, which means 
thin), in two strains of ob/ob mouse. In C57BL/6J ob/ob mice, a C—+T 
substitution resulted in a stop codon at position 105 instead of arginine and in 
synthesis of a truncated protein that is incapable of being secreted (Rau et a l, 
1999; Zhang et a l, 1994). Leptin mRNA expression is increased in C57BL/6J 
ob/ob mice, consistent with the view that the ob gene is under negative feedback 
regulation. In the ob^^/ob^ mouse mutant, a transposon inserted into the first 
intron of the ob gene, prevented the synthesis of mature ob mRNA (Zhang et 
a l, 1994). Both ob/ob mouse mutants are leptin deficient, hyperphagic.
hypothermie, morbidly obese and have several metabolic and neuroendocrine 
abnormalities including hyperinsulinaemia, hyperglycaemia and hypercorticism.
1.2.2 Characterisation of leptin
Mouse and human ob genes have been localised to chromosome 6 and 
7q31.3, respectively (Isse et al, 1995; Zhang et al, 1994). The ob gene 
encompasses 650 kb and consists of 3 exons separated by 2 introns, with the 
coding region for leptin located in exons 2 and 3. The mouse ob gene encodes a
4.5 kilobase mRNA transcript with a highly conserved 167-amino acid open 
reading frame (Zhang et al,  1994). Human leptin is 84% identical to mouse 
leptin and 83% identical to rat leptin.
Leptin is synthesised and secreted mainly, but not exclusively, by white 
adipose tissue (WAT) and circulates as a 16-kDa protein in plasma and is not 
modified post-translationally (Cohen et al,  1996a; Halaas et a l,  1995). 
Structural analysis indicated that leptin is similar to cytokines (Madej et al, 
1995; Zhang et al, 1997) and contains an intrachain disulphide bond that 
appears to be necessary for its biological activity (Grasso et al, 1997).
There is a strong positive correlation between leptin mRNA and protein 
levels in adipose tissue and circulating plasma leptin levels (Considine et al, 
1996; Frederich et a l,  1995; Maffei et a l,  1995). Moreover, the plasma level of 
leptin is highly correlated with adipose tissue mass and falls in both humans and 
mice after weight loss (Maffei et a l,  1995). Leptin deficiency due to mutations 
in the human ob gene are rare (see section 1.4.1) and most human forms of
obesity are associated with increased levels of leptin. Furthermore, leptin levels 
are generally increased in several genetic and environmentally induced forms of 
rodent obesity (Maffei et a i,  1995).
1.2.3 Localisation of leptin expression
Initial studies indicated that leptin expression was synthesised only in 
adipose tissue. However, leptin is also now known to be synthesised in some 
extra-adipose tissues including placenta, gastric epithelium, skeletal muscle, and 
mammary epithelium where it is secreted in colustrum, and absorbed by the 
neonate (Bado e ta l ,  1998; Casabiell e ta l ,  1997; Masuzaki et a l,  1997).
1.2.4 Regulation of leptin expression
Although leptin levels in blood correlate with total body fat stores 
(Considine et al,  1996; Frederich et a l,  1995; Maffei et a l,  1995), it is not 
known whether increased triglyceride levels, lipid metabolites, or mechanical 
factors associated with increased adipocyte size, influence leptin expression. 
Leptin levels increase within hours after a meal in rodents and after several days 
of overfeeding in humans (Harris et a l,  1996; Kolaczynski et al,  1996a; 
Saladin et a l,  1995), whereas levels decrease within hours after initiation of 
fasting in both species (Boden et a l,  1996; Frederich et a l,  1995; Saladin et al,
1995). The changes in leptin expression in response to fasting and feeding are 
out of proportion to the corresponding changes in body weight or body fat
(Boden et al,  1996; Kolaczynski et a l,  1996a), suggesting that leptin serves as 
an indicator of energy stores, as well as a mediator of energy balance.
Regulation of leptin expression by nutrition is probably mediated in part 
by insulin. Leptin expression increases after peak insulin secretion during the 
feeding cycle (Saladin et al,  1995; S inha et al, 1996). Insulin stimulates leptin 
expression directly in isolated adipocytes (Rentsch & Chiesi, 1996) and 
increases leptin levels when administered to rodents (Saladin et a l,  1995). In 
contrast, plasma leptin is decreased in low insulin states, such as in 
streptozotocin-induced diabetes, and increases after insulin treatment 
(Macdougald et al,  1995). In humans, leptin expression is correlated with 
insulin levels and is increased several days after insulin infusion (Kolaczynski et 
al,  1996b; Segal et al,  1996). Conversely, the fall in insulin levels may 
mediate the decline in leptin levels during fasting (Boden et al,  1997). 
Moreover, mutational analysis of the region between nucleotides -101 and -83 
of the leptin gene promoter showed that this region is critical for 
glucose/insulin-mediated stimulation of transcription (Fukuda & Iritani, 1999).
Several regulatory elements have been identified within the ob gene 
promoter, including cyclic AMP and glucocorticoid response elements, and 
CCATT/enhancer and SP-1 binding sites (Gong et a l,  1996; Hwang et al, 
1996; Miller et al., 1996). Placental leptin expression is stimulated by insulin 
and glucocorticoids (Mise et al,  1998; Shekhawat et a l,  1998). Moreover, 
glucocorticoids directly stimulate leptin synthesis in cultured adipocytes
(Murakami et a l,  1995; Slieker et al, 1996), and leptin expression increases in 
response to chronic elevation of cortisol in humans (Cizza et a l,  1997).
Administration of cholecystokinin or gastrin decreases leptin synthesis 
in the gastric fundus and increase plasma leptin (Bado et al,  1998). It is 
speculated that meal-related alterations in gastric and plasma leptin levels may 
be involved in the short-term regulation of appetite (Bado et a l,  1998). The 
hexosamine biosynthetic pathway also acts as a nutrient-sensing pathway to 
regulate leptin release and flux through the pathway increases with 
hyperglycaemia or excess fat intake (Wang et a l,  1998a). Glucosamine 
infusion, which increases the tissue concentrations of the end product of the 
hexosamine biosynthetic pathway, UDP-W-acetylglucosamine (UDP-GlcNAc), 
results in increased leptin expression in adipose tissue, rat skeletal muscle, and 
pancreatic islets (Considine et al,  2000; Emilsson et al,  2001; McClain et al, 
2000; Wang et a l,  1998a).
1.3 Leptin receptor
1.3.1 Discovei*y of leptin receptor
A high affinity leptin receptor (OB-R) was cloned by Tartaglia et al. 
from mouse choroid plexus using an expression cloning strategy and was 
genetically mapped to the same interval of mouse chromosome 4 that contains 
the db locus (Tartaglia et a l,  1995).
1.3.2 Structure of receptor/alternative splicing
To date, six common splice variants of the leptin receptor have been 
identified as a result of alternative splicing by RT-PCR, namely OB-Ra to OB- 
Rf (Figure 1) (Lee et al, 1996; Wang et al, 1996). Leptin receptor iso forms 
share an identical amino-terminal extracellular ligand-binding domain but differ 
in the length of the intracellular carboxy terminus. Five isoforms, OB-Ra, OB- 
Rb, OB-Rc, OB-Rd and OB-Rf have transmembrane and intracellular domains; 
however, only OB-Rb contains intracellular motifs required for activation of the 
Janus kinase and signal transducers and activators of transcription (JAK-STAT) 
signal transduction pathway (Bjorbaek et a l,  1997; Ghilardi et a l,  1996; Vaisse 
et al, 1996). The fact that OB-Rb is the receptor isoform not expressed in 
obese db/db mice proves that this is the fully functional receptor and that 
therefore, activation of the JAK-STAT pathway is essential for leptin effects on 
feeding and energy expenditure.
Figure 1.1 Leptin receptor isoforms
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Investigation of the structure of leptin reveals a four-helix bundle similar 
to that of the long-chain helical cytokine family (Zhang et a i,  1997). 
Confirmation of this similarity was attained when the leptin receptor was 
determined to be similar to the gpl30 signal transduction arm of class I cytokine 
receptor family members, which includes receptors for various interleukins (IL- 
2, -3, -4, -6, and -7) (Bazan, 1989; Idzerda et a i,  1990; Itoh et al,  1990), 
granulocyte colony stimulating factor (G-CSF) (Gearing et a l,  1989), growth 
hormone, prolactin, erythropoeitin (EPO) (Bazan 1989), and leukaemia 
inhibitory factor (LIF) (Tartaglia et a l,  1995).
The structure of OB-R consists of a signal sequence, two 
immunoglobulin domains, two cytokine receptor homology domains each 
containing a Trp-Ser-X-Trp-Ser motif (where the X residue is non-conserved).
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fibronectin type III domains, a transmembrane region and intracellular domain 
(except in OB-Re) (Haniu et a l,  1998). The leptin receptor contains a short 23 
amino acid transmembrane domain, which is followed by a cytoplasmic domain 
whose length varies among the isoforms (Lee et a l,  1996). OB-Ra and OB-Rb 
are the two major forms of the receptor expressed. The OB-Ra isoform found in 
most tissues has a short cytoplasmic domain of 34 amino acids and contains 
only box 1 that can bind JAK2, but the receptor is not able to activate STAT 
signalling (Bjorbaek et a l,  1997). The longest form of the leptin receptor, OB- 
Rb has a cytoplasmic domain of 302 amino acids that contains the JAK binding 
domains, box 1 and box 2, and a potential consensus sequence (YXXQ) for the 
binding of STATs (Ghilardi et a l,  1996; White & Tartaglia, 1996).
The intracellular portion of murine OB-Rb contains three different 
tyrosine residues that have been implicated in OB-Rb signalling (Banks et a l ,
2000). Within the folded protein, Tyr^^  ^ and Tyr^^^  ^ have been shown to be 
surrounded by hydrophilic sequences, whereas Tyr^°^  ^ is surrounded by 
hydrophobic sequences, suggesting Tyr^^  ^ and Tyr^^^  ^ are involved in leptin- 
mediated STAT signalling (Banks et al,  2000). Recent research has not only 
demonstrated that Tyr^^  ^ and Tyr^^^  ^ are accessible to JAK2 tyrosine kinase, but 
that mutation of these residues with intact Tyr^°^  ^ prevents tyrosine 
phosphorylation of OB-Rb (Banks et a l,  2000). Using a model system 
consisting of an EPO receptor with mutant intracellular OB-Rb domains, 
researchers have been able to further demonstrate that Tyr^^  ^ is necessary for the 
tyrosine phosphorylation of the SH2 domain-containing protein tyrosine
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phosphatase (SHP-2), and controls STAT3 activation (Banks et al,
2000).
1.3.3 Leptin receptor expression
In vitro hybridisation studies revealed that both OB-Ra and OB-Rb 
mRNA are widely expressed in the human, mouse and rat brain (Burguera et al, 
2000; Elmquist et al, 1998; Guan et al,  1997; Mercer et a l,  1996). 
Ultrastructural localisation studies showed OB-Rb to be predominantly located 
in the hypothalamus, a region of the central nervous system long known to be 
involved in body weight regulation. In particular, OB-Rb has been detected in 
the arcuate, ventromedial, paraventricular, dorsomedial, and ventral 
premammillary nuclei, as well as the lateral hypothalamic area (Elmquist et a l , 
1998; Fei et al,  1997; Mercer et a l,  1996). Furthermore, the expression of OB- 
Rb mRNA has been demonstrated in the Purkinje cells and dentate nuclei of the 
cerebellum, medulla, amygdala and neurons from both the neocortex and 
entorrhinal cortex (Burguera et al,  2000; Mercer et al, 1998). The expression 
of OB-Rb mRNA in the human and rat cerebellum (Burguera et a l,  2000; 
Couce et al,  1997; Elmquist et a l,  1998; Savioz et al,  1997) is intriguing and 
its significance is open to speculation. The cerebellum is involved in the control 
of posture and movement, as well as in the learning of complex motor tasks, and 
probably receives information from the periphery, such as that regarding total 
body fat content, in order to perform its function.
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A number of studies have show that OB-Ra mRNA is highly expressed 
in the choroid plexus epithelium and the ependymal lining (Burguera et. al,  
2000; Guan et a l,  1997; Tartaglia et al,  1995). The authors suggest that leptin 
in the cerebrospinal fluid (CSF) could bind to OB-Ra at the ependymal layer 
and cross through the ependymal barrier into the brain parenchyma and reach 
the nearby hypothalamic nuclei. There are also studies that have shown the 
presence of OB-R isoforms in the brain capillaries and endothelium (Boado et 
al,  1998; Burguera et al,  2000; Couce et a l,  1997). The presence of specific 
OB-R isoforms in endothelial cells may permit leptin access to specific 
hypothalamic nuclei and other locations where leptin exerts its effects. By this 
mechanism, leptin would not leave the bloodstream until reaching the particular 
target areas. This proposal is supported by the observation that Ob-Ra and OB- 
Rb mRNA is expressed in the brain microvessels (Bjorbaek et a l,  1998a).
Leptin receptor expression, in particular the OB-Rb isoform, has been 
observed in a number of peripheral tissues suggesting leptin may exert tissue- 
specific functions. A study by Ghilardi et al  showed, using a RNase protection 
assay of total RNA from C57BL/6J lean mice, that the short isoforms of the 
leptin receptor were ubiquitously expressed in a range of peripheral tissues: 
including the liver, kidney, stomach, small intestine, colon, pancreas, skeletal 
muscle lung, heart, adipose tissue, lymph nodes, ovary, uterus, mammary gland 
and testis (Ghilardi et a l,  1996). Although the expression of OB-Rb mRNA 
was only detected in a few peripheral tissues in this study, subsequent studies 
have shown the expression of OB-Rb mRNA in more peripheral tissues and cell
13
lines. Leptin function in some of these tissues has also been ascribed; for 
example the kidney plays a role in the clearance of leptin (Sharma & Considine,
1998), leptin may have a paracrine and/or autocrine effect on gastric epithelial 
cell function (Mix et a l,  2000), leptin increases glucose transport and utilisation 
in skeletal muscle (Ceddia et a l,  1998) and leptin is a growth factor for colonic 
epithelial cells (Hardwick et a l,  2001). The mRNA expression of leptin 
receptor isoforms, in particular OB-Rb, in the human (Dieterich & Lehnert, 
1998; Jin et al,  1999) and rat pituitary (Sone et al, 2001) indicates the pituitary 
might be involved in leptin regulation of pituitary hormone secretion. In the 
pancreas, expression of OB-Rb mRNA is expressed in the pancreatic p-cells of 
mice (Emilsson et al,  1997; Kieffer et al,  1996; Kieffer et a l,  1997) where 
leptin has been shown to inhibit insulin secretion. OB-Rb insulin-secreting cell 
lines, such as RINmSF and BRIN-BDll, have been shown to increase STATS 
activation upon leptin treatment (Briscoe et al, 2001a; Morton et a l,  1999). 
Leptin receptor isoforms are also expressed in WAT and brown adipose tissue 
(BAT) (Kutoh et al, 1997; Siegrist-Kaiser et a l,  1997), where leptin regulates 
lipolysis and glucose utilisation. Furthermore, OB-Ra and OB-Rb isoforms are 
also expressed in the small intestine of mice and rats where leptin has a rapid 
inhibitory effect on sugar absorption (Lostao et al, 1998; Morton et a l,  1998).
Little is known about the expression, or indeed the function, of the OB- 
Rc, OB-Rd, OB-Re and OB-Rf isoforms of the leptin receptor. There are a 
number of studies that have described the expression of the OB-Ra isoform, 
however the expression of each of the remaining short OB-R isoforms (c, d and
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f) containing short intracellular domains is low amongst the tissues tested (Fei et 
al,  1997). OB-R isoforms c, d and f have a box 1 motif similar to Ob-Ra and 
may perform reduced signalling. The expression of the OB-Rc isoform has 
been reported in the choroid plexus (Guan et a l,  1997), rat adrenal gland (Tena- 
Sempere et a l,  2000) and the rat testis (Tena-Sempere et a l,  2001). The 
expression of OB-Rf mRNA has been detected at higher levels in the rat liver 
and spleen compared to the brain, hypothalamus, stomach and kidney amongst 
other tissues, in contrast to the expression of OB-Ra and OB-Rb mRNA (Wang 
e ta l ,  1996).
The mRNA expression of the shortest splice variant, OB-Re, which is 
expected to encode a soluble form of the leptin receptor, was detected in 
relatively high amounts in many tissues (Lollmann et al,  1997). Expression of 
OB-Re mRNA is comparable to that of leptin in fat tissue, and it has been 
proposed that OB-Re may be secreted in sufficient amounts to act as a buffering 
system for freely circulating leptin (Lollmann et a l,  1997), Furthermore, the 
high mRNA expression of OB-Re in the placenta of pregnant mice may be 
attributable to the binding of leptin (Gavrilova et al, 1997).
1.3.4 Leptin receptor signalling
Class I cytokine receptor members typically lack intrinsic tyrosine 
kinase activity and are activated by formation of homo- or heterodimers upon 
ligand binding (Watowich et a l,  1996). Recent research has demonstrated that 
leptin receptors expressed in COS and Ba/F3 cells exist as both homodimer and
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homooligomer complexes without any evidence for heterodimer formation 
(Devos et al,  1997; Nakashima et a l,  1997; White et a l,  1997a). The fact that 
the expressed extracellular domain of OB-Rb is a dimer suggests that OB-Rb 
exists as a preformed homodimer, even in the absence of ligand (Devos et al, 
1997). OB-Rb therefore appears to be activated via ligand-induced 
conformational changes and homodimerisation rather than heterodimérisation or 
oligomerisation with other receptors of the class I cytokine family (Devos et al,
1997).
Leptin binding to its receptor induces a conformational change in the 
receptor that allows transphosphorylation of JAKs. The activation of JAK is 
followed by the phosphorylation of specific tyrosine residues on the intracellular 
domain of the receptor that provide docking sites for members of the STAT 
family and other Src Homology 2 (SH2) -containing proteins e.g. SHP-2. 
Phosphorylation of STATs by JAK is followed by their dimersiation and 
translocation to the nucleus where they regulate transcription of various genes.
1.3.4.1 JAK-STAT pathway
Given the number of different OB-R isoforms that exist, signals specific 
to OB-Rb's intracellular tail are crucial for the biological action of leptin. The 
JAK family was independently identified by low stringency hybridisation 
(Firmbach-Kraft et al, 1990) and by studies designed to identify novel protein 
tyrosine kinases using PCR (Partanen et a l,  1990; Wilks, 1989). There are 
presently four identified mammalian Janus kinase (JAK) family members:
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JAICl, JAIC2, JAK3 and TYK2, which range from 120 to 140 kDa (Pellegrini & 
Dusanter-Fourt, 1997). Cytokine receptors have no intrinsic catalytic activity 
and rely on JAKs, which are constitutively associated with their cytoplasmic 
regions, to transduce the extracellular ligand-binding event to an intracellular 
signal. Motifs called 'box 1', usually proline rich, and 'box 2' in the membrane 
proximal regions of the receptors are important for JAK association. JAKs can 
be roughly divided into an amino-terminal region, followed by a catalytically 
inactive kinase-like domain and a tyrosine kinase domain. The amino-terminal 
region is important for receptor recognition and association. The tyrosine 
kinase domain is responsible for catalytic activity and the catalytically inactive 
kinase-like domain is likely to play a regulatory role, which is not yet well- 
defined.
Research has demonstrated that the JAK2, and possibly JAKl, tyrosine 
kinases are activated during OB-Rb signalling (Baumann et a l,  1996; Ghilardi 
& Skoda, 1997). JAK activation is followed by the phosphorylation of tyrosine 
residues located on the intracellular tail of OB-Rb (Bjorbaek et a l ,  1997). Of 
all the OB-R isoforms, OB-Rb is the only form to contain tyrosine residues on 
its intracellular tail, partially explaining OB-Rb's unique role as the major 
signalling isoforms (Banks et a l,  2000; Bjorbaek et a l,  1997).
The STAT family of proteins are DNA binding transcription factors that 
contain serine-rich SH2 domains that interact with the cytokine receptors 
through phosphorylated tyrosine residues (Ghilardi et a l,  1996). Seven 
members of the STAT family have been identified in mammalian cells: STATl,
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STAT2, STATS, STAT4, STAT5a, STAT5b and STAT6 (Leonard & O'Shea,
1998), All STAT proteins isolated so far have a conserved domain structure 
(Figure 1.2). Differences in the SH2 domains of different STATs determines 
the selectivity of STAT binding to various cytokine receptors. A conserved 
tyrosine approximately 700 residues from the N-terminus is rapidly 
phosphorylated by activated JAKs following receptor binding, allowing STAT 
proteins to form dimers, based on the interaction between the SH2 domain of 
each STAT and the phosphorylated tyrosine on the other. Although STAT 
dimérisation is important for DNA binding activity, the highly conserved N- 
terminal domain is involved in oligomerisation of STAT dimers to form 
tetramers and potentially more highly ordered oligomers (Vinkemeier et al, 
1996; Xu e ta l ,  1996).
Figure 1.2 The structure of STAT proteius
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Leptin signalling via the JAK-STAT pathway has been well documented 
in several tissues and in vitro systems. The i.c.v. administration of recombinant 
leptin activates STATS, but not STATS, in the hypothalamus of wild-type and 
ob/ob mice (Vaisse et al,  1996). However, intravenous administration of leptin
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was found to induce STATS DNA-binding activity in the small intestine of lean 
and ob/ob mice after 30 minutes, but no effect was observed in the OB-Rb- 
deficient db/db mouse (Morton et al, 1998). This result was corroborated by 
the activation of STATS DNA-binding activity upon leptin treatment of Caco-2 
cells, a human model of small intestinal epithelium (Morton et al,  1998). The 
intravenous injection of leptin in lean (+/?) Zucker rats induced translocation of 
only STATl to the nucleus, as demonstrated by binding to the M67-SIE DNA 
element (Siegrist-Kaiser et al, 1997), whereas i.p. leptin administration was 
shown to activate both STATl and STATS, in epididymal adipose tissue of 
wild-type and ob/ob mice (Bendinelli et a l,  2000).
Leptin activates STATS in pancreatic islets and in insulinoma cell lines; 
leptin activates STATS in RINmSF cells (Morton et al, 1998), STATS and 
STATS in BRIN-BDll cells (Briscoe et al, 2001a) and STATl and STATS in 
MIN6 cells (Tanabe et al,  1997). Other examples of leptin receptor JAK-STAT 
signalling in vitro include STATS and STATS activation in the human liver cell 
line WRL68 cells (Briscoe et al, 2001b) and COS cells, but results for STATl 
and ST AT6 were equivocal (Baumann et a l,  1996; Ghilardi & Skodal997). 
Rosenblum et a l  reported formation of STATl, STATS and mixed 
STATl;STATS dimers in cells transfected with OB-Rb and treated with leptin 
(Rosenblum et al, 1996). Tyrosine phosphorylation of STATl has also been 
demonstrated in a human renal adenocarcinoma cell line after treatment with 
leptin (Takahashi e ta l ,  1996).
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1.3.4.2 SOCS and CIS
CIS (Yoshimura et a l,  1995) and SOCS-1 (Starr et a l,  1997), also 
known as SSI-1 (STAT-induced STAT inhibitor) (Naka et a l,  1997) and JAB 
(JAK binding protein), are the two founder members of the family of inhibitors 
of STAT signalling. CIS and SOCS-1 contain a N-terminal regions of variable 
length, a central SH2 domain, and a conserved C-terminal region termed the 
SOCS box, consisting of 40 amino acids (Starr et al, 1997). Searches in DNA 
databases of the conserved SOCS box and SH2 domain identified 6 structurally 
related genes, which were termed SOCS-2 to SOCS-7 (Hilton et a l,  1998), 
however SOCS-3 appears to be the one mainly involved in leptin-mediated 
signalling (Bjorbaek et al,  1998b). The SOCS genes have the main 
characteristics of immediate-early genes; they are small genes, contain a few or 
no introns and their expression is induced by cytokine stimulation. STAT 
response elements have been identified in the promoter sequences of the SOCS 
genes.
The mRNA for these genes is usually present at low levels in 
unstimulated cells, SOCS expression is induced by, and can inhibit signalling by 
many cytokines, growth factors and hormones (Krebs & Hilton, 2000). 
However, there appears to be some divergence in the mechanisms by which 
individual SOCS protein accomplish this inhibition. Investigation of the human 
CIS promoter has shown it contains four STAT binding elements that can bind 
STAT5-containing complexes (Verdier et a l,  1998a). The overexpression of 
CIS can inhibit STATS activation (Matsumoto et al, 1997), and CIS has been
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demonstrated to bind specifically to phosphotyrosine of the EPO receptor 
(Verdier et al., 1998b), one of two docking sites for STATS. This suggests CIS 
may act by competing with STATS for receptor binding sites, preventing its 
subsequent phosphorylation and activation. However, CIS does not appear to 
bind to phosphotyrosine Y^ "^  ^of the EPO receptor, which can also be involved in 
STATS activation (Gobert et al, 1996; Klingmuller et a l,  1996) suggesting that 
the mechanism of inhibition of STAT signalling by CIS may be more complex 
than simple competition for STAT binding.
Recent evidence has shown that SOCS-3 preferentially binds to 
phosphotyrosine Y^ ^^  of OB-Rb to mediate feedback inhibition of OB-Rb 
signalling (Bjorbaek et a l,  2000), and that inhibition of JAK2 activity by 
SOCS-3 can occur when recruited by the growth hormone receptor (Hansen et 
al,  1999). This suggests SOCS-3 may act via a distinct mechanism to that of 
CIS. The recruitment of SOCS-3 to activated receptors may bring it into close 
proximity to JAKs possibly allowing inhibition of the catalytic activity of JAKs 
through direct interaction with the kinase domain (Nicholson et al,  1999; 
Yasukawa et al,  1999). The fact that the binding sites for SOCS-3 on gpl30 
and the leptin receptor are identical to the SHP-2 binding sites (Bjorbaek et al,  
2000; Nicholson et al,  2000) suggests that SOCS-3 may also influence the 
Ras/mitogen-activated protein kinase (MAPK) signalling pathway (refer to 
section 1.3.4.S).
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1.3.4.3 MAPK pathway
Many cytokines stimulate a kinase cascade involving Ras, Raf-1, MEKK 
(MAPK kinase), and MAPK (Schiemann & Nathanson, 1998; Winston & 
Hunter, 1995; Yamashita et a l,  1998), which in turn phosphorylate a number of 
nuclear transcription factors and cytoplasmic proteins involved in various 
aspects of cellular function including cell proliferation (Aliaga et a l,  1999; 
Begum a/., 1998; Crawley e /a /., 1997; Sun e ta l ,  1999).
Leptin treatment of C3HIOT1/2 cells, a mouse embryonic cell line, 
resulted in the phosphorylation of MAPKs (Takahashi et a l,  1997). In CHO 
cells stably expressing OB-Rb, leptin stimulation has been shown to increase 
tyrosine phosphorylation of STATS and MAPK , whereas in CHO cells 
expressing OB-Ra only the phosphorylation of MAPK was detected (Bjorbaek 
et a l,  1999; Yamashita et al,  1998). OB-Rb-stimulated MAPK activation is 
thought to be mediated through insulin receptor substrate-1 (IRS-1) by the 
adapter protein, growth factor receptor bound protein 2 (GRB-2), which binds to 
JAK2 via the SH2 domain it contains (Banks et a l,  2000; Bjorbaek et a l,
1997). The OB-Ra isoform has a box 1 motif in the intracellular domain that is 
known to bind JAK2, therefore the phosphorylation of MAPK in OB-Ra- 
mediated signalling is also thought to be mediated through JAK2 (Bjorbaek et 
al,  1997). MAPK acts together with STATs, in the leptin-stimulated gene 
expression of the immediate early response genes c-fos, c-jun and jun-B (Banks 
et a l,  2000; Murakami et al, 1997). These findings suggest that MAPKs in 
addition to STATs are involved in leptin signal transduction.
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1.3.4.4 PI 3-kinase
The phosphoinositide 3-kinase (PI 3-kinase) family is ubiquitously 
expressed and acts by phosphorylating membrane inositol lipids. Through the 
generation of phospholipid second messengers, PI 3-kinase plays a key role in 
the regulation of many cellular processes, including cell proliferation and 
carbohydrate metabolism. The primary enzymatic activity of PI 3-kinase is the 
phosphorylation of inositol lipids at the 3 position with the major substrate 
being phosphatidylinositol (4,5)-bisphosphate (Ptdlns(4,5)p2). Hence 
PtdIns(4,5)P2 is converted to phosphatidylinositol (3,4,5 )-trispho sph ate 
(PtdIns(4,5)P3):
PI 3-kinase
PtdIns(4,5)P2 ----------------------------------^  PtdIns(3,4,5)P3
Leptin has been reported to stimulate glucose transport in C2 C12 
myotubules via a PI 3-kinase-dependent process, which was inhibited by 
Wortmannin (a PI 3-kinase inhibitor) (Berti et a l,  1997). Leptin-stimulated PI 
3-kinase activation in the C2C12 cells was found to employ JAK2 and 1RS-2 
(Kellerer et al,  1997). There have been several reports that leptin reduces 
insulin secretion from pancreatic (3-cells (Emilsson et al,  1997; Fehmann et al,  
1997a; Kulkarni et al,  1997; Seufert et al, 1999a). One mechanism proposed 
to explain the leptin-induced reduction in insulin secretion is via activation of 
ATP-sensitive ( K a t p )  channels (Harvey et a l,  1997; Kieffer et al,  1997). 
Harvey et al  have recently shown that leptin activation of K a t p  channels in
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CRI-Gl cells is sensitive to both Wortmannin and LY 294002 (inhibitors of PI 
3-kinase), suggesting the possible involvement of a PI 3-kinase (Harvey et al,  
2000a). Most of the cellular roles of PI 3-kinase have been attributed to the 
lipid products of these enzymes, which bind to target molecules via specific 
lipid binding domains.
1.3.4.5 SHP-2
Recent data suggests that Tyr^^  ^ of OB-Rb is required for maximal 
activation of the MAPK pathway by leptin (Banks et a l,  2000). The SH2- 
domain containing protein tyrosine phosphatase, SHP-2, binds to Tyr^^  ^
allowing the protein to be tyrosine phosphorylated by JAKs following leptin 
treatment (Banks e ta l ,  2000; Carpenter e ta l ,  1998; Li & Friedman, 1999).
The relative roles of the phosphatase activity and tyrosine 
phosphorylation of SHP-2 in regulation of signalling pathways are not well 
characterised and may differ in different signalling systems. SHP-2 has been 
shown to play a positive role in mediating MAPK activation by cytokine 
receptors and by receptor tyrosine kinases (Gu et al,  1998; Kim & Baumann, 
1999; Shi et a l,  1998a). Studies have suggested that SHP-2 acts as both a 
negative and a positive regulator of STAT signalling in a cytokine receptor- 
specific manner (Kim & Baumann!999; You et a l,  1999).
One study suggested that SHP-2 is a negative regulator of leptin-induced 
STAT3-mediated transcription (Carpenter et al,  1998). This conclusion was 
based on indirect evidence showing that the Tyr^^  ^ mutant of OB-Rb does not
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bind SHP-2 and that this receptor exhibits increased STAT-mediated gene 
transcription following 24 hours of leptin treatment. However, several reports 
have shown that mutation of Tyr^^  ^ on OB-Rb, which results in loss of SHP-2 
binding, does not affect STAT3 tyrosine phosphorylation (Banks et al,  2000; 
Carpenter et al,  1998; Li & Friedman 1999). Moreover, Bjorbaek et al found 
dominant negative SHP-2 had no effect on leptin-induced STAT3 tyrosine 
phosphorylation (Bjorbaek et a l,  2001). Recently, it was demonstrated that 
SOCS-3 binds to Tyr^^  ^ and that SOCS-3 requires this residue to mediate 
inhibition of OB-Rb signalling (Banks et al, 2000). These studies suggest that 
signalling effects that have previously been attributed to SHP-2, following 
mutagenesis of tyrosine docking sites, may be due to the inability of SOCS-3 to 
bind to OB-Rb and inhibit STAT signalling. Bjorbaek et al  have demonstrated 
functional competition between SHP-2 and SOCS-3 for Tyr^^  ^ of OB-Rb 
suggesting SHP-2 is an indirect positive regulator of STAT signalling, acting by 
preventing SOCS-3 from inhibiting leptin signalling via Tyr^^  ^ (Bjorbaek et a l,  
2001). The authors further speculate that SOCS-3 can inhibit MAPK signalling 
by two mechanisms; one involving prevention of SHP-2 binding to Tyr^^  ^ and 
the other by inhibition of JAK activity after binding to Tyr^^  ^ (Bjorbaek et a l,
2001). Therefore, SHP-2 is a positive regulator of MAPK activation and may 
also act as an indirect positive mediator of STAT signalling, by inhibition of 
SOCS-3 action via competition for Tyr^^ .^
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1.3.5 Cross-talk with other signalling pathways
A number of in vitro and in vivo studies support the existence of cross­
talk between the leptin and insulin signalling pathways. Briefly, insulin binds to 
its receptor and activates the intrinsic protein tyrosine kinase leading to 
autophosphorylation of the receptor on multiple tyrosine residues (Taha & Klip,
1999). This enables the receptor to bind to and phosphorylate the 1RS proteins, 
which can recruit PI 3-kinase amongst other enzymes and adapter proteins. The 
downstream effects of these enzymes eventually mediate the effects of insulin 
on metabolism and gene expression. Therefore, the leptin and insulin signalling 
pathways may cross-talk through PI 3-kinase activated through JAKs for OB-Rb 
and through 1RS for insulin.
The cross-talk between the leptin and insulin signalling pathways is 
supported by the observation that the intravenous infusion of leptin in mice 
increases glucose turnover and stimulates glucose uptake in skeletal muscle and 
BAT (Kamohara et a i,  1997). Furthermore, in rats, intraperitoneal leptin 
enhances the inhibitory effect on hepatic glucose output, while antagonising 
insulin action on the gene expression of glucokinase and phosphoenolpyruvate 
carboxylase (PEPCK) (Liu et a l,  1998; Rossetti et a l,  1997).
In HepG2 human hepatoma cells, leptin antagonises insulin down- 
regulation of PEPCK expression and decreases insulin-stimulated tyrosine 
phosphorylation of IRS-1 but enhances 1RS-1-associated PI 3-kinase activity 
(Cohen et al, 1996b). In C2C 12 cells, leptin stimulates a non-IRS-1-associated 
PI 3-kinase and mimics insulin action on glucose transport and glycogen
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synthesis (Berti et al,  1997). Insulin occludes leptin activation of K a t p  
channels in the CRI-Gl insulinoma cell line(Harvey & Ashford, 1998). 
However, there is also a study that reports leptin does not play a role in insulin 
action. The leptin treatment of OB-Rb-transfected HepG2 cells resulted in the 
recruitment of p85 to IRS-2 but did not modulate the response to insulin (Wang 
et al, 1997a). These studies point toward cell- and tissue-specific interactions 
between leptin and insulin signalling.
1.4 Leptin function
Leptin was first described as a hormone of energy balance, however it 
soon became evident following identification of OB-Rb expression in many 
peripheral sites that its effects were more extensive. For example, leptin has 
important actions on the reproductive system, restoring the fertility of female 
ob/ob mice (Chehab et a l,  1996) and advancing the time of first estrus in 
normal mice (Chehab et a l,  1996). The effects of leptin on the reproductive 
axis have led to a reappraisal of its overall role, suggesting that the hormone 
may not solely provide a precise homeostatic control for energy balance, but 
rather that it acts primarily to maintain energy supplies for both reproduction 
and the normal care and maintenance functions of the animal (Ahima et al,
1996).
In the pancreas, leptin inhibits insulin gene transcription and insulin 
gene expression (Pallett et al, 1997), causes naturesis in the kidney (Jackson & 
Li, 1997) and stimulates sugar transport in the intestine (Lostao et al, 1998).
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Some of the metabolic functions of leptin are mediated by the opening of the 
membrane ATP-sensitive potassium channel found in many tissues (e.g. 
pancreas (Harvey et al,  1997), hypothalamic neurons (Spanswick et al., 1997), 
intestinal mucosa (Liu et al,  1999)). It has also been postulated that leptin's 
primary function is to prevent triglyceride overload by stimulating fatty acid 
metabolism and up-regulating enzymes of fatty acid oxidation (Shimabukuro et 
a l,  1998a; Unger e/a/., 1999).
Amongst other effects, leptin has also been implicated in activating the 
immune system (Lord et al, 1998), haematopoiesis (Gainsford et a l,  1996) and 
angiogenesis (Bouloumie e/'a/., 1998; Sierra-Honigmann g/ nr/., 1998). Leptin 
may also play a role in the growth and development of the brain (Steppan & 
Swick, 1999) and fetus (Hoggard e ta l ,  1997a).
1.4.1 What we know from human mutations
There are several animal models of monogenic obesity that involve 
mutations in leptin or its receptor. The obese phenotype of ob/oh mice results 
from single mutations in either the coding region or the 5' non-coding end of the 
leptin gene (Zhang et al, 1994). The obese phenotype of db/db micQ, fa/fa 
Zucker and Koletsky rats is due to mutations in the leptin receptor gene
(Chen et a l,  1996; Chua et al, 1996a; Lee et al, 1996; Takaya et a l,  1996). 
However, human obesity is clearly a multifactorial and multigenic disease and, 
until very recently, there was no evidence to implicate mutations of leptin or its 
receptors as causative agents. However, very rare forms of human obesity have
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now been identified where mutations in leptin or its receptors play a major role 
in the development of the disease.
Two independent groups were the first to publish reports of mutations in 
the leptin genes of obese patients expressing very low or undetectable leptin in 
their serum. Sequencing of the leptin genes in these patients revealed, in the 
case of two siblings of Pakistani origin, a deletion of a guanidine at codon 133 
corresponding to residue 112 (Montague et a l,  1997). This resulted in the 
appearance of a stop codon at position 145 and thus the synthesis of a truncated 
protein of 121 residues. In a Turkish obese patient with a very low serum leptin 
level, sequencing of the leptin gene revealed a missense mutation in codon 105 
(C ^T ), the same codon that is mutated in ob/ob mice (Strobel et a l,  1998). In 
mice this mutation creates a stop codon, however, in this patient the mutation 
leads to the substitution of an Arg for a Trp at position 84 of the mature protein. 
A protein of normal size is synthesised but is not secreted in serum. Two other 
morbidly obese members of the same Turkish family are both homozygous for 
the mutation and also lack immunoreactive leptin in their serum, but 
heterozygotes have normal leptin levels and are not obese (Strobel et al,  1998).
Support for the role of leptin in the control of appetite, body weight and 
sexual development in humans was provided by the study of the Pakistani 
leptin-deficient children treated with recombinant leptin (Farooqi et al, 1999). 
Leptin treatment of the elder sibling resulted in reduced food intake and body 
weight, increased physical activity and the commencement of pubertal changes 
at an appropriate age.
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A systematic search for mutations in the human leptin receptor gene was 
launched by Goto da et al, with a sensitive RT-PCR procedure using 
lymphocyte RNA (Gotoda et a l,  1997). None of the five single-point 
polymorphisms found in the human leptin receptor gene were found to be 
associated with obesity. Clement et al recently reported the discovery of a 
G->A base substitution in the splice donor site of exon 16 in the receptor gene 
of an obese North African patient (Clement et al, 1998). This mutation resulted 
in the synthesis of a truncated receptor lacking both the transmembrane and the 
intracellular domains, similar to the OB-Re splice variant. The patient had 
serum leptin concentrations six-to-ten-fold higher than expected for obese 
patients with a similar body fat mass. Heterozygotes in the family are also 
overweight or obese, and the only homozygotes found so far are sisters, the 
mutation in the leptin receptor gene is the most likely cause of the obesity in this 
family.
1.4.2 Central leptin function
1.4,2.1 OB-Rb function
Leptin is secreted primarily from WAT and stimulates OB-Rb receptors 
in the hypothalamus to mediate effects on food intake and energy expenditure. 
Moreover, leptin interacts with a number of orexigenic and anorexigenic 
peptides that are involved in maintaining energy balance. The orexigenic 
peptides favour food intake, reduce energy expenditure and facilitate fat storage, 
whereas the anorexigenic peptides reduce food intake, increase energy
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expenditure, and facilitate the loss of fat stores. Leptin inhibits many of the 
orexigenic neuropeptides (e.g. neuropeptide (NPY), orexins, agouti-related 
protein (AGRP)) and favours many of the anorexigenic ones (e.g. 
proopiomelanocortin (POMC), corticotropin-releasing hormone (CRH), 
cocaine- and amphetamine-regulated transcript (CART)).
Figure 1.3 Leptin effects on orexigenic and anorexigenic peptides in the 
hypothalamus
Plasma
Leptin
OB-Rl
I NPYmRNA 
I AŒPmRNA
t POMCmRNA 
j  CARTinRNA
OB-Rb receptors are found in a variety of hypothalamic nuclei including 
the arcuate nucleus (ARC) and paraventricular nucleus (PVN) (Elmquist et al, 
1998; Hakansson et al, 1998; Mercer et al, 1996). Leptin was shown to inhibit 
expression of hypothalamic AGRP mRNA in mice (Mizuno & Mobbs, 1999)
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and hypothalamic NPY mRNA in rats (Schwartz et al, 1996a). Furthermore, 
AGRP and NPY are coexpressed in the same neurons (Hahn et al,  1998). 
Leptin increases expression of the anorexic peptides POMC (Schwartz et al,
1997), CART genes (Kristensen et a l,  1998) and CRH (Uehara et a l,  1998). 
Similar to the orexigenic neuropeptides AGRP and NPY, the anorexigenic 
peptides POMC and CART are colocalised in the same neurons (Elmquist et al,
1999). Leptin thus modulates activity in the neurons of the arcuate nucleus to 
release a range of orexigenic and anorexigenic neuropeptides.
Although leptin activates STATl, 3, and 5 through OB-Rb in in vitro 
systems, intravenous leptin activates only STAT3 in the mouse hypothalamus 
(Ghilardi et a l,  1996; Vaisse et a l,  1996). STAT3 protein is expressed in NPY 
and POMC neurons in the arcuate hypothalamic nucleus, consistent with the 
concept that leptin regulates the transcription of these genes at least in part 
through the JAK-STAT signal transduction pathway (Hakansson & Meister,
1998). Leptin also regulates the expression of other STAT3 target genes in 
hypothalamus, including Q-fos and SOCS-3 (Bjorbaek et a l,  1998b; Elmquist et 
al,  1997).
Leptin inhibits glucose-responsive neurons in the hypothalamus through 
effects on ATP-sensitive potassium channels (Kieffer et a l,  1997; Spanswick et 
al,  1997). Furthermore, leptin depolarises paraventricular hypothalamic 
neurons (Powis et a l,  1998) and regulates vagal afferents in the stomach (Wang 
et al, 1997b). The mechanisms underlying these rapid electrophysiological 
actions of leptin are not known but are not likely to involve STAT-mediated
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transcription and may involve leptin-stimulated PI 3-kinase activation and 
cross-talk with the insulin signalling pathway (Kieffer et a l,  1997; Spanswick et 
al,  1997).
1.4.2.2 Other OB-R isoforms
The distribution of mRNA encoding OB-R isoforms was examined by in 
situ hybridisation using isoform-specific probes. A differential expression 
pattern of leptin receptors was observed in several brain areas (Guan et al,
1997). The OB-Ra and OB-Rb isoforms, but not OB-Rc and OB-Rf, are 
abundantly expressed in the hypothalamus, whereas OB-Ra, OB-Rc and OB-Rf, 
but not OB-Rb, are significantly expressed in the choroid plexus. In a further 
study, the OB-Ra isoform was demonstrated to be widely expressed in the brain 
and high levels were detected in the choroid plexus epithelium and the 
ependymal lining (Burguera et a l,  2000).
The OB-Ra isoform has been hypothesised to be involved in leptin 
transport, a proposal supported by a number of observations. Firstly, leptin 
enters the rat brain by a saturable transport mechanism (Maness et al,  1998), 
possibly by receptor-mediated transcytosis across the blood-brain barrier, as is 
the case for some other large proteins (Pardridge, 1986). Secondly, brain 
microvessels express high levels of OB-Ra, which is increased in rats fed a high 
fat diet (Boado et al, 1998), and are capable of binding and internalising leptin 
(Bjorbaek et a l,  1998a; Golden et a l,  1997). Furthermore, the Koletsky strain
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of rats, which lack the OB-Ra isoform (Takaya et a l, 1996), show reduced 
transport of leptin across the blood-brain barrier (BBB) (Kastin et a l, 1999).
The blood-cerebrospinal fluid (CSF) barrier at the choroid plexus and 
the BBB at the cerebral endothelium are two major controlling sites for the 
entry of proteins into the brain (Zlokovic et a l, 2000). Bjoerbaek et a l have 
suggested the transport of leptin into the CSF via the choroid plexus is not the 
major transport route by which leptin reaches the hypothalamus and that JAK- 
STAT signalling is unlikely to occur given the low concentrations of leptin in 
the CSF (Bjorbaek et a l, 1998a). On the other hand, Zlokovic et a l have recent 
evidence by in situ brain perfusion that leptin entry into the CSF via the choroid 
plexus and hypothalamus occurs by a fast transport system in contrast to the 
slower uptake at the BBB (Zlokovic et a l, 2000).
The OB-Ra isoform may play a role other than leptin transport in the 
brain. The co-expression of OB-Ra and OB-Rb mRNA in the hypothalamus 
suggests that there may be a possible interaction between the two isoforms 
(Guan et a l, 1997). Although the OB-Ra isoform cannot signal via activation 
of STATs, it may signal via the activation of the MARK pathway or PI 3-kinase 
although the signalling capacity of OB-Ra in vivo is not well defined (see 
sections 1.3.4.3 and 1,3.4.4). Furthermore, leptin hyperpolarises glucose- 
receptive hypothalamic neurons of lean Sprague-Dawley and Zucker rats by 
activation of K a t p  channels (Spanswick et a l, 1997). The authors suggest that 
the K a t p  channel may fonction as the molecular end-point of the pathway 
following leptin activation of the OB-Rb receptor in hypothalamic neurons. In
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the p“Cells of the pancreas, leptin reduces insulin secretion by the activation of 
K a t p  channels which may involve leptin-stimulated PI 3-kinase activation 
(Harvey et a l, 2000b). Similarly, activation of K a t p  channels in the 
hypothalamic neurons may involve PI 3-kinase stimulated via OB-Ra or OB- 
Rb.
1.4.3 Peripheral leptin function
Initially, leptin was only believed to signal via the OB-Rb isoform in the 
hypothalamus to reduce food intake and increase energy expenditure. However, 
the increasing number of reports of OB-Rb mRNA expression in a number of 
peripheral tissues suggested leptin may have an important role in these tissues. 
The expression of the signalling competent OB-Rb isoform was observed in the 
pituitary, pancreatic P-cells, adipose tissue, small intestine, skeletal muscle, 
lungs, kidneys (although mainly Ob-Ra), adrenal medulla, placenta, ovaries, and 
testes amongst others (Hoggard et a l, 1997b; Karls son et a l, 1997; Kieffer et 
a l, 1996; Kutoh et a l, 1997; Liu et a l, 1997; Morton et a l, 1998; Sharma & 
Considinel998; Zamorano et a l, 1997). Details of leptin fonction in the 
peripheral tissues analysed are presented in chapters 3 and 4 and summarised 
below.
1.4.3.1 Pituitaiy
The expression of leptin and the Ob-Rb isoform has been identified in 
human, mouse and rat pituitaries by RT-PCR and in situ hybridisation (Jin et a l.
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1999; Jin et a l, 2000), indicating that leptin has the potential to regulate 
pituitary function via endocrine, paracrine and/or autocrine mechanisms. Leptin 
has been shown to control gonadotropin secretion in the anterior pituitary (Yu et 
a l, 1997a). Furthermore, it has been shown that high concentrations of leptin 
(10'®-10'  ^M) inhibit cell proliferation in human and rat pituitary cell lines in 
vitro (Jin et a l, 2000). Consequently, leptin might directly and positively 
influence the function of the gonadotropes and be involved in the regulation of 
the growth and differentiation of pituitary cells.
1.4.3.2 Pancreas
The expression of OB-Rb has been identified in the p-cells of the 
pancreas, where leptin reduces insulin secretion by the opening of K a t p  
channels (Emilsson et a l,  1997; Kieffer et a l, 1997). The OB-Rb-mediated 
signalling events leading to effects on insulin secretion are believed to involve 
the activation of PI 3-kinase-dependent phosphodiesterase-3B (PDE3B) and 
subsequent suppression of cAMP levels (Zhao et a l, 1998). However, leptin 
may also regulate gene expression in pancreatic p-cells by the activation of 
STAT proteins. Leptin treatment of MIN6 cells produced an increase in the 
tyrosine phosphorylation of STAT3 (Tanabe et a l, 1997) and activated STAT3 
in rat isolated islets and RINmSF cells (Morton et a l, 1999). Furthermore, the 
treatment of the rat insulinoma cell line BRIN-BDll was recently shown to 
activate STAT3 and STAT5 (Briscoe e ta l,  2001a).
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1.4.3.3 Adipose Tissue
The observation that the functional form of the leptin receptor, OB-Rb, 
was expressed in adipose tissue suggests leptin may have a role in lipid 
metabolism (Kutoh et a l, 1997). Adipose tissue mass is determined by the rate 
of rival pathways for triglyceride synthesis, versus fatty acid oxidation. Leptin 
reduces lipid synthesis and stimulates the enzymes necessary for p-oxidation 
(Wang et a l, 1999a). Furthermore, leptin prevents fatty acid synthesis by 
specifically inhibiting the fatty acid synthase gene (Fukuda et a l, 1999). 
Leptin is also known to exert its effects by increasing energy expenditure and it 
has been shown that leptin directly induces expression of uncoupling proteins 
(UCPs) in WAT and BAT (Scarpace et a l, 1998).
1.4.3.4 Small Intestine
The functional isoform of the leptin receptor, OB-Rb, was identified in 
the jejunum and in the ileum of lean and ob/ob mice by RT-PCR, suggesting 
leptin may be involved in nutrient absorption (Morton et a l, 1998). This was 
confirmed by the observation that leptin produced a rapid inhibitory effect on 
sugar absorption in rat intestinal rings (Lostao et a l, 1998). Furthermore, the 
intravenous administration of leptin resulted in a two-fold reduction in 
apolipoprotein of chylomicrons (APO-AIV) mRNA levels in the jejunum of 
ob/ob mice (Morton et a l , 1998), suggesting leptin may reduce the transport of 
triglycerides into plasma.
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1.5 Leptin insensitivity
The majority of obese humans exhibit elevated plasma leptin levels in 
proportion to their body fat mass (Considine et a l, 1996; Schwartz et a l, 
1996b) and leptin mRNA has been shown to be increased in obese humans 
relative to non-obese humans (Maffei et a l, 1995). As a result, it has been 
suggested that obese humans may be insensitive to the leptin signal. 
Mechanisms thought to underlie leptin insensitivity include dysregulation of 
leptin synthesis and/or secretion, defects in the transport of leptin in the brain, 
and abnormalities of leptin receptors and/or post-receptor signalling.
1.5.1 Leptin access to the hypothalamus
The reduced ratio of CSF/plasma leptin observed in obese humans (Caro 
et a l, 1996; Schwartz et a l, 1996b) and the ability to respond to central but not 
peripheral leptin administration in diet-induced and New Zealand obese mice 
(Halaas et a l, 1997; Lin et a l, 2000; Van Heek et a l, 1997), suggests the 
transport of leptin is not functioning optimally in obesity. There are two 
proposed mechanisms that could explain the reduced leptin transport in obesity. 
The leptin transporter could be saturated by the increased plasma leptin levels or 
the BBB could have a reduced capacity for leptin transport (Banks et a l, 1999). 
The injection of radioiodinated leptin into 12-month old obese CD-I mice 
resulted in the reduced rate of leptin transport across the BBB compared to leans 
(Banks et a l, 1999). Moreover in a follow-up experiment using a perfusion 
method containing a buffer with low levels of radioactive leptin, the obese mice
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still had lower rates of leptin transport compared to leans (Banks et a l, 1999). 
These findings suggest that the reduced BBB transport rate associated with high 
levels of leptin in obesity is not due to the saturation of transport, but the 
reduced capacity of the BBB to transport leptin. In support of this proposal, 
intravenous administration of radioiodinated leptin in ob/ob and db/db mice 
showed there was no significant difference in the rate of leptin transport 
compared to leans (Maness et a l, 2000). This suggests that the impaired leptin 
transport is not directly explained by the absence of leptin or OB-Rb, which as a 
result of their respective genes result in obesity in mice. Therefore, obesity may 
not always be related to a defect of the transport of leptin across the BBB and 
alternative factors may be involved in the transport of leptin, emphasising the 
dynamic regulatory role of the BBB in leptin transport.
1.5.2 Leptin receptor expression
Leptin insensitivity could also reside at the level of receptor expression 
or steps downstream from the initial step of receptor interaction. A number of 
studies have shown that leptin receptor expression is increased in the 
hypothalamus of the hypersensitive ob/ob mice compared to leans (Baskin et 
a l, 1998; Emils son et a l, 1999; Huang et a l, 1997). However, there is no 
change in leptin receptor expression in the liver, small intestine or WAT of 
ob/ob mice compared to leans. A recent study showed no change in the 
expression of hypothalamic OB-Rb mRNA in diet-induced obese mice (El
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Haschimi et a l, 2000). Therefore, changes in the leptin receptor expression 
may occur as a result of leptin sensitivity in a tissue-specific manner.
1.5.3 Post-receptor signalling
Leptin sensitivity may also involve a number of components 
downstream of the receptor signalling pathway. In diet-induced obese mice, 
there was no change in the expression of hypothalamic STATS mRNA, however 
reduced STATS activation was observed by electrophoretic mobility shift assays 
(EMSA) in the hypothalamus (El Haschimi et a l, 2000), A recent study that 
examined the expression of STATS mRNA in the hypothalamus of ob/ob mice 
compared to leans showed that STATS mRNA was reduced. In contrast, 
Emilsson et a l, observed no change in STATS or STAT5 mRNA expression in 
the hypothalamus, liver, small intestine or WAT of ob/ob mice compared to 
leans (Emilsson e ta l ,  1999).
The increased expression of SOCS-3 mRNA after leptin treatment of 
lean and ob/ob mice has suggested SOCS-3 may be a potential mediator of 
leptin insensitivity (Bjorbaek et a l, 1998b). The observation that the expression 
of SOCS-3 and CIS mRNA was increased in the hypothalamus of ob/ob mice 
compared to leans (Emilsson et a l, 1999) is inconsistent with their proposed 
roles as negative regulators of leptin-mediated signalling. The authors suggest 
that the increased expression of OB-R mRNA may counteract the effect of the 
increased expression of SOCS-3 and CIS mRNA in ob/ob mice. In diet-induced 
obese rodents, there was no change in the expression of SOCS-3 mRNA in the
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hypothalamus (El Haschimi et a l, 2000) or in the WAT, BAT and liver (Peiser 
et a l, 2000). However, in a different study of dietary obese rats and acquired 
obesity caused by ventromedial hypothalamus lesioning, the expression of 
SOCS-3 mRNA was increased in the adipose tissue (Wang et a l,  2000). This 
suggests that effects on SOCS-3 expression may be tissue-specific.
1.6 Animal models used to study leptin function
1.6.1 Diet-induced obese mice
There are few examples of human monogenic disorders such as a 
mutation in leptin or its receptor, as observed in ob/ob and db/db mice (Clement 
et a l, 1998; Gotoda et a l, 1997; Montague et a l, 1997; Strobel et a l, 1998). 
Obesity in humans is the result of a complex interaction of many factors; two 
major influences being genetic predisposition and diet.
Leptin insensitivity has been described in diet-induced obese mice fed a 
high fat diet for 8 weeks, which closely reflects the human condition (Van Heek 
et a l, 1997; Widdowson et a l, 1997). A recent study describes the 
development of high fat diet-induced obesity in C57BL/6J mice (Lin et a l, 
2000). After 8 weeks of feeding, C57B1/6J mice were insensitive to the leptin 
effect on food intake but still retained central leptin sensitivity. However, after 
19 weeks of feeding a high fat diet a reduction of central leptin sensitivity was 
observed. The high fat diet-induced obesity model is a more accurate depiction, 
compared to genetic disorders, of the human situation and therefore provides 
researchers with an invaluable tool to study obesity.
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1.6.2 ob/oh mice
The leptin gene is one of the most extensively studied in obesity 
research, because a spontaneous mutation of this gene in mice
prohibits secretion of mature leptin causing hyperphagia, hypothermia, 
hypercorticosteronaemia, hyperglycaemia, hypothyroidism, growth hormone 
deficiency, hyperinsulinaemia reduced energy expenditure, decreased linear 
growth and, infertility and early-onset morbid obesity (Friedman & Halaas, 
1998; Zhang et a l, 1994). Leptin administration of ob/ob mice normalises all 
aspects of the obesity and diabetes syndrome and restores reproductive function 
(Campfield et a l, 1995; Halaas et a l, 1995; Pelleymounter et a l, 1995).
1.6.3 ZDF fa/fa  rats
Obese Zucker rats have a mutation in the extracellular domain of the 
leptin receptor and exhibit morbid obesity, dislipidaemia, hyperphagia, 
hypothyroidism, reduced fertility and impaired glucose tolerance, as recessive 
traits (Unger, 1995; Unger & Orci, 2001). The fa/fa  mutation observed in 
Zucker rats, an nucleotide missense mutation resulting in
Gln^^^->Pro^^^ amino acid substitution, reduces the expression of the leptin 
receptor on the cell surface, with marked intracellular retention, decreased leptin 
binding and diminished signal transduction (Chua et a l,  1996b; Crouse et a l, 
1998; Da Silva et a l, 1998; Yamashita et a l, 1997). ZDF rats were isolated 
from a colony of obese Zucker rats and become diabetic after about 8 weeks 
when presented with a high fat diet (Clark & Palmer, 1982).
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1.7 Aims
The phenotype of ob/ob and db/db mice makes it clear that leptin plays a 
major role in obesity. Furthermore, it is now clear that leptin functions not only 
in the hypothalamus but also in peripheral tissues. Investigation into the 
signalling mechanism of the functional form of the leptin receptor, OB-Rb, has 
identified key components of the leptin receptor-mediated signalling pathway 
that might be involved in leptin sensitivity.
The aim of this thesis was to examine the relationship between changes 
in expression of genes involved in leptin receptor signalling and leptin 
sensitivity. Gene expression was analysed in central and peripheral tissues of 
leptin-insensitive dietary obese mice compared to leptin-hypersensitive ob/ob 
obese mice. To gain further insight into some of the mRNA changes in genes 
involved in leptin receptor-mediated signalling that might be involved in leptin 
sensitivity, expression was quantified in ob/ob mice treated with leptin for 24 
hours and 2 weeks. Research into the factors that are involved in leptin 
sensitivity may help identify therapeutic targets for the treatment of obesity.
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Chapter 2 
Materials and Methods
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2.1 Materials
Ambion. Austin. U.S.A.
Glyco Blue.
Anachem. Luton. England.
2M sodium acetate pH 4.2.
Crystal Chem. Chicago. I.L.. U.S.A.
Leptin and insulin ELISA.
Harlan Olac Ltd. Bicester. England.
AKR/J and C57BL/6J mice and Zucker diabetic fatty (ZDF) rats.
Life Technologies. Paisley. Scotland.
TRIzol reagent, chloroform: iso amyl alcohol, DNase I amplification grade, 
RNase OUT (RNase inhibitor), Superscript II.
Lin CO Research Inc.. St. Charles. Missouri. U.S.A.
Rat leptin RIA kit.
MJ Research Inc. Waltham. M.A.. U.S.A.
Peltier Thermal Cycler (FTC-225) supplied by Genetic Research 
Instrumentation, Braintree, England.
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Molecular Devices Ltd.. Wokingham. England.
Thermo plus microplate reader.
Oncor Appligene. Parc d'Innovation. France.
AquaPhenol, Ready Red.
Perkin-Elmer Applied Biosystems. Foster City. C.A.. U.S.A.
2X Universal PCR Master Mix, TaqMan primers and probes, MicroAmp optical 
96-well PCR plate, MicroAmp optical cap strips and ABI PRISM 7700 
Sequence Detector.
Promega. Southampton. England.
Guanidine thiocyanate and mineral oil.
Roche Diagnostics Ltd.. Lewes. England.
Unimate 5 Glucose HK and COB AS MIRA Plus.
Siema-Aldrich Company Ltd. Dorset. England.
Isopropanol, sodium citrate, p-mercaptoethanol, 7.5M ammonium acetate and 
N-laurylsarcosine,
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Stratagene. La Jolla. C.A.. U.S.A.
Random 9-mers.
Wako Chemicals. Richmond. V.A.. U.S.A.
NEFA C test kit.
2.2 Animals
This work was conducted in compliance with the Home Office Guidance 
on the operation of the Animals (Scientific Procedures) Act 1986, and was 
reviewed and approved by the SmithKline Beecham Procedures Review Panel.
2.2.1 Diet-induced obesity
Five-week old female AKR/J and C57BL/6J (lean and ob/ob) mice were 
housed in groups of 10 and maintained at 24 + 2 °C on a 12 hour light/12 hour 
dark light cycle (lights on at 06;00hr), for at least 1 week before the experiment 
in order to acclimatise to the new research environment. Mice were provided 
with a standard laboratory diet and water ad libitum for the acclimatisation 
period. After the acclimatisation period, the mice were weighed and divided 
into groups of approximately equal mean body weight, in two cages of 4 and 6 
mice.
AKR/J mice were fed either a normal chow diet or a palatable diet and 
C57B1/6 lean and ob/ob mice were fed a standard laboratory diet for a period of
47
14 weeks. The palatable diet consisted of 33% powdered laboratory diet, 33% 
condensed milk (Nestle), 7% sucrose and 6% corn oil by body weight.
Body and food weights were measured using an analytical balance. 
Body weights were taken every week and food weights taken over a 24 hour 
period each week, for the duration of the 14-week study. The difference in food 
weight was assumed to represent the amount of food eaten per day, taking into 
account any spillage of food in the cages. Mice were sacrificed by increasing 
the CO2 concentration in a gas chamber; then the tissues were removed and 
immediately frozen in liquid nitrogen and stored at -80°C.
2.2.2 Leptin treatment of ob/oh mice
Five-week old female C57BL/6J (lean and ob/ob) mice were maintained 
and acclimatised as described in 2.2.1, then weighed and divided into groups of 
approximately equal mean body weight and housed in cages of 2 mice in each. 
Mice were provided with a standard laboratory diet and water ad libitum for the 
duration of the study.
The ob/ob mice were injected intraperitoneally (i.p.) twice a day (08.00 
and 17.00 hours) with 1 mg/kg recombinant murine leptin or saline vehicle for 2 
days and 14 days. Body weights were measured daily, as was the food intake of 
the ob/ob mice (11.00 hours) undergoing the 14-day leptin infusion. The 
equivalent food intake to that of ob/ob mice over 24 hours was given to the pair- 
fed group to account for changes in food intake as a result of the leptin 
treatment. Mice were sacrificed and tissues removed as described in 2.2.1.
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2.2.3 Zucker diabetic fatty rats
Five-week old female ZDF rats were obtained from Harlan Olac Ltd. 
The rats were maintained and acclimatised as described in 2.1.1, then weighed 
and divided into groups of approximately equal mean body weight in two cages 
of 4 mice each. Mice were provided with a standard laboratory diet and water 
ad libitum for the duration of the study. At the age of 24 weeks, the rats were 
sacrificed and the tissues removed as described in 2.2.1.
2.3 Assays
Following termination of the animal, truncal blood was collected for 
measurement of leptin and insulin by enzyme-linked immunosorbent assay 
(ELISA). As well as removing the tissues for RNA extraction, a small section 
of the pancreas was homogenized in 5 mis of acid-ethanol [ethanol/hydrochloric 
acid/water 50:1:10] in order to determine the pancreatic insulin content by 
ELISA.
2.3.1 Leptin and insulin ELLSA
The major steps of the mouse leptin and insulin ELISA assays are 
described in Figure 2.1. All the solutions were supplied as part of a kit, the 
components of which are anonymous unless otherwise indicated.
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(al Serum leptin ELISA
Microplate wells, coated with a rabbit anti-mouse leptin antibody, were 
washed twice with 300 ql washing buffer and incubated overnight with 50 p,l 
guinea pig anti-mouse serum, 45 pi sample diluent and 5 pi sample to be 
analysed (or standards 0-12.8 ng/ml). Each well was then washed five times 
with 300 pi washing buffer to remove any unbound material. 100 pi of horse 
radish peroxidase (POD)-conjugated anti-guinea pig IgG antibody was then 
added to each well for 3 hours at 4°C. Subsequently each well was washed 
seven times with 300 pi washing buffer to remove any unbound materials, 
before adding 100 pi of 3, 3% 5, 5 '-tetramethylbenzidine (TMB) substrate 
solution to detect the bound POD conjugate. The plate was incubated in the 
dark for 30 minutes at room temperature before the enzyme reaction was 
stopped by the addition of 100 pi 1 N sulphuric acid. The absorbance was 
measured on a Thermo plus microplate reader plate reader (measuring wave 
length: 450 nm, subtracting wave length: 630 nm). The leptin concentration in 
each sample was determined from the standard curve.
(bl Serum insulin ELISA
The insulin ELISA assay was essentially the same as the leptin ELISA 
assay except that an anti-insulin antibody was used as the primary antibody, o- 
phenylenediamine (o-OPD) was used as the substrate solution, the standard 
curve was generated using 0-10 ng insulin/ml and there were 5 washes 
following addition of POD-conjugated antibody. The washing buffer comprises 
o f  phosphate buffered saline (PBS) powder and 20% Tween 20.
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Figure 2.1 Mouse leptin and insulin ELISA assay
1. Microplate well coated with a rabbit anti-mouse leptin (or mouse anti-insulin) 
antibody.
2. Leptin (or insulin) in the sample simultaneously binds to the rabbit anti­
mouse leptin (or mouse anti-insulin) antibody and the guinea pig anti-mouse 
leptin IgG (or guinea pig anti-insulin antibody).
3. POD-conjugated anti-guinea pig IgG antibody (no IgG in insulin assay) is 
binds to the guinea pig anti-mouse leptin IgG (or guinea pig anti-insulin 
antibody) complex immobilised on the microplate well.
4. TMB (or o-OPD) substrate solution is added and the absorbance measured 
(measuring wavelength: 450 nm, subtracting wavelength: 630 nm) to determine 
the mouse leptin concentration in the sample.
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(c) Pancreatic insulin ELISA
Analysis of pancreatic insulin by ELISA was essentially as described, 
except that 50 |uil of diluted sample (1:100 for AKR/J mice on the normal diet 
and C57B1/6 lean mice and 1:1000 for AKR/J mice on the palatable diet and 
C57B1/6 ob/ob mice) was added to 50 pi of the anti-insulin antibody, and the 
standards ranged from 0-2.5 ng/ml.
2.3.2 Rat leptin radioimmunoassay (RIAI
Rat leptin RIAs were performed in boro silicate glass tubes (12 X 75 
mm) and the assay procedure is described in table 2.1. The assay buffer 
consisted of 0.05M phosphosaline, pH 7.4, containing 0.025M EDTA, 0.08% 
sodium azide, 0.05% Triton X-100 and 1% RIA grade BSA. After the addition 
of the precipitating reagent, vortex and incubation for 20 minutes at 4°C, all the 
tubes (except total count tubes) were centrifuged at 2000-3000 xg for 20 
minutes at 4°C, where
xg = 1.11*10"^ (r) ((rpm)^ 
and r = radial distance in cm (from axis of rotation to the bottom of the tube), 
and r.p.m = rotation velocity of the rotor.
The supernatant was removed from all the tubes, except the total count 
tubes, by draining for 15-60 seconds. The tubes were counted in a gamma 
counter for 1 minute, and the concentration of rat leptin (ng/ml) was calculated 
in unknown samples from the standard curve using the gamma counters' 
processing data reduction capabilities.
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Table 2.1 Rat leptin radioimmunoassay procedure flow chart
This table describes the RIA method as a flow chart begiiming from left to right. 
(Abbreviations; NSB = Non-Specific Binding; QC = Quality Control)
53
C e n t r i f u g e ,  d e c a n t ,  a n d  c o u n t  p e l l e t .  
V o r t e x  a n d  i n c u b a t e  f o r  2 0  m i n u t e s  a t  4 ° C .
11 
& ■ 1-------------- ►1— 1
V o r t e x ,  c o v e r  a n d  i n c u b a t e  2 0 - 2 4  h o u r s ,  a t  R T
•3 .8
T— (
V o r t e x ,  c o v e r  a n d  i n c u b a t e  2 0 - 2 4  h o u r s ,  a t  R T
a i f '3. .' ' 8
t - H
If1 ^
l l l l l l l g g l l
1 9 .  "3 . "3 .'  i i § ----------- "
0 l i f l --------sslJ
 ^J ft'R 0 2 ^  ^  ^   ^  ^^  ^
2.3.3 Non-estenfied fatty acids (NEFAl
The NEFA C test kit utilises an in vitro enzymatic colorimetric method 
for the quantitation of NEFA. The enzymatic method relies upon the acylation 
of Coenzyme A (CoA) by the fatty acids in the presence of added acyl-Co A 
oxidase (ACOD) with concomitant generation of hydrogen peroxide. Hydrogen 
peroxide, in the presence of POD, permits the oxidative condensation of 3- 
methyl-N-ethyl-N-(p-hydroxyethyl)-aniline (MEHA) with 4-aminoantipyrine to 
form a purple coloured adduct, which can be measured using a 
spectrophotometer at 550 nm.
50 pi of the sample serum, standards and deionised water was pipetted 
into the appropriate tubes (see Table 2.2). All the tubes were added with 1.0 ml 
of Colour Reagent A [3 U /10 ml acy 1-coenzyme A synthetase (ACS), 30 U/10 
ml ascorbate oxidase (AOD), 7 mg/10 ml CoA, 30 mg/10 ml adenosine 
triphosphate (ATP), 3 mg/10 ml 4-aminoantipyrine, 0.05 mol/1 phosphate buffer 
pH 6.9, 3mmol/1 magnesium chloride, surfactant and stabilisers], mixed by 
inversion and incubated for 10 minutes at 37°C. A further 2.0 ml of Colour 
Reagent B [132 U/10 ml ACOD, 150 U/10 ml POD, 1.2 mmol/1 MEHA (3- 
methyl-N-ethyl-N-(p-hydroxyethyl)-aniline) and surfactant] was added to the 
tubes, which were then mixed and incubated for another 10 minutes at 37°C. 
The tubes were removed from the incubator and equilibrated to room 
temperature for 5 minutes. Finally, the optical density of all the tubes was read 
using a spectrophotometer at 550 nm versus the Reagent Blank (B).
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Table 2.2 Procedure outline for the measurement of NEFA
The table below describes the steps for the quantitative determination of NEFA 
in serum using the ACS-ACOD method.
S p e c i m e n S t a n d a r d
( S T D )
R e a g e n t  
B l a n k  ( B )
S a m p l e S e r u m  
5 0  p i
S t a n d a r d  
S o l u t i o n  
5 0  p i
D e i o n i s e d  
W a t e r  
5 0  p i
C o l o u r  R e a g e n t  A 1 .0  m l 1 .0  m l 1 .0  m l
M i x  w e l l  a n d  i n c u b a t e  a t  3 7 ° C  f o r  1 0  m i n u t e s
C o l o u r  R e a g e n t  B 2 .0  m l 2 .0  m l 2 . 0  m l
M i x  w e l l  a n d  i n c u b a t e  a t  3 7 ° C  f o r  1 0  m i n u t e s
S p e c t r o p h o t o m e t e r  
w i t h  f i l t e r  o f  5 5 0  
n m
M e a s u r e  t h e  o p t i c a l  d e n s i t y  o f  a l l  
t u b e s  v e r s u s  t h e  R e a g e n t  B l a n k  
( B )  a t  5 5 0  n m
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2.3.4 Glucose tolerance test
Glucose (3 g/kg in a volume not exceeding 10 ml/kg) was injected into 
mice after taking an initial blood sample (0 minutes). Further blood samples 
were then taken after 45 minutes, 90 minutes and 135 minutes. Blood samples 
(lOpl) were added to 0.5 ml of haemolysis reagent (50 mg/1 digitonin, 100 mg/1 
maleimide). Quantitative determination of blood glucose concentration was 
performed using a Unimate 5 Glucose HEC (hexokinase) in vitro diagnostic 
reagent system. The principle of the method is outlined in the following two 
reactions:
D-Glucose + ATP — — ---- ► D-Glucose-6-P + ADP
D-Glucose-6-P + NAD+ G6P-PH ^  D-gluconate-6-P + NADH + iT
The formation of NADH is directly related to the glucose concentration and is 
measured spectrophotometrically using the COBAS MIRA Plus analyser.
The area under the [blood glucose] versus time curve (glucose tolerance 
curve) was calculated trigonometrically using the trapezoid rule.
Area Under Curve (AUC) = (Gluo+(2*Glu45)+(2*Glu9o)+Glui35)*(ti/2) 
where Gluo...i35 is the blood concentration (mmol/1) at the various time points 
and ti is the time (minutes) between blood sampling.
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2.4 Extraction of total RNA
The TRIzol method of total RNA extraction was used for the 
hypothalamus, pituitary, WAT, BAT and small intestine. The guanidine 
thiocyanate method (Sparmann et a l, 1997) was used for total RNA extraction 
from the pancreas.
2.4.1 Extraction of total RNA using the TRIzol method
The tissue samples were homogenised in TRIzol reagent using 1 ml of 
TRIzol per 50 mg of tissue. 0.2 ml chloroform:isoamyl alcohol was added for 
each 1 ml TRIzol reagent used. The tubes were mixed by vortex for 10 seconds 
and left on ice for 5 minutes. Samples were then centrifuged at 14,000 rpm for 
15 minutes at 4°C. The resultant upper aqueous phase was transferred to a tube 
containing 0.5 ml isopropanol for each 1 ml TRIzol reagent used. The tubes 
were mixed and incubated at -20°C for 1 hour to precipitate the RNA before 
being centrifuged at 14,000 rpm for 20 minutes at 4°C to pellet the RNA 
precipitate. The supernatant was removed and the RNA pellet washed twice by 
adding 1 ml 75% ethanol for each 1 ml TRIzol Reagent used, centrifuging at 
14,000 rpm for 5 minutes at 4°C and removing the supernatant before repeating 
the procedure. The RNA pellet was air-dried and resuspended in DBPC water.
The quality of the RNA was tested by running 1 ql sample on a 1% 
agarose gel containing 0.5 pg/ml ethidium bromide (ETBr), which was 
visualised under U.V. light. An example of the quality of hypothalamic RNA 
from diet-induced obesity (DIO) mice extracted by the TRIzol method is shown
57
in figure 2.2(a). The RNA concentration was determined by measuring 
absorbance of 1:100 dilutions of samples at 280 and 260 nm using a 
SPECTRAmax Plus microplate spectrophotometer. Samples were stored at - 
80°C.
2.4.2 Extraction of pancreatic RNA using the Guanidine Thiocvanate 
method
The pancreas was removed and added to a guanidine buffer [10 ml 4 M 
guanidine thiocyanate, 25 mM sodium citrate pH 7 and 7 pl/ml |3- 
mercaptoethanol] and chilled on ice. The tissue was homogenised using a large 
Ultra Turrax dispersing tool for 10-20 seconds, after which 250 ql 20% N- 
laurylsarcosine was added and the sample mixed by swirling. The lysate was 
left on ice for 5 minutes, frozen on cardice in 0.7 ml aliquots and stored at - 
80°C.
When samples were ready to be processed, the lysate was thawed rapidly 
and shaken to dissolve the precipitated salt. All steps were performed at 0°C to 
+4°C to avoid RNA dénaturation. 0.1 volume of 2 M sodium acetate pH 4.2, 1 
volume of AquaPhenol and 0.3 volume of Ready Red chloroform/isoamyl 
alcohol was added to the lysate, with 10 seconds of vigorous shaking after each 
addition. Samples were placed on ice for 10 minutes, then centrifuged for 30 
minutes at 14,000 rpm. Approximately 75% of the resultant aqueous phase was 
removed and 0.1 volume sodium acetate, 1 volume AquaPhenol and 0.3 volume 
Ready Red was added and samples shaken and centrifuged as described above.
58
Following centrifugation, 50-75% of the aqueous phase was taken to a fresh 
sterile tube to which was added 0.075 volume 7.5 M ammonium acetate, 4 jal of 
15 mg/ml Glyco Blue and 1 volume isopropanol. The samples were mixed and 
centrifuged for 30 minutes at 14,000 rpm to collect the RNA pellet. The RNA 
pellet was washed once with 1 ml cold 100% ethanol and twice with 1 ml cold 
75% ethanol with samples centrifuged at 14,000 rpm for 5 minutes between 
each wash. The residual ethanol was removed by air-drying the RNA pellet for 
5 minutes before resuspending the RNA in DEPC water.
The quality of the RNA was tested by running 1 |al sample in a 1% 
agarose gel containing 0.5 |ig/ml ETBr, which was visualised under U.V. light. 
An example of the quality of pancreata RNA from DIO mice extracted by 
guanidine thiocyanate method is shown in figure 2.2(b). The RNA 
concentration was determined by measuring absorbance of 1:100 dilutions of 
samples at 280 and 260 nm using a SPECTRAmax Plus microplate 
spectrophotometer. Samples were stored at -80°C.
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Figure 2.2 Agarose gel of RNA extracted from hypothalami and pancreata 
of DIO mice
1 |il of RNA was run on a 1% agarose gel containing 0.5 p,g/ml ETBr at 100 V 
for 60 minutes
(a) RNA extracted by the TRIzol method from hypothalami of DIO mice
(b) RNA extracted by the guanidine thiocyanate method from pancreata of DIO 
mice
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2.5 TaaMan RT-PCR
The cDNA-specific 5' nuclease assay for quantitatively detecting RT- 
PCR products uses a nonextendable oligonucleotide hybridisation probe. The 
probe is labelled with a reporter fluorescent dye, 6-carboxyfluorescein (FAM), 
at the 5' end and a quencher fluorescent dye, 6-carboxytetramethylrhodamine 
(TAMRA), at the 3' end. When the probe is intact, the reporter dye emission is 
quenched due to the physical proximity of the reporter and quencher fluorescent 
dyes. During the extension phase of the PCR cycle, the nucleolytic activity of 
the DNA polymerase cleaves the hybridisation probe and releases the reporter 
dye from the probe (see figure 2.3). The resulting relative increases in reporter 
fluorescent dye emission was monitored in real time during PCR amplification 
using the 7700 Sequence Detector (Heid et a l, 1996).
The sequence detector is a combination thermal cycler, laser, and 
detection software system that automates 5' nuclease-based detection and 
quantitation of nucleic acid sequences. A computer algorithm compares the 
amount of reporter dye emission (R) with the quenching dye emission (Q) 
during the PCR amplification, generating a AR„ value (R/Q). The ARn value 
reflects the amount of hybridised probe that has been degraded. The algorithm 
fits an exponential function to the mean ARn values of the last three data points 
of every PCR extension cycle, generating an amplification plot. A relative 
fluorescent emission threshold was set, based on the baseline of the AR„ during 
the first 10-15 cycles. The algorithm calculates the cycle at which each PCR
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amplification reaches a significant threshold (usually 10 times the standard 
deviation of the baseline) (C t)  (Heid et al., 1996). Serial dilutions of a known 
quantity of cDNA were used to construct a standard curve relating threshold 
cycle to quantity of template cDNA. This standard curve was used to determine 
relative amounts of amplified cDNA in samples.
2.5.1 DNase treatment
RNA (2 qg) was added to a tube containing 2 pi DNase I Amp Grade 
and 2 pi lOX DNase I Reaction Buffer and in a final volume of 20 pi. The tube 
was then incubated for exactly 15 minutes at room temperature. The DNase I 
was then inactivated by adding 2 pi of 25 mM EDTA solution and heating the
tube for 10 minutes at 65°C. The total solution was divided into 2 sets of 10 pi 
each for reverse transcription (RT) and non-reverse transcription (non-RT) 
controls.
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Figure 2.3 Diagrammatic representation of the steps of a typical TaqMan 
reaction
1. The primers and probe anneal to the cDNA transcript. There is no
fluorescence because the reporter dye emission is quenched.
2. The primers are extended during the extension phase of the PCR cycle.
3. The 5-3' exonuclease activity of the DNA polymerase cleaves the
hybridised probe and releases the reporter dye emission resulting in an
increase in reporter fluorescent dye emission.
4. The primers continue to be extended until polymerisation of the amplicon is 
complete
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2.5.2 cDNA synthesis
The 10 pi of total RNA solution was combined with 1 pi 500 ng/pl 
random 9 mers in a MicroAmp optical 96-well reaction plate and sealed with 
optical caps. The RNA was denatured by incubation for 15 minutes at 70°C on 
a Peltier Thermal Cycler (PTC-225), then immediately chilled on ice for 5 
minutes before a brief centrifugation in a bench-top centrifuge. 9 pi of a reverse 
transcription master mix [4 pi 5X First Strand Buffer; 2 pi 0.1 M DTT; 1 pi of 
40 U/pl RNaseOUT ribonuclease inhibitor; 1 pi 10 mM dNTP Mix (10 mM 
each dATP, dGTP, dCTP and dTTP at neutral pH] and 1 pi 200 U/pl 
Superscript II reverse transcriptase or 1 pi DBPC-water for non-RT controls was 
then added to appropriate wells. The plate was sealed using optical caps, 
samples mixed by inversion and then centrifuged briefly. The microplate was
subsequently incubated using the PTC-225 for 15 minutes at 25°C, then for 50
minutes at 42°C to reverse transcribe the RNA. The reaction was inactivated by
heating for 15 minutes at 70°C. The microplate was briefly centrifuged and the 
cDNA volume was made up to 100 pi by the addition of 80 pi of sterile water.
2.5.3 TaaMan PCR
TaqMan PCR was carried out on the cDNA samples using an ABI Prism 
7700 sequence detector in a 25 pi reaction consisting of TaqMan Universal PCR 
Master Mix [IX TaqMan buffer, 8% glycerol, 0.2 mM dATP, dCTP, dGTP and 
dUTP, 5.5 mM MgCL, 0.025 U/pl Amplitaq Gold DNA polymerase and 0.01
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u/pl Amp Erase uracil-N-glycosylase], 300 nM of each primer, 100 nM 
TaqMan probe. Each sample was covered with 20 pi mineral oil. Cycle 
conditions were 50°C for 2 minutes, 95°C for 10 minutes followed by 40 cycles 
of 95°C for 15 seconds, 60°C for 1 minute. Known quantities of mouse brain 
poly A cDNA was used for standard curves for all tissues except the pancreas, 
where mouse pancreas poly A cDNA was used in order to construct a standard 
curve relating Ct to template amount.
2.5.4 Design of TaaMan primers and probes for OB-Ra and QB-Rb
TaqMan primer and probe sequences for all genes (Table 2.3) were 
designed from sequences in the Genbank database using Primer Express 
software. A number of important guidelines were followed by this program in 
order to design suitable TaqMan assays:
• a difference of at least 10°C in the Tm of primers and probes
• the 5' end of the probe must not start with a guanosine (G) nucleotide
• the primers and probes must be approximately 50% guanosine, cytosine
(GC) rich
• the ideal amplicon size is around 100 bp and should not exceed 150 bp.
Since the leptin receptor isoforms occur as a result of alternative
splicing, the assay was designed such that the forward primer and probe are 
common to both OB-Ra and OB-Rb, but the reverse primers span the last 
intracellular splice site. Thus the RT-PCR is specific for OB-Ra or OB-Rb 
(Figure 2.4).
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Figure 2.4 Illustration of OB-Ra and OB-Rb TaqMan assay design
(a) Alternative splicing of the leptin receptor.
Exons are illustrated as boxes and introns by solid lines. The clear boxes 
coiTespond to translated exon sequences, and the dark boxes to 3'-untranslated 
sequences. Alternative splicing results in transcripts that encode either
OB-Ra ( ------------- )o r
OB-Rb (-------------  ).
(b) Design of OB-Ra and OB-Rb primers and probe
The forward primer and probe are common to both forms of the leptin receptor, 
but the reverse primer spans the exon splice site between the penultimate and 
the final exon, thus specifically amplifying either OB-Ra or OB-Rb.
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2.5.5 Primer and probe optimisation 
W  Primer optimisation
The purpose of this procedure was to determine the minimum primer 
concentrations giving the maximum ARn. To determine the optimal primer 
concentration, a PCR reaction mix was prepared such that at least three or four 
replicates of each of the nine conditions shown in Table 2.4 were performed.
The PCR reaction mix for primer optimisation (25 |al) consisted of IX 
TaqMan Universal PCR Master Mix, 50-900 nM forward and reverse primer, 
200 nM TaqMan probe and 25 ng of genomic DNA or mouse brain polyA 
cDNA (for OB-Ra and OB-Rb primer optimisation). The cycling conditions 
were as described in 2.5.3. At the end of the run, the results were tabulated for 
ARn- The minimum forward and reverse primer concentrations that yielded the 
maximum ARn were used for future experiments.
Table 2.4 Combinations of forward and reverse primer for primer 
optimisation
Fomard Primer (nM)
Reverse 
Primer (nM) 50 300 900
50 50/50 300/50 900/50
300 50/300 300/300 900/300
900 50/900 300/900 900/900
6 8
tbi Probe optimisation
The purpose of this procedure was to determine the minimum probe 
concentrations that give the minimum Ct for each probe target. To determine 
the optimal probe concentration, a PCR reaction mix was prepared such that 
three or four replicates at 25 nM intervals from 25-225 nM were performed, 
using the optimal forward and reverse primer concentrations as determined in
2.5.5 in the reaction mix.
The PCR reaction mix for probe optimisation (25 |l i 1)  consisted of IX 
TaqMan Universal PCR Master Mix, optimal forward and reverse primer 
concentrations, 25-225 nM TaqMan probe and 25 ng of genomic DNA or 
mouse brain poly A cDNA (for OB-Ra and OB-Rb primer optimisation). The 
cycling conditions were as described in 2 .5 .3 . At the end of the run, the results 
were tabulated for C t . The minimum forward and reverse primer 
concentrations that yielded the minimum Cx were used for further experiments.
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fc) optimal primer and probe concentrations
From the optimisation experiments described above, the primer and 
probe concentrations used in RT-PCR are listed in Table 2.5.
Table 2.5 Optimal primer and probe concentrations used for TaqMan 
analysis
Transcript Forward 
Primer (nM)
Reverse 
Primer (nM)
TaqMan 
Probe (nM)
OB-Ra 900 50 200
OB-Rb 900 50 200
STAT3 300 300 100
STAT5 300 300 100
SOCS-3 300 300 100
CIS 300 300 100
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2.6 Statistical analysis
Analysis of individual genes (both test and housekeeper) was performed 
by independent t-test on log transformed data (base 10). Differences between 
treatment means were calculated along with the standard error for the difference 
between means (sed). These were used in both the calculation of 95% 
confidence intervals (95%CI) for the difference and the t-statistic 
(difference/sed). The p-value for each t-statistic was calculated and the 
difference and 95%CI for the difference were back-transformed to the quantity 
scale to calculate fold-differences (the ratio of geometric means) and the 95%CI 
for the fold difference.
For each sample the ratio of test to housekeeper was calculated for every 
combination of test and housekeeping gene. Each ratio was analysed by 
independent t-tests. Differences between treatment means, 95%CI, t-statistic 
and p-value were calculated for each gene. The ratios were log transformed 
(base 10) and again submitted to an independent t-test. The same statistics were 
calculated as in the analysis of individual genes.
Analysis of the test genes was performed by an analysis of covariance 
(ANOCOVA) using, in turn, each one of the 4 housekeeping genes as a 
covariate. Post-hoc comparisons were performed using the t-test. The same 
statistics were calculated as in the analysis of individual genes. However, the 
sed was based on the residual mean square of the ANOCOVA and covariate 
efficiency factors for both the treatment and residual were calculated.
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Chapter 3
Quantitative Expression of Genes Involved in 
the Leptin Receptor-Mediated STAT 
Signalling Pathway in the Hypothalamus and 
Pituitary of Diet-Induced and Genetically
Obese Mice
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3.1 Introduction
3.1.1 Hypothalamus
Most cases of human obesity are characterised by elevated serum leptin 
levels, leading to the suggestion that reduced sensitivity to endogenous leptin 
contributes towards the increase in body weight. Potential sites involved in 
central leptin insensitivity include the blood-brain-barrier transport system 
(Caro et a l, 1996; Schwartz et a l, 1996b), reductions in functional long-form 
leptin receptor expression (Martin et a l, 2000) and changes in expression of 
components of the leptin signalling mechanism in leptin-responsive neurons in 
the hypothalamus (Vaisse et a l, 1996).
Mice that become obese as a result of feeding on a high-fat diet become 
hyperleptinaemic and do not reduce their food intake or body weight in response 
to peripheral administration of leptin (Van Heek et a l, 1997; Widdowson et a l, 
1997). However, these mice remain sensitive to central leptin administration 
suggesting a defective blood-brain-barrier transport system, which may 
therefore prevent leptin accessing the hypothalamus to affect food intake and 
body weight (Van Heek et a l, 1997; Widdowson et a l, 1997). The molecular 
mechanism for the apparent defect in central leptin access or transport involves 
the short OB-Ra isoform, which, as mentioned in Chapter 1, is highly expressed 
within the blood-brain barrier (Bjorbaek et a l, 1998a). A recent report by 
Maness et a l showed no change in leptin transport across the BBB in ob/ob (no 
leptin production) and db/db (high leptin levels, but no OB-Rb) mice compared 
to lean controls (Maness et a l, 2000). This suggests impaired leptin transport is
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not a result of obesity where animals are leptin-sensitive or where elevated 
levels of circulating leptin occur.
However, it has been found that DIO mice have alterations in central 
leptin sensitivity. Mice fed a high-fat diet for 19 weeks, have reduced central 
leptin sensitivity, compared to those fed a high-fat diet for 8 weeks (Lin et a l, 
2000). The mechanism causing this central leptin insensitivity is unclear, but it 
has been suggested that desensitisation of the hypothalamic leptin receptor or 
saturation of the receptors with high levels of endogenous leptin may have 
occurred (Lin et a l, 2000; Widdowson et a l, 1997). Leptin insensitivity could 
also occur through leptin receptor downregulation as observed by Martin et a l 
(Martin et a l, 2000), or disruption of leptin-mediated signal transduction.
In some cases of human obesity a mutation in the ob gene results in 
reduced levels of circulating leptin, hyperphagia and obesity. Due to the lack of 
circulating leptin, the ob/ob mice are hypersensitive to exogenous leptin and 
have significantly reduced body weight after the administration of exogenous 
leptin. These mice have been instrumental in the elucidation of the leptin- 
mediated signalling pathway. Peripheral leptin administration to normal and 
ob/ob mice rapidly induces hypothalamic leptin receptor-mediated signalling 
through the JAK/STAT pathway, primarily through STATS (Vaisse et a l,
1996). Negative regulation of STATS was found to occur in the hypothalamus 
through induction of SOCS-3 but not CIS mRNA after an hour of exogenous 
leptin treatment (Bjorbaek et a l, 1998b). However, an increase in both SOCS-3
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and CIS mRNA in the hypothalamus was reported following peripheral leptin 
administration for 48 hours (Emilsson e ta l ,  1999).
3.1.2 Pituitary
There are various studies that implicate leptin in anterior pituitary 
function. Yu et a l first reported that leptin controlled gonadotropin secretion in 
the anterior pituitary (Yu et a l, 1997a) and stimulated nitric oxide release from 
the anterior pituitary (Yu et a l, 1997b). Zamorano et a l (Zamorano et a l,
1997) showed that the leptin receptor was expressed in the rat anterior pituitary 
by RT-PCR, whereas other investigators reported that growth hormone (GH) 
and/or growth hormone releasing hormone (GHRH) increased the leptin 
receptor gene expression in human GHRH transgenic mice (Cai & Hyde, 1998). 
Leptin deficiency in humans, due to a homozygous mutation in the human leptin 
receptor gene that results in a truncated leptin receptor lacking both the 
transmembrane and the intracellular domains, has been associated with early- 
onset obesity and pituitary dysfunction (Clement et a l, 1998). This observation 
emphasises the important role of leptin in pituitary function. Moreover, the 
recent localisation of leptin receptor isoforms in human, mouse and rat 
pituitaries by RT-PCR and in situ hybridisation suggest a functional role of 
leptin in the pituitary (Jin et a l, 1999; Jin et a l, 2000). Indeed, leptin inhibits 
the proliferation of human and rat anterior pituitary cell lines in vitro, which 
suggests leptin is important in the growth and differentiation of anterior
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pituitary cells. Few studies have looked at gene expression changes of leptin 
receptor-mediated signalling components in the pituitary.
In summary, changes in central leptin sensitivity may be manifest at 
several levels, not only in the blood-brain transport system, but also at the 
receptor level or in further downstream pathways. In this study I have 
investigated the quantitative expression of genes involved in the leptin receptor- 
mediated STAT signalling pathway in different models of obesity using an RT- 
PCR technique involving a double-labelled fluorescent probe. I have compared 
the expression of genes in the hypothalamus and pituitary of palatable diet-fed 
AKR/J mice compared to chow-fed mice and also in the leptin-sensitive 
genetically obese C57BL/6 ob/ob mice relative to lean controls. In this way I 
hope to clarify how changes in central expression of the leptin receptor or 
downstream signalling components may alter with obesity and leptin sensitivity.
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3.2 Results
3.2.1 Body weights
The body weights of the mice were monitored for the duration of the 14 weeks 
and are shown in Figure 3.1. The lean (+/?) mice in both groups showed a 
small, but steady, increase in body weights. However, a sharper increase in 
body weight was observed for the AKR/J mice fed a palatable diet and C57BL/6 
ob/ob mice. At the end of the study, the palatable diet-fed AKR/J mice weighed 
40.25 + 3.42 g compared to 27.65 ± 1.02 g for the chow-fed AKR/J mice, and 
the ob/ob mice weighed 54.25 ± 0.96 g compared to 22.86 ± 0.48 g for lean 
controls.
3.2.2 Leptin, insulin and NEFA
Leptin, insulin and NEFA concentrations were determined from terminal 
blood samples of all the groups and are shown in Table 3.1. Leptin levels were 
significantly elevated by about 16-fold in palatable diet-fed AKR/J mice 
compared to AKR/J mice fed a normal chow diet (P<0.05). There was no 
detectable leptin in ob/ob mice. There was no significant difference in insulin 
levels in diet-induced obese mice compared to those on a normal diet, whereas 
the ob/ob mice had a 4.8-fold elevation in insulin compared to C57BL/6J mice 
(P<0.05). NEFA levels in AKR/J mice fed a palatable diet and ob/ob mice fed a 
chow diet were significantly increased by 31% and 30% compared to AKR/J 
mice and C57BL/6J +/? mice fed a chow diet, respectively (P<0.01).
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Figure 3.1 Changes in body weight of AKR/J mice fed a palatable diet and 
C57BL/6 ob/oh mice
Effect of feeding a normal or palatable diet on the body weight of obesity-prone 
AKR/J mice and a normal diet on C57BL/6J lean and ob/ob mice for 14 weeks. 
■  AKR/J mice fed a normal diet 
□  AKR/J mice fed a palatable diet 
® C57BL/6 lean mice fed a normal diet 
O C57BL/6 ob/ob mice fed a normal diet
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Table 3.1 Leptin, insulin and NEFA levels in terminal blood samples of 
AKR/J mice fed either a chow or palatable diet, and C57BL/6 lean and 
ob/ob mice fed a chow diet for 14 weeks
Leptin, insulin and NEFA concentrations in terminal blood samples of AKR/J 
mice fed a chow or palatable diet for 14 weeks, and C57BL/6 lean and ob/ob 
mice fed a chow diet were measured by ELISA. Leptin was not detectable 
(ND) in ob/ob mice. Leptin, insulin and NEFA values are represented as mean 
± S.E.M in ng/ml or mmol/1. * P<0.05 **P<0.01
Group Leptin
(ng/ml)
Insulin
(ng/ml)
NEFA
(mmol/1)
AKR/J +/? 
chow diet
7 ±  1 1 0.09 ± 0.01
AKR/J +/? 
palatable diet
117 ±49=" 1 0.13 ±0.01**
C57BL/6J +/? 
chow diet
3 ±  1 2 0.08 ± 0.01
C57BL/6J ob/ob 
chow diet
ND 12 ±2* 0.11 ±0.01**
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3.2.3 Glucose tolerance test
In order to determine whether the animals had developed glucose 
intolerance, glucose tolerance tests were performed as described in section 
2.3.4. The area under the curve for AKR/J mice fed a palatable diet was 
significantly increased by 14% compared to that of AKR/J mice on a normal 
chow diet indicating a small decrease in glucose tolerance (P<0.05). Figure 3.2 
shows that the ob/ob mice were glucose intolerant, which is represented by the 
36% increase in area under the hyperbolic curve compared to that of C57BL/6J 
+/? lean mice (P<0.01).
3.2.4 Changes in gene expression in the hypothalamus
TaqMan analysis of gene expression in the hypothalamus was adjusted 
for hypoxanthine phosphoribosyItransferase (HPRT) expression to reduce 
sample variability (see Appendix 1). The expression of OB-Ra and OB-Rb 
mRNA in AKR/J mice fed a palatable diet compared to chow and ob/ob 
compared to lean mice is shown in figure 3.3 (a). OB-Ra mRNA expression 
was significantly reduced by 40% (P<0.05) in AKR/J mice fed a palatable diet 
compared to chow-fed mice. There was no significant change in either OB-Ra 
or OB-Rb mRNA expression in the hypothalamus of ob/ob mice compared to 
lean control mice. However, comparison of the two lean mice strains showed 
that there was a 66% higher level in OB-Ra mRNA in the hypothalamus of 
AKR/J lean mice compared to C57BL/6 lean mice, fed on a chow diet for 14 
weeks.
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Figure 3.2 Glucose tolerance test
Blood was taken from the tail of mice at 45-minute intervals from 0 to 135 
minutes after injection of glucose, in order to measure blood glucose 
concentrations.
(a) A plot of blood glucose concentrations at 0, 45, 90 and 135 minutes from the 
time of glucose injection, expressed as mean ± S.E.M. mmol/1.
■  AKR/J mice fed a normal diet 
□  AKR/J mice fed a palatable diet 
® C57BL/6 lean mice fed a normal diet 
O C57BL/6 ob/ob mice fed a normal diet
(b) The area under the curve of each group following the glucose tolerance test, 
expressed as mean ± S.E.M. mmol/1. * P<0.05 or ** P<0.01.
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Figure 3.3 Changes in gene expression of components of the leptin receptor- 
mediated signalling pathway in the hypothalamus of AKR/J mice fed either 
a chow or palatable diet, and C57BL/6 lean and ob/ob mice fed a chow diet
A comparison of gene expression changes are shown in the hypothalamus of 
AKR/J mice fed a palatable diet compared to those fed a chow diet, C57BL/6 
ob/ob compared to leans on a chow diet and AKR/J lean mice compared to 
C57BL/6 lean mice. Following TaqMan analysis, the mRNA levels for the 
control animals have been ascribed a value of 1 and the symbols indicate 
relative changes from this baseline (as described in Appendix 1). Error bars 
indicate 95% confidence intervals and changes are shown as significant where * 
P<0.05 and ** P<0.01.
(a) ® OB-Ra mRNA 
□  OB-Rb mRNA
(b) •  STAT3 mRNA 
O STAT5 mRNA
(c) A SOCS-3 mRNA 
A CIS mRNA
(d) ♦  NPYmRNA
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The expression of STATS and STATS mRNA in AKR/J mice fed a 
palatable diet compared to chow and ob/ob compared to lean mice is shown in 
figure 3.3 (b). In the hypothalamus of ob/ob mice, STATS mRNA was reduced 
by 27% (P<0.05) compared to lean controls although no changes were observed 
in AKR/J mice. On the other hand, STATS mRNA expression was reduced by 
24% (P<0.01) in the hypothalamus of AKR/J mice fed a palatable diet 
compared to those fed a chow diet, but there was no change in ob/ob mice 
compared to leans.
The expression of SOCS-3 and CIS mRNA in AKR/J mice fed a 
palatable diet compared to chow and ob/ob compared to lean mice is shown in 
figure 3.3 (c). The only significant difference was a 20% decrease of SOCS-3 
expression in ob/ob mice compared to lean controls (P<O.OS). There was no 
significant change in NPY expression in the hypothalamus of any of the group 
comparisons (Figure 3.3 (d)).
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3.2.5 Changes in gene expression in the pituitary
TaqMan analysis of gene expression in the pituitary was adjusted for 
cyclophilin expression to reduce sample variability (see Appendix 1). The 
changes in expression of genes involved in leptin receptor-mediated signalling 
are shown in figure 3.4. In the pituitary of AKR/J mice fed a palatable diet 
compared to chow, there were no significant changes in OB-Ra, OB-Rb, 
STAT3, STATS, SOCS-3 or CIS mRNA expression compared to AKR/J mice 
fed a chow diet. However, in the pituitary of ob/ob mice compared to leans, 
OB-Rb mRNA was reduced by 55% (P<0.01) whereas OB-Ra mRNA remained 
unchanged. A comparison of AKR/J and C57BL/6 lean mice demonstrated an 
increase in OB-Ra and OB-Rb mRNA expression of 110% (P<0.01) and 67% 
(P<0.05), respectively, in AKR/J lean mice (Figure 3.4a). The expression of 
STAT3 and STATS mRNA was reduced in the pituitary of ob/ob mice 
compared to leans by 41% (P<0.05) and 61% (P<0.01), respectively. Moreover, 
STATS mRNA was increased by 51% increase (P<O.OS) in the pituitary of 
AKR/J lean mice compared to CS7BL/6 lean mice (Figure 3.4b). The 
expression of SOCS-3 mRNA was reduced by 53% (P<0.05) in the pituitary of 
ob/ob mice compared to leans and increased by 140% (P<0.05) in AKR/J lean 
mice compared to C57BL/6 lean mice (Figure 3.4c). However, there was no 
change in the expression of CIS mRNA in comparing ob/ob and lean mice or 
the AKR/J and C57BL/6 lean mice.
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Figure 3.4 Changes in gene expression of components of the leptin receptor- 
mediated signalling pathway in the pituitaiy of AKR/J mice fed either a 
chow or palatable diet, and C57BL/6 lean and ob/oh mice fed a chow diet
A comparison of gene expression changes are shown in the pituitary of AKR/J 
mice fed a palatable diet compared to those fed a chow diet, C57BL/6 ob/ob 
compared to leans on a chow diet and AKR/J lean mice compared to C57BL/6 
lean mice. Following TaqMan analysis, the mRNA levels for the control 
animals have been ascribed a value of 1 and the symbols indicate relative 
changes from this baseline (as described in Appendix 1). Error bars indicate 
95% confidence intervals and changes are shown as significant where * P<0.05 
and ** P<0.01.
(a) ® OB-Ra mRNA 
□  OB-Rb mRNA
(b) •  STATS mRNA 
O STAT5 mRNA
(c) A SOCS-3 mRNA 
A CIS mRNA
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3.3 Discussion
3.3.1 Hypothalamus
Leptin is thought to act primarily on the hypothalamic nuclei that are 
associated with the control of feeding and energy expenditure (Baskin et al., 
1999; Schwartz et a l, 1996a). The aim of the study presented in this chapter 
was to investigate whether changes in central expression of the leptin receptor 
or leptin-mediated signalling components may alter with obesity, either 
following feeding of a palatable diet in which leptin levels are high, or in a 
genetically obese, leptin sensitive model, in which there is no leptin.
As a result of feeding AKR/J mice a palatable diet, there was an increase 
in body weight and food consumption, elevated serum levels of leptin and 
NEFA, unchanged plasma insulin levels and a small but significant decrease in 
glucose tolerance compared to AKR/J mice fed a normal chow diet. In the 
hypothalamus, OB-Ra mRNA was reduced in AKR/J mice fed a palatable diet 
compared to mice fed a chow diet but OB-Rb mRNA remained unchanged. 
Expression in the BBB was not measured in this study and as a result, 
conclusions regarding potential effects on leptin transport cannot be made. The 
leptin receptor is known to form homo-oligomers, however OB-Rb signalling 
may be reduced by the overexpression of OB-Ra, a homo-dimerising partner 
that does not signal via the JAK-STAT pathway (White et a l, 1997a). In vitro 
studies have observed that OB-Rb shows very weak dominant negative 
repression in the presence of excess OB-Ra (White et a l, 1997a). However, it 
is unclear if there is any effect exerted in vivo in the hypothalamus. Thus,
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whether the reduction in hypothalamic OB-Ra observed in AKR/J mice has a 
functional effect on OB-Rb signalling remains to be determined.
A number of investigations have shown an increase in leptin receptor 
expression in the hypothalamus of ob/ob mice compared to lean controls 
(Baskin et a l, 1998; Bmilsson et a l, 1999; Huang et a l, 1997), Huang et a l 
observed a 2-fold increase in all isoforms of the leptin receptor in the arcuate 
and ventromedial nuclei of ob/ob mice compared to lean controls by in situ 
hybridisation (Huang et a l, 1997). Also, using in situ hybridisation Baskin et 
a l reported a 2-fold increase in OB-Rb mRNA in the arcuate nucleus of ob/ob 
mice compared to lean controls by in situ hybridisation (Baskin et a l, 1998). 
Furthermore, Emilsson et a l showed a 2-fold increase of total leptin receptor 
mRNA expression relative to P-actin mRNA expression by RT-PCR in the 
whole hypothalamus of ob/ob mice compared to lean controls (Emilsson et a l, 
1999). It was therefore surprising that we observed no increase in OB-Ra or 
OB-Rb mRNA expression in the hypothalamus of ob/ob mice compared to lean 
controls. The exact reason for this is unclear, but could be because these 
changes are not evident in the whole of the hypothalamus. Although Emilsson 
et a l observed changes in the whole hypothalamus using RT-PCR, their data 
was expressed as a ratio to P-actin mRNA expression (Emilsson et a l, 1999). 
Appendix 1 includes a discussion of the use of housekeeping in the analysis of 
gene expression.
Little is known about the mRNA expression profile of leptin receptor- 
mediated signalling components in different strains. There was a significant
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increase in OB-Ra mRNA in the hypothalamus of AKR/J lean mice compared 
to C57BL/6 lean mice; however there was no change in OB-Rb mRNA. The 
only notable difference between these two strains is that the AKR/J mice gain 
more weight in comparison to the C57BL/6 as a result of being fed a high fat 
diet (communicated by Mohammad Tadayyon). Perhaps this is manifest in part 
by the different physiological characteristics of AKR/J lean mice compared to 
C57BL/6 lean mice, notably the increased body weight and leptin.
Reduced expression of STAT5 mRNA was observed in the 
hypothalamus of AKR/J mice fed a palatable diet compared to mice on a chow 
diet, but not in ob/ob mice compared to lean mice. However, as only leptin- 
mediated STATS activation in the hypothalamus has been demonstrated (Vaisse 
et a l, 1996), the effect of changes in STAT5 on the leptin signalling pathway 
per se is unclear. A decrease in STATS mRNA expression may reflect changes 
in the expression of as yet unidentified signals that are activated by STATS in 
the hypothalamus.
El-Haschimi et a l showed reduced STATS activation by electrophoretic 
mobility shift assays (EMSA) in the hypothalamus of mice fed a high-fat diet 
for 1S weeks (El Haschimi et a l , 2000). However, they were unable to detect a 
change in hypothalamic mRNA expression of OB-Rb, STATS or SOCS-S in 
mice fed a low-fat or high-fat diet for IS weeks (El Haschimi et a l,  2000). In 
the hypothalamus of ob/ob mice, we have observed reduced STATS mRNA 
expression compared to lean mice. The reduced STATS mRNA expression in 
the hypothalamus of ob/ob mice has previously been observed at comparable
8 8
levels by Hakansson-Ovesjo et a l (Hakansson-Ovesjo et a l, 2000), who also 
showed reduced STATS protein expression and localised the changes in 
expression to the arcuate nucleus. This suggests that the absence of functional 
leptin in ob/ob mice results in downregulation of STATS mRNA and 
consequently also of STATS protein levels.
The observation that SOCS-S gene expression is STATS-dependent and 
is negatively autoregulated by SOCS-S protein (Auernhammer et a l, 1999), 
may explain the reduced SOCS-S mRNA observed in the hypothalamus of 
ob/ob mice compared to lean controls, assuming the reduced levels of STATS 
and SOCS-S mRNA is an indication of reduced levels of activated protein. 
However, Emilsson et a l showed an approximate 2-fold increase of SOCS-3 
and CIS mRNA expression in the hypothalamus of leptin-sensitive ob/ob mice 
(Emilsson et a l, 1999), which is inconsistent with the proposed role of these 
genes as suppressors of cytokine signalling. The authors suggested that the 
increase in SOCS-S and CIS may be counteracted by the observed 2-fold 
increase in OB-R mRNA in the ob/ob hypothalamus.
In agreement with the diet-induced obesity study of El-Haschimi et a l 
(El Haschimi et a l, 2000), no change in the suppressor of STAT signalling 
SOCS-S was observed in AKR/J mice fed a palatable diet. Bjorbaek et a l 
demonstrated that acute (between 1-3 hour) peripheral leptin administration 
induced SOCS-S mRNA expression in the hypothalamus of ob/ob mice, but had 
no effect on SOCS-1, SOCS-2 or CIS mRNA expression (Bjorbaek et a l, 
1998b). Emilsson et. a l showed that peripheral leptin administration of lean
89
mice, over a period of 48 hours, induces both SOCS-3 and CIS mRNA 
expression in the hypothalamus (Emilsson et a l, 1999). Our findings suggest 
that in AKR/J mice fed a palatable diet, the elevated leptin levels does not 
induce SOCS-3 and reduction in leptin sensitivity is not at the level of SOCS-3. 
As described, based on the time- and dose-dependent leptin treatment of mice, 
there are conflicting reports of whether CIS is involved in leptin signalling in 
the hypothalamus (Bjorbaek et a l, 1998b; Emilsson et a l, 1999). In my study, 
there appeared to be no effect on CIS mRNA expression in the hypothalamus as 
a result of high-fat feeding or in ob/ob mice compared to leans.
3.3.2 Pituitaiy
In the pituitary of AKR/J mice fed a palatable diet, there were no 
changes in leptin receptor-mediated signalling components, indicating that the 
elevated serum leptin levels and obesity does not affect leptin signalling in the 
pituitary, Conversely, in the pituitary of ob/ob mice, OB-Rb, STAT3, STAT5 
and SOCS-3 were all reduced. There are no studies that compared leptin 
receptor-mediated signalling components in the pituitary of mouse models of 
obesity. In the pituitary of ob/ob mice, it is evident that the lack of circulating 
plasma leptin results in reduced leptin receptor-mediated signalling components, 
which may, in part, be responsible for the infertility and prepubertal 
gonadotropin secretion pattern observed in these mice. Furthermore, there is 
increasing evidence of the importance of leptin receptor-mediated signalling in 
the functioning of the pituitary. For example, the chronic treatment of ob/ob
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mice with leptin can induce recovery in the reproductive system by promoting 
growth and function of the reproductive organs and fertility by increasing 
secretion of gonadotropins (Barash et a l, 1996; Chehab et a l, 1996). In 
addition, it has been observed that humans with a mutation in the leptin receptor 
gene have a dysfunctional pituitary (Clement et a l, 1998).
A comparison of leptin receptor-mediated signalling components in the 
pituitary of AKR/J lean compared to C57BL/6 lean mice shows that the mRNA 
expression of OB-Ra, OB-Rb, STAT5 and SOCS-3 are significantly increased. 
These changes may be a result of differences in circulating leptin, or perhaps 
other factors, which may affect expression of leptin receptor-mediated 
signalling components in the pituitary. For instance, GH and prolactin are 
known to activate STATS, and SOCS-3 can inhibit GH-induced STATS 
dependent transcription in transfected COS cells (Gouilleux et a l, 199S; Ram & 
Waxman, 1999). The localisation of the changes in leptin receptor-mediated 
signalling components to pituitary cell types would give a further indication of 
the factors that may regulate these changes.
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3.4 Conclusion
In summary, of all the leptin receptor-mediated signalling components 
analysed in AKR/J mice fed a palatable diet, only OB-Ra and STATS mRNA 
were reduced in the hypothalamus and no changes were observed in the 
pituitary. This suggests that leptin signalling in diet-induced obese mice are not 
primarily regulated at the level of leptin receptor signalling components 
investigated in the hypothalamus or pituitary. In ob/oh mice, STAT3 and 
SOCS-3 mRNA were reduced in both the hypothalamus and the pituitary, 
whereas OB-Rb and STATS mRNA were attenuated in the pituitary, indicating 
downregulation of key leptin receptor-mediated signalling components, which 
may contribute to the sensitivity of leptin in these mice. Finally, a comparison 
of AKR/J and CS7BL/6 lean mice showed that some of the leptin receptor- 
mediated signalling components in the hypothalamus and pituitary were 
increased in AKR/J mice, suggesting that the regulation of leptin responses in 
the hypothalamus and pituitary may be controlled in a tissue and strain-specific 
manner.
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Chapter 4
Quantitative Expression of Genes Involved in 
the Leptin Receptor-Mediated STAT 
Signalling Pathway in Peripheral Tissues of 
Diet-Induced and Genetically Obese Mice
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4.1 Introduction
The short form of the leptin receptor was initially identified in the 
choroid plexus and hypothalamus, but several differentially expressed splice 
variants were subsequently detected in various other tissues (Chen et a l, 1996; 
Ghilardi et a l, 1996; Lee et al., 1996; Tartaglia et a l, 1995). OB-Ra is 
expressed in many tissues and although the OB-Rb isoform is highly expressed 
in the hypothalamus and the lymphoid system, small amounts of OB-Rb mRNA 
have also been demonstrated in many other tissues, including pancreatic p-cells, 
WAT, BAT and the small intestine (Emilsson et a l, 1997; Ghilardi et a l, 1996; 
Kutoh et a l, 1997; Morton et a l, 1998). This suggests that leptin has direct 
physiological effect in these tissues, facilitating the regulation of feeding and 
maintaining energy balance.
4.1.1 Pancreas
4.1.1.1 Leptin receptor expression
The OB-Rb isoform of the leptin receptor is expressed in the pancreatic 
P-cells that produce insulin, raising the possibility that leptin directly regulates 
insulin release (Kieffer et a l, 1996). Using a probe common to all leptin 
receptor isoforms, Kieffer et al. (Kieffer et a l, 1996) showed that the leptin 
receptor mRNA was detected in rat islets in greater abundance than in total 
brain. Furthermore, of 21 tissues examined by sensitive RNase protection 
assay, the pancreas appeared to have the most abundant proportion of OB-Rb 
mRNA relative to OB-Ra mRNA of all the peripheral tissues examined. The
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expression of OB-Ra and OB-Rb in pancreatic p-cells has since been confirmed 
by a number of groups (Briscoe et a i, 2001a; Emilsson et a l, 1997; Islam et a l, 
1997; Kieffer et a l, 1997; Kulkarni et a l, 1997; Pallett et a l, 1997; P oit out et 
a l,  1998; Tanizawa et a l, 1997; Zhao et a l, 1998).
4.1.1.2 Effect of leptin on insulin synthesis and release
The first evidence of OB-Rb-mediated leptin action on pancreatic islets 
was the observation that leptin reduced plasma insulin levels in the leptin- 
deficient ob/ob mice but not in the leptin signalling defective db/db mice 
(Emilsson et a l, 1997; Kulkarni et a l, 1997). Since insulin is adipogénie and 
stimulates leptin secretion from WAT there appears to be a bidirectional 
adipoinsular axis (Kieffer et a l, 1996).
The ob/ob mice are hypersensitive to the feeding effects of leptin 
treatment due to the lack of circulating leptin and as a result have been 
instrumental in determining the effects of leptin on insulin secretion. In 
contrast, the P-cells in normal rodents are continually exposed to leptin and 
therefore may be expected to be less sensitive. Leptin treatment (6.25-100 nM) 
of pancreatic islets isolated from ob/ob mice for 1-2 hours reduced leptin 
secretion from between 13 to 29% (Emilsson et a l, 1997; Kieffer et a l, 1997). 
Furthermore, leptin reduced insulin release in the perfused pancreas of ob/ob 
mice, a model used to assess islet function (Emilsson et a l, 1997). It is 
important to note that increasing glucose level in vivo reduces the suppressive 
effect of leptin on insulin release in the islets of ob/ob mice. Overall, however,
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there are conflicting reports regarding leptin effects on insulin secretion in 
normal rodents. Some investigators have found that leptin (0.625-100 nM) had 
no effect on insulin release in isolated rat or mouse islets (Karlsson et a l, 1998; 
Poitout et a l, 1998), or in the perfused rat pancreas (Leclercq-Meyer et a l, 
1996; Leclercq-Meyer & Malaisse, 1997; Leclercq-Meyer & Malaisse, 1998). 
One study found that leptin (1 nM) stimulates insulin release from isolated rat 
islets (Tanizawa et a l, 1997). However, in most studies, insulin was reduced by 
leptin (1-20 nM) in the perfused rat pancreas and isolated rat or mouse islets in 
the presence of low, normal or high glucose (Emilsson et a l,  1997; Fehmann et 
a l, 1997b; Ishidac/a/., 1997; Kulkarni c/a/., 1997; Pallett c/a/., 1997).
Leptin may also exert its effect at the level of insulin mRNA expression. 
However, again there are conflicting reports. Leptin suppresses preproinsulin 
mRNA expression in isolated rat islets (Kulkarni et a l, 1997; Pallett et a l,
1997), in mouse pTC6 cells (Kulkarni et a l, 1997), in ob/ob mouse islets, in the 
rat pancreatic p-cell line INS-1 (Seufert et a l, 1999b), and in human islets 
(Seufert et a l, 1999a). However, some studies showed leptin had no effect on 
insulin biosynthesis (Karlsson et a l, 1998; Roduit & Thorens, 1997), whilst 
another study showed leptin increased insulin preproinsulin mRNA in H3T-T15 
cells (Shimizu et a l, 1997).
4.1.1,3 Signalling pathways
To investigate the effects of leptin in the pancreatic P-cells, it is 
necessary to outline the mechanism by which insulin is released from P-cells.
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Insulin secretion from pancreatic P-cells is controlled in part by the activity of 
K a t p  channels. Closure (or inactivation) of K a t p  channels in response to 
metabolism of glucose depolarises p-cells, resulting in the activation of voltage- 
dependent Ca^’*’ channels, a rise in cytosolic calcium concentration ([Ca^^Ji), and 
exocytosis of insulin granules (Ashcroft & Rorsman, 1989). Glucose 
metabolism within p-cells also results in an elevation of fatty acyl-CoA esters, 
which accompanied by increased [Ca^^ji causes induction of insulin release 
(Prentki et a l, 1997). Glucose-induced insulin secretion is further regulated by 
hormone-mediated elevation of the intracellular second messengers cAMP/PKA 
(Holz & Habener, 1992) and phospholipase C/PKC (Zawalich e ta l ,  1997).
In pancreatic p-cells, leptin reduces insulin secretion by the opening of 
ATP-sensitive ( K a t p )  channels (Kieffer et a l, 1997). Harvey et a l 
investigated the mechanism by which leptin activates K a t p  channels and found 
that inhibitors of PI 3-kinase (e.g. wortmannin) prevented opening of K a t p  
channels by leptin (Harvey et a l, 2000a). Consistent with an involvement of 
PI 3-kinase, leptin suppressed any increase in cAMP, and as a result insulin 
secretion, after treatment with agents known to increase cAMP (e.g. GLP-1), 
through the activation of a PI 3-kinase-dependent PDE3B (Zhao et a l, 1998). 
Furthermore, leptin reduced insulin secretion induced by PMA (a PKC 
activator) in mouse ob/ob islets and rat islets (Chen et a l, 1997; Ookuma et a l,
1998). These observations suggest that the leptin receptor-mediated signalling 
pathway interacts with both cAMP-dependent PKA and PKC pathways.
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Leptin signalling in the P-cell
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DNA-binding assays suggest that STAT proteins may mediate the 
inhibition o f  insulin gene expression after leptin treatment. Sequences between 
-307 and -410 bp o f the rat insulin I gene promoter bind multiple protein 
complexes contained in nuclear extracts from leptin-treated oh/ob islets (Seufert 
et a i,  1999b). One o f the complexes contained STATSb, which formed on a 
previously described consensus STAT binding site (Seufert et ai,  1999b). 
Leptin was shown to activate STAT3 in B R JN -B D ll cells, RJNmSF cells and 
isolated rats islets, though STATS activation was detected in BRlTsI-BDl 1 cells 
(Briscoe et ai, 2001a; Morton et a i,  1999). The treatment o f rat pancreatic 
islets with leptin produced an increase in the tyrosine phosphorylation o f 
STAT3, but not STATS (Tanabe et a i,  1997). These observations implicate 
STAT3 and STATS activation as a potential mechanism by which leptin
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regulates gene expression in P-cells. Although STAT proteins are generally 
considered to be activators of gene transcription, they may also be inhibitory, 
depending on the promoter context and cell type. For example, STATSb 
stimulated by prolactin induces the p-casein promoter but inhibits the interferon 
regulatory factor-1 promoter (Luo & Yu-Lee, 1997).
There are no publications to date of leptin-mediated induction of SOCS- 
3 or CIS mRNA in the pancreas in vivo, but SOCS-3 and CIS have been 
implicated as negative regulators of leptin signalling in the hypothalamus, liver 
and small intestine of lean mice (Bjorbaek et a l, 1998b; Emilsson et a l, 1999). 
An in vitro study has shown that the forced expression of CIS in RINm5F cells, 
a leptin-responsive p-cell line, prevented leptin-mediated STAT3 transcriptional 
activation of STAT3-dependent reporter constructs in a dose dependent manner 
(Emilsson et a l, 1999). To date, there are no studies demonstrating reduced 
leptin sensitivity in the pancreas after feeding of a high-fat diet.
Glucose-induced insulin secretion occurs through a sensing pathway that 
requires glucose metabolism, a process which is initiated by the uptake of the 
glucose transporter GLUT2 (Orel et a l, 1989; Thorens et a l, 1988). The 
transcriptional control of GLUT2 in P-cells involves PDX-1 (Waeber et a l, 
1996), a transcription factor that controls the expression of the insulin and 
glucokinase genes (Ohlsson et a l, 1993; Watada et a l, 1996). Expression of 
PDX-1 is regulated by glucose, fatty acids and glucocorticoids (Gremlich et a l, 
1997; Shinozuka et a l, 2001). The expression of GLUT2, glucokinase and
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PDX-1 mRNA has been shown to be altered in type II diabetes (Leibowitz et 
a l, 2001; Weir et a l, 1997).
In order to identify gene changes that may be involved in obesity and 
leptin sensitivity, a number of genes involved in leptin receptor-mediated 
signalling and glucose sensing have been analysed in the pancreas of dietary 
obese and genetically obese mice.
4.1.2 Adipose Tissue
There are two distinct types of adipose tissue, white and brown, which 
have different physiological functions. WAT is widely distributed throughout 
the body and serves as a major depot of stored energy in the form of 
triglycerides. The triglycerides are stored during periods of excess energy 
availability and are mobilised during periods of energy deprivation. Therefore, 
WAT has enormous potential for changes in cell mass in accordance to the 
energy state. The adipose mass reflects the net balance between energy intake 
and energy expenditure and is stable over a long period of time.
BAT resides in the central axis of the body and functions to dissipate 
energy and provide heat. BAT plays a major role in the regulation of body 
temperature in small animals such as mice and rats, which have a high surface 
area to body volume and require hormonal regulation of thermogenesis to 
maintain body temperature. Although BAT is well developed in human infants, 
where it contributes to maintaining body temperature, it atrophies in adults.
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Several studies have shown the presence of OB-Rb mRNA in WAT and 
BAT (Fei et a l, 1997; Ghilardi et a l, 1996; Kutoh et a l, 1997; Siegrist-Kaiser 
et a l, 1997), suggesting leptin has direct effects on these tissues. Evidence for a 
direct effect of leptin on WAT came from the observation that leptin 
administration of lean Zucker +/? rats after 2 hours increased the rate of 
lipolysis in WAT (Siegrist-Kaiser et a l, 1997). Commins et a l observed 
reduced WAT mass in wild-type (+/+) mice treated with leptin (i.p.), but not in 
UCPl-deficient (-/-) mice, suggesting UCP-1 is required for leptin to decrease 
WAT mass (Commins et. a l, 2001). Furthermore, there was a 3-fold increase in 
UCPl mRNA and protein in BAT of leptin-treated wild-type mice (Commins et 
a l, 2001). The chronic i.p. administration of leptin in vivo for 4 days had direct 
effects on BAT, resulting in increased glucose utilisation, whereas i.c.v. leptin 
administration had no significant effect (Siegrist-Kaiser et a l, 1997).
Further investigations have shown that in vivo i.p. leptin administration 
can activate STATl and STAT3 in WAT of C57BL/6J wild-type and ob/ob 
mice (Bendinelli et a l , 2000). The peripheral, but not central, administration of 
leptin in vivo activates STATl in BAT (Siegrist-Kaiser et a l, 1997). Moreover, 
in terms of negative regulators of leptin signalling, SOCS-1 and SOCS-3 have 
been shown to be increased in WAT of DIO rats suggesting that increased 
expression of these genes may play a role in leptin sensitivity in WAT (Wang et 
a l, 2000). Furthermore, the ability of A/J mice (obesity-resistant) to resist diet- 
induced obesity is associated with increased UCPl and UCP2 mRNA
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expression in BAT and WAT, respectively, which is not observed in obesity- 
prone C57B1/6J mice (Watson et a l, 2000).
In summary, leptin appears to have differential effects in WAT and 
BAT. The studies to date in WAT, where leptin regulates lipolysis, suggest 
regulation of leptin sensitivity may be at the level of STAT-1 and 3, and/or 
SOCS-1 and SOCS-3, whereas leptin directly affects glucose utilisation and the 
expression of UCP mRNA. In BAT, there are no studies to date of leptin 
affecting the expression of components of the leptin receptor-mediated 
signalling pathway. To identify some of the genes which may be involved in 
leptin sensitivity, the expression of leptin receptor-mediated signalling 
components were analysed in WAT of dietary obese mice and in BAT of dietary 
and genetically obese mice.
4.1.3 Small Intestine
Multiple short forms of the leptin receptor are expressed throughout the 
gastrointestinal tract suggesting a potential role of leptin in nutrient absorption 
(Morton et a l, 1998). However, the functional OB-Rb is predominantly 
expressed in the jejunum and with weaker expression in the ileum, the two 
major sites that are involved in nutrient handling (Morton et a l, 1998). In 
addition, OB-Rb expression was readily detected in the human intestinal 
epithelial Caco-2 cells, implying a role for leptin in enterocyte function (Morton 
et a l, 1998). In this context, it has been shown that leptin produced a rapid 
inhibitory effect on sugar absorption in rat intestinal rings (Lostao e ta l,  1998).
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Western blot analysis of STAT proteins in lean and ob/ob jejunum 
readily detects ST AT5 but more weakly detects STATl and STATS (Morton et 
a l, 1998). The intravenous injection of leptin induced STATS, but not STATS, 
DNA binding activity in the jejunum of lean and ob/ob mice but had no effect in 
the db/db mouse (Morton et a l, 1998). Furthermore, the leptin-induced 
activation of STATS in the jejunum is associated with a reduction of the 
apolipoprotein-AIV mRNA levels 90 minutes after a pure fat load, suggesting 
leptin might be involved in lipid handling (Morton et a l, 1998). The increased 
STATS activation in the jejunum contrasts with the effect of leptin in the 
hypothalamus, where only STATS is activated (Vaisse et a l, 1996). The 
possible importance of STATS in mediating the effect of leptin on body weight 
homeostasis is suggested by in vitro evidence from the obese (fa/fa) Zucker rat, 
which contain a missense mutation (Gln->Pro) in the extracellular domain of 
the leptin receptor Streamson et a l, 1996). 0B-R(/2?) mediates a leptin-
independent (constitutive) activation of STATl and STATS, whereas the 
activation of STATS is completely abolished (White et a l, 1997b) suggesting a 
lack of leptin effect through STATS in the small intestine in addition to other 
tissues could in part contribute to the obesity phenotype.
The expression of SOCS-3 and CIS mRNA has been analysed in the 
small intestine of leptin treated (48 hours) lean and ob/ob mice. Emilsson et a l 
demonstrated that leptin treatment of lean and ob/ob mice induced expression of 
CIS mRNA, whereas SOCS-3 mRNA was only induced upon leptin treatment 
of lean mice (Emilsson et a l, 1999). Furthermore, CIS mRNA, but not SOCS-3
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mRNA, was elevated 2-fold in the small intestine of ob/ob mice compared to 
leans. The authors suggest increased expression of CIS mRNA dampens the 
response to leptin and that some tissues, such as the small intestine in ob/ob 
mice, might be less sensitive to leptin compared to the same tissues in leans. As 
the CIS promoter contains multiple STAT5 binding sites, the increased 
expression of CIS mRNA upon leptin treatment further suggests that STATS is 
the STAT protein predominantly activated by leptin in the small intestine 
(Matsumoto, A., e ta l,  1997).
In this study, therefore, the expression of components of leptin receptor- 
mediated signalling pathway was analysed in the small intestine of dietary obese 
and genetically obese mice to identify genes that may be involved in obesity and 
leptin sensitivity.
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4.2 Results
The tissues analysed in this chapter are from the study described in 
Chapter 3. The physiological characteristics of the dietary-induced obese 
AKR/J mice and the C57BL/6 ob/ob mice are detailed in sections 3.2.1-3.2.3. 
This section details pancreatic insulin-content and changes in gene expression in 
the pancreas, WAT, BAT and small intestine of palatable diet-fed AKR/J and 
C57BL/6 ob/ob mice.
4.2.1 Pancreatic Insulin
Pancreatic insulin content was determined by ELISA, as described in 
section 2.3.1 (c). Table 4.1 shows the insulin levels in the pancreas of AKR/J 
mice fed either a chow or palatable diet and C57BL/6 lean and ob/ob mice fed 
on chow diets. Pancreatic insulin levels were increased 4.5-fold (P<0.01) in 
palatable diet-fed AKR/J mice compared to chow-fed mice and 23-fold 
(P<0.01) in C57BL/6 ob/ob mice compared to lean controls. There was no 
significant difference in pancreatic insulin content of AKR/J lean mice 
compared to C57BL/6 lean mice.
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Table 4.1 Insulin levels in the pancreas of AKR/J mice fed either a chow or 
palatable diet, and C57BL/6 lean and ob/ob mice fed a chow diet
AKR/J mice were fed either a chow or palatable diet, and C57BL/6 lean and 
ob/ob mice were fed a chow diet for 14 weeks. A1 values are represented as 
mean + S.E.M. ng/ml, where ** P<0.01.
Group Pancreatic Insulin (ng/mg)
AKR/J +/? mice on chow diet 22 ± 4
AKR/J +/? mice on palatable diet 99 ± 1 7
C57BL/6J +/? mice on chow diet 9 + 2
C57BL/6J ob/ob mice on chow diet 227 + 34
4.2.2 Changes in gene expression in the pancreas
In the whole pancreas, the mRNA expression of cyclophilin was found 
to be the most suitable housekeeper (see Appendix 1) and was used as a 
covariate for ANCOVA analysis. In addition to the genes OB-Ra, OB-Rb, 
STATS, STAT5, SOCS-3 and CIS, a number of other genes important for (3-cell 
function were also analysed, namely insulin, PDX-1, glucokinase and GLUT2. 
Unfortunately, whilst analysing the expression of OB-Ra or OB-Rb in the 
pancreas, the amplification plots were inconsistent and there was too much
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variation of the data to make any accurate comparisons of leptin receptor 
expression in the pancreas.
Figure 4.1 shows that there was no significant change in STATS, 
STAT5, SOCS-3 or CIS mRNA in palatable diet-fed AKR/J mice compared to 
those fed a chow diet, although there was a trend towards a decrease in CIS 
mRNA expression (28% decrease). In the pancreas of ob/ob mice compared to 
leans, ST AT5 and SOCS-3 mRNA expression was increased by 26% and 36% 
(P<0.05), respectively. The expression of STATS mRNA tended to increase 
(30%), whilst CIS mRNA showed little change. A comparison of the lean 
AKR/J and C57BL/6 strains showed that SOCS-3 mRNA was unchanged but 
STATS, ST AT 5 and CIS were all increased in the pancreas of AKR/J lean mice 
by 31% (P<0.05), 35% (P<0.01) and 120% (P<0.01), respectively.
Figure 4.2 shows that in the pancreas of AKR/J mice fed a palatable 
compared to a chow diet, there was no change in the mRNA expression of 
insulin, PDX-1 or GLUT2, whereas glucokinase was reduced by 40% (P<0.01). 
In the pancreas of ob/ob mice compared to leans, insulin mRNA was increased 
by 11.7-fold (P<0.01), PDX-1 was increased by 25% (P<0.05) and GLUT2 was 
reduced by 53% (P<0.01), but there was no difference in expression of 
glucokinase. Figure 4.2 also shows that compared to C57BL/6 lean mice, the 
AKR/J lean mice have a 52% increase in insulin mRNA expression (P<0.05), a 
45% increase in PDX-1 expression (P<0.01) and a 50% reduction in 
glucokinase expression (P<0.01), but no significant change in GLUT2 
expression.
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Figure 4.1 Changes in STAT3, STAT5, SOCS-3 and CIS mRNA in the 
pancreas of AKR/J mice fed either a chow or palatable diet, and C57BL/6 
lean and oh/ob mice fed a chow diet
Comparisons of STAT3, STAT5, SOCS-3 and CIS mRNA are shown in the 
pancreas of AKR/J mice fed a palatable diet compared to those fed a chow diet, 
C57BL/6 oh/ob compared to leans fed on chow and AKR/J lean mice compared 
to C57BL/6 lean mice. Following TaqMan analysis and adjustment for 
cyclophilin, the mRNA levels for the control animals have been ascribed a value 
of 1 and the symbols indicate relative changes from this baseline (as described 
in Appendix 1). Error bars indicate 95% confidence intervals and changes are 
shown as significant where * P<0.05, **P<0.01.
■  STAT3 mRNA 
□  STAT5 mRNA 
#  SOCS-3 mRNA 
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Figure 4.2 Changes in insulin, PDX-1, glucokinase and GLUT2 mRNA in 
the pancreas of AKR/J mice fed either a chow or palatable diet, and 
C57BL/6 lean and ob/oh mice fed a chow diet
Comparisons of insulin, PDX-1, glucokinase and GLUT2 mRNA are shown in 
the pancreas of AKR/J mice fed a palatable diet compared to those fed a chow 
diet, C57BL/6 ob/ob compared to leans fed a chow diet and AKR/J lean mice 
compared to C57BL/6 lean mice. Following TaqMan analysis and adjustment 
for cyclophilin, the mRNA levels for the control animals have been ascribed a 
value of 1 and the symbols indicate relative changes from this baseline (as 
described in Appendix 1). Error bars indicate 95% confidence intervals and 
changes are shown as significant where * ?<0.05, ** P<0.01 
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4.2.3 Changes in gene expression in WAT
For WAT, the mRNA expression of cyclophilin was found to be the 
most suitable as a housekeeper (see Appendix 1) and was used as a covariate for 
ANCOVA analysis. Only a comparison of leptin receptor-mediated signalling 
components were made in WAT of AKR/J mice fed palatable diet compared to 
mice on chow, since some of the WAT RNA samples from the ob/ob mice were 
lost whilst extracting the RNA. In palatable diet-fed AKR/J mice compared to 
chow fed mice, the change in expression of OB-Ra and OB-Rb mRNA tended 
to increase, altering by 72% and 40% (Figure 4.3), respectively, but these 
changes were not significant. There was little change in STATS mRNA but the 
expression of STAT5 mRNA was increased by 61% (P>0.01). Furthermore, 
expression of SOCS-3 mRNA was reduced by 60% whereas CIS mRNA 
expression was increased by 241% (P<0.01).
4.2.4 Changes in gene expression in BAT
In BAT, none of the housekeeping genes tested were suitable to use as a 
covariate for ANCOVA analysis, hence the data was represented as unadjusted. 
The changes in gene expression of OB-Ra and OB-Rb mRNA are shown in 
figure 4.4 (a). In AKR/J mice fed a palatable diet compared to mice on chow, 
there was no change in OB-Ra mRNA. OB-Rb mRNA was reduced by 34%, 
though the change was not significant. Both OB-Ra and OB-Rb mRNA 
expression was increased in ob/ob mice compared to leans by 62% and 53% 
(P<0.01), respectively. Furthermore, OB-Ra and OB-Rb were increased in
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AKR/J lean mice compared to C57BL/6 lean mice by 125% and 224% 
(P<0.01), respectively.
The changes in gene expression of STATS and STATS mRNA are 
shown in figure 4.4 (b). The expression of STATS and STATS mRNA was 
increased, but not significantly, in AKR/J mice fed a palatable diet compared to 
chow by 15% and 20%, respectively. In ob/ob mice compared to leans, only 
STATS mRNA was increased by 145% (P<0.01), whereas STATS mRNA 
remained unchanged. No changes of STATS or STATS mRNA expression were 
observed in lean AKR/J mice compared to lean C57BL/6 mice.
The changes in gene expression of SOCS-S and CIS mRNA are shown 
in figure 4.4 (c). In AKR/J mice fed a palatable diet compared to chow, SOCS-S 
mRNA was increased by 24% and CIS was reduced by 29%, but the changes 
were not significant. The expression of SOCS-S mRNA was substantially 
increased in ob/ob mice compared to leans by 406% (P<0.01), but CIS mRNA 
showed a non-significant S9% reduction. A comparison of AKR/J lean and 
C57BL/6 lean mice showed that CIS mRNA was increased by 280% in the BAT 
of AKR/J lean mice, but SOCS-S mRNA remained unchanged.
I l l

Figure 4.3 Changes in gene expression of components of the leptin receptor- 
mediated signalling pathway in WAT of AKR/J mice fed either a chow or 
palatable diet
Comparisons of OB-Ra, OB-Rb, STATS, STATS, SOCS-S and CIS mRNA are 
shown in WAT of AKR/J mice fed a palatable diet compared to those fed a 
chow diet. Following TaqMan analysis and adjustment for cyclophilin, the 
mRNA levels for the control animals have been ascribed a value of 1 and the 
symbols indicate relative changes from this baseline (as described in Appendix 
1). Error bars indicate 95% confidence intervals and changes are shown as 
significant where * P<0.05, ** P<0.01.
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Figure 4.4 Changes in gene expression of components of the leptin receptor- 
mediated signalling pathway in BAT of AKR/J mice fed either a chow or 
palatable diet, and C57BL/6 lean and oh/ob mice fed a chow diet
A comparison of gene expression changes are shown in BAT of AKR/J mice 
fed a palatable diet compared to those fed a chow diet, C57BL/6 oh/ob 
compared to leans on a chow diet and AKR/J lean mice compared to C57BL/6 
lean mice. Following TaqMan analysis, the mRNA levels for the control 
animals have been ascribed a value of 1 and the symbols indicate relative 
changes from this baseline (as described in Appendix 1). Error bars indicate 
95% confidence intervals and changes are shown as significant where * P<0,05 
and**P<0.01.
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4.2.5 Changes in gene expression in small intestine
For the small intestine, the mRNA expression of HPRT was found to be 
the most suitable as a housekeeper (see Appendix 1) and was used as a covariate 
for ANCOVA analysis. The changes in gene expression of OB-Ra and OB-Rb 
mRNA are shown in figure 4.5 (a). OB-Ra and OB-Rb mRNA was reduced by 
44% and 50% (P<0.01), respectively, in AKR/J mice fed a palatable diet 
compared to chow. Whilst OB-Ra mRNA was unchanged in ob/ob mice 
compared to lean, OB-Rb mRNA was reduced by 30% (P<0.01). In AKR/J lean 
mice compared to C57BL/6 lean mice, OB-Ra tended to increase but not 
significantly whereas OB-Rb was significantly increased by 46% (P<0.01).
The changes in gene expression of STATS and STAT5 mRNA are 
shown in figure 4.5 (b). In palatable diet-fed compared to chow-fed AKR/J 
mice, both STATS and STAT5 were reduced by 25% (P<0.01). However, only 
STATS mRNA, but not STAT5 mRNA, was increased in ob/ob mice compared 
to lean mice by 12% (P<0.05) and in AKR/J lean mice compared C57BL/6 lean 
mice by S2% (P<0.01). The expression of STAT5 mRNA was increased by 
1S% in AKR/J lean mice compared to C57BL/6 lean mice, but the change was 
not significant.
The changes in gene expression of SOCS-S and CIS mRNA are shown 
in figure 4.4 (c). In AKR/J mice fed a palatable diet compared to chow fed 
mice, SOCS-S mRNA was reduced by 45% (P<0.05) but CIS mRNA was 
unchanged. However, in ob/ob mice compared to leans, CIS mRNA was 
reduced by 47% (P<0.01) and SOCS-S mRNA was unchanged. SOC-3 mRNA
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was increased by 55% in AKR/J lean mice compared to C57BL/6 lean mice, but 
the change did not reach significance. Whilst CIS mRNA was also increased in 
AKR/J lean mice, the change was not as large as that in SOCS-3 mRNA and 
was not significant.
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Figure 4.5 Changes in gene expression of components of the leptin receptor- 
mediated signalling pathway in the small intestine of AKR/J mice fed either 
a chow or palatable diet, and C57BL/6 lean and oh/ob mice fed a chow diet
A comparison of gene expression changes are shown in the small intestine of 
AKR/J mice fed a palatable diet compared to those fed a chow diet, C57BL/6 
ob/ob compared to leans on a chow diet and AKR/J lean mice compared to 
C57BL/6 lean mice. Following TaqMan analysis, the mRNA levels for the 
control animals have been ascribed a value of 1 and the symbols indicate 
relative changes from this baseline (as described in Appendix 1). Error bars 
indicate 95% confidence intervals and changes are shown as significant where * 
P<0.05 and**P<0.01.
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4.3 Discussion
The identification of leptin receptors in the hypothalamus implied that 
leptin action in the hypothalamus was responsible for the regulation of food 
intake and energy expenditure. However, the subsequent detection of leptin 
receptors in many peripheral tissues suggested leptin action was not restricted to 
the hypothalamus. The present chapter investigates the changes in expression of 
components of the leptin receptor-mediated signalling pathway in some of the 
peripheral tissues where leptin is known to exert its effects. The tissues 
examined were the pancreas, WAT, BAT and small intestine of AKR/J mice fed 
either a chow diet or a palatable diet and of C57BL/6 lean and genetically obese 
ob/ob mice fed on chow.
4.3.1 Pancreas
Of all the peripheral tissues examined by Ghilardi et a l (Ghilardi et a l ,
1996), the pancreas was the most abundant in expression of OB-Rb mRNA, 
suggesting that it may play an important role in peripheral leptin action. Insulin 
is adipogénie, increases body fat mass, and stimulates the production and 
secretion of leptin (Barr et a l, 1997; Malmstrom et a l, 1996; Patel et a l, 1998), 
which acts centrally to reduce food intake and increase energy expenditure. 
Leptin in turn suppresses insulin secretion both centrally and through direct 
actions on p-cells (Ahren & Havel, 1999; Fehmann et a l, 1997b; Ishida et a l, 
1997; Kulkarni et a l, 1997; Pallett et a l, 1997; Poitout et a l, 1998; Seufert et 
al., 1999a; Shi et a l, 1998b; Shimizu et al., 1997; Tanizawa et a l,  1997). Since
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plasma leptin levels are directly proportional to body fat mass, an increase in 
adiposity increases plasma leptin, thereby curtailing insulin production and a 
further increase in fat mass. This bidirectional feedback loop may maintain 
nutrient balance and a dysregulation of this adipoinsular axis may contribute to 
obesity and the development of hyperinsulinaemia associated with diabetes. 
Analysis of changes in expression of components of the leptin receptor- 
mediated signalling pathway in leptin insensitive dietary obese and leptin- 
sensitive ob/ob mice compared to lean mice may indicate whether dysregulation 
of the adipoinsular axis is at the level of leptin signalling in the pancreas and 
adipose tissue.
In the pancreas, quantitative TaqMan RT-PCR amplified all the 
transcripts investigated efficiently except for OB-Ra and OB-Rb. Therefore, no 
conclusions regarding the expression of OB-Ra and OB-Rb in this tissue of 
obesity could be made. The exact reason for this is unclear, but it may be due to 
the reduced expression of leptin receptors over the whole pancreas compared to 
the islets (Emilsson et a l, 1997) or problem with amplification in the pancreas 
using the primer and probe set although this set worked well in other tissues.
Analysis of TaqMan data showed that there were no changes in the 
expression of STAT3 mRNA in the pancreas of AKR/J mice fed a palatable diet 
compared to chow-fed mice and chow-fed C57BL/6 ob/ob mice compared to 
leans. STAT3 activation has been reported in RINmSF cells, isolated rat islets, 
MIN6 cells and BRIN-BDll cells (Briscoe et a l, 2001a; Morton et a l, 1999; 
Tanabe et a l, 1997) upon leptin treatment. This suggests that leptin sensitivity
118
in the pancreas of ob/ob mice or palatable diet-fed AKR/J mice is not regulated 
at the level of STAT3 mRNA. However, levels of STAT3 protein were not 
determined in this series of experiments to corroborate this suggestion. This 
observation is in contrast to the 27% reduction in hypothalamic STAT3 mRNA 
in ob/ob mice compared to leans suggesting leptin sensitivity in different tissues 
may be regulated in different ways. A comparison of STAT3 mRNA 
expression in the pancreas of AKR/J lean and C57BL/6 lean mice showed an 
increase in STAT3 mRNA in AKR/J lean mice.
Table 4.2 Summary of gene expression changes involved in leptin receptor- 
mediated signalling in the pancreas
STAT3 STATS SOCS-3 CIS
Palatable vs Chow NC NC NC 28% t
ob/ob vs lean T 30% t T 26% * t  36% * NC
AKR/J vs C57BL/6 t  31% * t  35% ** NC T 120% **
Key: NC -  no change, f  - non-significant change, * P<0.05, ** P <0.01
The increased STAT3 and STAT5 mRNA in ob/ob mice compared to 
leans may be related to the increased insulin signalling through STAT3 (Ceresa 
et a l, 1997; Ceresa & Pessin, 1996; Coffer et a l, 1997) and STATS (Chen et 
a l, 1997; Storz et a l, 1999). Interestingly, it has been shown that leptin reduces 
the transcriptional activity of the rat insulin I gene promoter in ob/ob mice and 
alters binding of distinct proteins, including STAT5b complexes to upstream
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sequences within the 5' promoter region of the rat insulin I gene (Seufert et a l, 
1999b). The expression of STATS mRNA, though not significant, was 
increased by a similar magnitude in ob/oh mice to that of STAT5 mRNA 
suggesting the increased STATS and STAT5 mRNA may be due to increased 
leptin sensitivity or perhaps a result of increased insulin signalling. 
Furthermore, in the pancreas of ob/ob mice compared to leans, SOCS-3 mRNA 
was increased by 36%. It has recently been shown that triglyceride lowering in 
pancreatic islets, a major biologic action of leptin, was largely prevented by the 
overexpression of SOCS-3 (Wang et a l, 2000). The recent observations that 
insulin can induce SOCS-3 expression (Emanuelli et a l, 2000) and tyrosine 
phosphorylation (Peraldi et a l, 2001) suggest that the increase in SOCS-3 
mRNA may be insulin-mediated and due to the hyperinsulinaemia in ob/ob 
mice. A comparison of AKR/J and C57BL/6 lean mice showed that STAT3 and 
STAT5 mRNA was increased by 31% and 35%, respectively, in AKR/J lean 
mice. The elevated STAT3 and STAT5 mRNA in the pancreas may be intrinsic 
to the AKR/J strain. In the pancreas of AKR/J mice fed a palatable diet and 
C57BL/6 ob/ob mice compared to their relative lean mice, there was no change 
in the expression of CIS mRNA. However, a comparison of CIS mRNA 
expression in the pancreas of AKR/J lean and C57BL/6 lean mice showed a 
120% increase in AKR/J lean mice. It has been observed that the forced 
expression of CIS in RINm5F cells prevented leptin-mediated STATS 
transactivation (Emilsson et a l, 1999), suggesting the increased CIS mRNA in 
AKR/J lean mice may indicate reduced leptin sensitivity in the pancreas.
1 2 0
Insulin mRNA and pancreatic insulin was increased by 12-fold and 23- 
fold (see Table 4.1), respectively, in the pancreas of ob/ob mice with plasma 
insulin being increased 4.8-fold (see section 3.2.2), which is not surprising 
considering the ob/ob mice have an increased number of pancreatic P-cells and 
are insulin resistant. However, insulin mRNA was not significantly changed in 
the pancreas of AKR/J mice fed a palatable diet compared to chow, nor was 
plasma insulin significantly changed (see section 3.2.2). However, the 
pancreatic insulin content in these mice was significantly increased by over 4- 
fold compared to chow-fed mice suggesting the increased pancreatic insulin 
content in AKR/J mice fed a palatable diet may be due to increased proinsulin 
synthesis. A comparison of insulin mRNA between AKR/J lean and C57BL/6 
lean mice showed that insulin mRNA was increased by 52% in the pancreas of 
AKR/J lean mice. A comparison of plasma insulin and pancreatic insulin 
content in AKR/J and C57BL/6 lean mice showed that there was no statistically 
significant difference between the two strains.
Table 4.3 Summary of changes in glucose-responsive genes in the pancreas
Insulin PDX-1 Gluco kinase GLUT2
Palatable vs Chow NC NC i  40% ** NC
oh/oh vs lean tl070%  ** t25%  * NC 4. 53% *
AKR/J vs C57BL/6 T 52% * t  45% ** 4. 50% NC
Key: NC -  no change, * P<0.05, ** P <0.01
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PDX-1 mRNA was increased in the pancreas of ob/ob mice compared to 
leans but remained unchanged in AKR/J mice fed a palatable diet compared to 
mice on chow. Since PDX-1 is a P-cell specific transcription factor, which 
binds to promoters of several P-cell specific transcripts, including insulin and 
glucokinase, the observed increase along with that of insulin is probably related 
to the p-cell hyperplasia observed in ob/ob mice. The increase in PDX-1 
corresponds with the increase in insulin mRNA expression also observed in 
AKR/J lean mice compared to C57BL/6 lean mice. Reduced glucose tolerance 
is usually associated with reduced glucokinase and/or GLUT2 (Ishihara et a l, 
1995; Valera et a l, 1994). In the pancreas of AKR/J mice fed a palatable diet 
compared to chow, glucokinase mRNA was reduced by 40% though GLUT2 
mRNA was unchanged. GLUT2 mRNA was reduced by 53% in the pancreas of 
ob/ob mice compared to leans, but glucokinase mRNA was unchanged, 
suggesting glucose sensitivity may be regulated more through glucose transport 
than through glucokinase expression in ob/ob mice. The reduced expression of 
glucokinase mRNA in AKR/J compared to C57BL/6 lean mice suggests the 
AKR/J strain are more susceptible to reduced glucose sensitivity.
4.3.2 WAT
The components of the leptin receptor-mediated signalling pathway were 
also analysed in WAT, but only in AKR/J mice fed a palatable diet because the 
RNA was not extracted appropriately from the ob/ob mice. The expression of 
OB-Ra and OB-Rb mRNA was increased by 72% and 40%, respectively, in
1 2 2
AKR/J mice fed a palatable diet, but the changes were not significant. The 
variability in these measurements are large, however if there is an actual 
increase of OB-R mRNA, then it may be that regulation of leptin sensitivity is at 
a post-transcriptional level.
Table 4.4 Summary of gene expression changes involved in leptin receptor- 
mediated signalling in WAT
OB-Ra OB-Rb STATS STATS SOCS-3 CIS
Palatable 
vs Chow
T 72% t T 40% t NC t  61% ** 4< 60% ** t  241% **
Key: NC -  no change, t  - non-significant change, ** P <0.0
Investigations of leptin-mediated STAT activation in BAT and WAT 
have implicated the involvement of STATl and STATS. Bendinelli et a l 
(Bendinelli et a l, 2000) showed that intraperitoneal leptin administration to 
C57BL/6 lean and ob/ob mice activates STATS and STATl in epididymal 
adipose tissue after 10 minutes. Siegrist-Kaiser et a l (Siegrist-Kaiser et a l,
1997) showed leptin-in du cible binding of STATs to the M67-SIF element that 
binds STATl and STATS in nuclear extracts from brown and white adipocytes. 
Despite evidence of STATl as well as STATS involvement in leptin signalling 
in WAT and BAT, the present study investigated changes in STATS and 
STAT5 mRNA in these tissues as a comparison with changes in these genes 
with other tissues. There were no changes in STATS mRNA in AKR/J mice fed
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a palatable diet compared to chow, but STATS mRNA was increased. There 
have been no indications of STAT5 responsiveness to leptin action in WAT and 
so the increase in ST AT5 mRNA may be leptin-independent.
Wang et a l have demonstrated that a negative feedback loop links 
circulating leptin to its own biosynthesis in adipose tissue (Wang et a l,  1999b). 
The authors demonstrated that the protein expression of SOCS-3 was increased 
in adipocytes of diet-induced obese rats, which were hyperleptinaemic, and 
consistent with a role of SOCS-3 in the resistance of the adipocyte to 
autosuppression by leptin (Wang et a l, 2000). Analysis of SOCS-3 mRNA in 
WAT of AKR/J mice fed a palatable diet showed a 60% reduction compared to 
mice on chow. Therefore, the reduced SOCS-3 mRNA does not support the 
hypothesis of Wang et al, although it is conceivable that the decrease is not 
reflected at the protein level. The expression of CIS mRNA was increased by 
240% in WAT of AKR/J mice fed a palatable diet. Although CIS has not been 
implicated in any leptin-mediated effects in WAT, it is conceivable that it is the 
increased expression of CIS mRNA rather than SOCS-3 that mediates the 
reduced sensitivity to leptin in this study. Alternatively, the increased CIS 
mRNA may be a result of increased STATS mRNA expression and activity 
(assuming STATS basal activity is increased if STATS protein is increased) and 
may also be leptin independent.
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4.3.4 BAT
In BAT, leptin increases the expression of UCP-1 (Commins et a l, 
2000), which is consistent with the role of BAT in regulating the body heat in 
small animals, and shifting fuel selection by reducing carbohydrate oxidation 
and increasing fat oxidation (Hwa et a l, 1996; Hwa et a l, 1997). This change 
in fuel consumption is thought to involve changes in gene expression including 
both centrally mediated effects and direct effects through the OB-Rb isoform. 
Therefore, it is possible, that there may be changes in expression of components 
of the leptin receptor-mediated signalling pathway in BAT of dietary obese and 
genetically obese mice.
Table 4.5 Summai*y of gene expression changes involved in leptin receptor- 
mediated signalling in BAT
OB-Ra OB-Rb STAT3 STATS SOCS-3 CIS
Palatable vs 
Chow
NC 4- 34% t t  15% t T 20% t NC NC
ob/ob vs 
lean
t  62% ** t  53% * t  145% ** NC t406%  ** ^39%  t
AKR/J vs 
C57BL/6
t  125% ** T 224% ** NC NC NC t  279% **
Key: NC -  no change, f  - non-significant change, * P<0.05, ** P <0.01
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In BAT of AKE7J mice fed a palatable diet compared to chow, the 
expression of OB-Rb was reduced by 34% but not significantly suggesting 
leptin sensitivity in BAT may be low in these mice. However, in ob/ob mice, 
both OB-Ra and OB-Rb mRNA was increased by 62% and 53%, respectively, 
which is in line with the high levels of leptin sensitivity in these mice due to 
reduced circulating leptin. The expression of OB-Ra and OB-Rb mRNA was 
also increased in AKR/J compared to C57BL/6 lean mice by 125% and 224%, 
respectively. It is not clear why there is such a large difference in leptin 
receptor mRNA expression between AKR/J and C57BL/6 lean mice, but may be 
due to strain-specific differences.
The expression of STAT3 and STAT5 mRNA was marginally increased, 
but not significantly, in AKR/J mice fed a palatable diet compared to chow by 
15% and 20%, respectively. The increased fat oxidation in BAT may result in 
increased expression of STAT mRNA amongst other genes. The expression of 
STAT3 mRNA was also increased by 145% in BAT of ob/ob mice, again in line 
with an increase in leptin sensitivity in this tissue. There was no difference in 
STAT5 mRNA expression in BAT of ob/ob mice compared to lean animals or 
in either of the STATs in BAT of AKR/J compared to C57BL/6 lean mice. The 
lack of change in STAT5 mRNA expression in BAT of ob/ob mice may suggest 
that changes in STAT5 are not leptin-mediated or that STAT3 is more important 
in leptin signalling in this tissue.
In AKR/J mice fed a palatable diet compared to chow, the expression of 
SOCS-3 mRNA was increased by 24% and CIS was reduced by 29%, however
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these changes were not significant. The expression of SOCS-3 mRNA was 
considerably increased in BAT of ob/ob mice by about 400%, which would be 
expected to lead to reductions in leptin sensitivity. It is possible that the change 
in SOCS-3 mRNA may be due to compensation for the increased STAT3 or due 
to other obesity related factors. However, CIS mRNA was reduced by 39%, but 
not significantly, in ob/ob mice compared to leans, suggesting it is not involved 
in increased leptin sensitivity of ob/ob mice if it is involved in leptin-mediated 
signalling in BAT. A comparison of AKR/J and C57BL/6 lean mice showed no 
change in SOCS-3 mRNA, but CIS mRNA was increased in AKR/J lean mice 
by about 280% compared to C57BL/6 lean mice. It is not clear why there are 
such large changes of CIS mRNA expression in AKR/J lean mice but this may 
play a role in the phenotype of this mouse possibly in decreasing leptin 
sensitivity or as a compensatory mechanism for increases in OB-Rb.
4.3.4 Small Intestine
Several studies have reported the expression of leptin receptors in the 
small intestine (Lostao e ta l,  1998; Morton et a l, 1998). STAT5 was activated 
by leptin in the small intestine with STAT3 and STAT5 being activated by 
leptin in CACO-2 cells, a human model of small intestine epithelium (Emilsson 
et a l, 1999). In particular, Morton et a l have demonstrated that the multiple 
short isoforms are expressed throughout the gastrointestinal tract, whereas the 
functional OB-Rb is predominantly expressed in the jejunum and more weakly 
in the ileum, the two major sites that are involved with nutritional absorption
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and lipid uptake (Morton et a l, 1998). Furthermore, Emils son et al. showed 
CIS mRNA was increased 2-fold in the small intestine of ob/ob mice compared 
to leans, but no changes in expression of OB-R, STATS, ST AT5 or SOCS-3 
mRNA were observed (Emilsson et a l, 1999). Leptin has an inhibitory effect on 
intestinal sugar uptake (Lostao et a l, 1998), consistent with leptin's effect on 
appetite suppression and increases in basal metabolism in order to maintain 
body weight.
The expression of OB-Ra and OB-Rb mRNA was reduced by 44% and 
50%, respectively, in the small intestine of AKR/J mice fed a palatable diet 
compared to chow. It may be that the increased circulating leptin levels may 
have had an inhibitory effect on OB-Ra and OB-Rb mRNA expression. 
However, in the small intestine of ob/oh mice compared to leans, OB-Rb 
mRNA was reduced although these mice are hypersensitive to leptin. Perhaps 
OB-Rb mRNA may be regulated in the small intestine of ob/ob mice by obesity- 
related factors other than leptin. A comparison of AKR/J lean and C57BL/6 
lean mice showed that OB-Ra and OB-Rb mRNA was increased in AKR/J lean 
mice by 21 and 46%, respectively, however, the increased OB-Ra mRNA was 
not statistically significant. The increased OB-R expression may be related to 
the AKR/J strain being more prone to dietary obesity compared to the C57BL/6 
strain.
Investigations published to date in the small intestine, have only looked 
at the difference in expression of components of the leptin receptor-mediated 
signalling pathway in C57BL/6 lean and ob/ob mice, but not in a diet-induced
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model of obesity. Emilsson et al. reported no change in the expression of OB-R 
mRNA (common to all isoforms) in the small intestine of ob/ob mice compared 
to lean (Emilsson et a l, 1999). Similarly, Morton et a l observed no change of 
OB-R mRNA (common to all isoforms) in the duodenum, jejunum or ileum of 
the small intestine in ob/ob mice (Morton et a l, 1998). However, both of the 
above studies have quantified the expression of OB-R mRNA as a ratio of P- 
actin mRNA assuming the expression of P-actin remains unchanged in all the 
tissue they have tested. It may be that changes in the level of housekeeping 
genes may influence the expression of leptin receptors in any given tissue. In 
this study, four different housekeeping genes were analysed and the most 
suitable housekeeping gene (HPRT) was selected that changed the least and is 
independent of the test gene in the tissues analysed. These differences in 
housekeeping genes may account for the differences observed in OB-R 
expression. It is also important to consider that the small changes observed in 
this study may not have a significant effect on leptin signalling. Alternatively, 
these mRNA changes may not be reflected at the protein level.
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Table 4,6 Summaiy of gene expression changes involved in leptin receptor- 
mediated signalling in the small intestine
OB-Ra OB-Rb STAT3 STATS SOCS-3 CIS
Palatable vs 
Chow
i  44% ** 4<50% ** 25% ** i2 5 %  ** 4- 45% * ^  25% t
ob/ob vs 
lean
NC 4.30% ** t  12% * NC NC i  47% **
AKR/J vs 
C57BL/6
t2 1 %  t T 46% ** t  32% ** T 13% t T 55% t NC
Key: NC -  no change, f  - non-significant change, * P<0.05, ** P <0.01
The analysis of STATS and STAT5 mRNA expression showed that both 
genes were reduced by 25% in the small intestine of AKR/J mice fed a palatable 
diet compared to chow-fed mice. This reduction, albeit small is consistent with 
the reductions observed in Ob-Ra and Ob-Rb suggesting a general decrease in 
leptin signalling capacity. In ob/ob mice, STATS mRNA was increased by 12% 
compared to lean mice, yet STAT5 mRNA remained unchanged. Emilsson et 
al observed no changes in the expression of STATS or STAT5 in ob/ob mice 
compared to lean mice (Emilsson et a l, 1999). Therefore, it is unclear whether 
such a small increase in STATS mRNA is biologically significant. A 
comparison of AKR/J and C57BL/6 lean mice showed that both STATS and 
STAT5 mRNA expression was increased in AKR/J mice by 32% and 13%, 
respectively, but the change in STAT5 mRNA was small and not significant.
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The expression of SOCS-3 and CIS mRNA in the small intestine of 
AKR/J mice fed a palatable diet compared to chow-fed mice was reduced by 
45% and 25%, respectively, but the reduced CIS mRNA was not significant. 
The reduced expression of SOCS-3 and CIS mRNA in AKR/J mice fed a 
palatable diet may be due to the reduced expression of STATs, or by a general 
downregulation of leptin signalling as indicated by the reduced expression of 
leptin receptor and STATs in these mice. As mentioned previously, Emilsson et 
a l observed no change in SOCS-3 mRNA, but CIS mRNA was increased 2-fold 
in ob/ob mice compared to leans Emilsson et a l (1999). In this study, SOCS-3 
mRNA was unchanged, however, CIS mRNA was reduced by 47% in ob/ob 
mice compared to leans. Contrary to the reduced CIS mRNA observed here, 
Emilsson et a l observed a 2-fold increase of CIS mRNA in ob/ob mice 
compared to leans (Emilsson et a l, 1999). The reduced expression of CIS 
mRNA may compensate for the reduced OB-Rb in the small intestine of ob/ob 
mice and is consistent with elevated leptin sensitivity in ob/ob mice. In AKR/J 
compared to C57BL/6 lean mice, the expression of SOCS-3 mRNA was 
increased by 55%, but not significantly, and CIS mRNA remained unchanged, 
suggesting the increased SOCS-3 mRNA may be involved in AKR/J lean mice 
being more prone to dietary obesity.
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4.3.5 Summaiy
In summary, there were no changes in STATS, STAT5 or SOCS-3 
mRNA in the pancreas of AKR/J mice fed a palatable diet compared to those 
fed chow, suggesting leptin sensitivity is not regulated at the level of these 
components of leptin receptor-mediated signalling pathway. The increased 
STAT3, STAT5 and SOCS-3 mRNA in the pancreas of ob/ob mice could 
perhaps be due to increased insulin signalling. In WAT of AKR/J mice fed a 
palatable diet, the increased OB-Ra and OB-Rb mRNA, and reduced SOCS-3 
mRNA are inconsistent with low leptin sensitivity in this tissue, however 
instead this could be controlled at the level of CIS.
In BAT of AKR/J mice fed a palatable diet, OB-Rb mRNA was reduced, 
which is consistent with low leptin sensitivity in this tissue. Furthermore, the 
increased expression of STAT3 and STAT5 mRNA may be indicative of 
increased fat oxidation or UCP expression in BAT. The increased OB-Ra and 
OB-Rb mRNA in BAT of ob/ob mice is consistent with increased leptin 
sensitivity. However, the increased STAT3 and SOCS-3 mRNA may be due to 
other obesity related factors. In the small intestine of AKR/J mice fed a 
palatable diet, Ob-Ra and OB-Rb mRNA may be downregulated due to elevated 
plasma leptin levels and the reduced STAT3, STAT5, SOCS-3 and CIS mRNA 
may be a result of reduced leptin signalling, The reduced OB-Rb and increased 
STAT3 mRNA in the small intestine of ob/ob mice may be regulated by 
obesity-related factors other than leptin deficiency as an increase in OB-Rb may 
be expected. In AKR/J lean mice, the increased expression of components of
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the leptin receptor-mediated signalling pathway in the pancreas (STAT3, 
STAT5 and CIS), BAT (OB-Ra, OB-Rb and CIS) and small intestine (OB-Ra, 
OB-Rb, STAT3, STATS and SOCS-3) may contribute to the phenotype and 
susceptibility to diet-induced obesity of AKR/J mice.
The observation that diet-induced obese mice respond to central but not 
peripheral leptin administration with respect to reduced food intake (Lin et a l, 
2000; Van Heek et a l, 1997), suggests that peripheral tissues may exhibit 
changes in leptin sensitivity. However, changes in leptin sensitivity in 
peripheral tissues have not been demonstrated. The changes in expression of 
genes involved in leptin receptor-mediated signalling in peripheral tissues may 
be better understood knowing the effects of leptin sensitivity on other metabolic 
effects in these models of obesity.
133
Chapter 5
Quantitative Expression of Genes Involved in 
the Leptin Receptor-Mediated STAT 
Signalling Pathway in ob/ob mice treated 
with Intraperitoneal Leptin
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5,1 Introduction
The homology of the leptin receptor to the class I cytokine family of 
receptors suggested that leptin signals via the activation of JAKs and STAT 
transcription factors. This hypothesis was verified in a number of in vitro and in 
vivo studies that investigated leptin signalling by the long form of the leptin 
receptor. OB-Rb can activate JAK2 upon leptin binding and JAK2 can be co- 
immunoprecipitated with OB-Rb both in the presence or absence of leptin in 
BaF3 cells, a factor-dependent haematopoietic cell line (Ghilardi & 
Skodal997). In vitro studies showed that leptin can activate STATs 1,3,5 and 
6 in COS cells transfected with leptin receptor (Baumann et a l, 1996; Ghilardi 
et a l, 1996), but in vivo leptin activated only STAT3 in the hypothalamus of 
ob/ob mice and normal rats with maximal activation achieved after 30 minutes 
(Mccowen et a l, 1998; Vaisse et a l, 1996). Leptin was also shown to activate 
STAT5 in the jejunum of wild-type and ob/ob mice but not db/db mice (Morton 
et a l, 1998). Peripheral leptin administration of lean mice can induce the 
transcription of cytokine-inducible inhibitors of signalling genes, SOCS-3 and 
CIS, in the hypothalamus, liver and small intestine (Emilsson et a l, 1999). 
These proteins can in turn negatively regulate leptin signalling, either through 
inhibition of JAK kinases or by directly binding to STATs (Starr et a l, 1997; 
Starr & Hilton, 1998; Yoshimura et a l, 1995).
As discussed in chapter 3, there are a number of possible reasons for 
changes in leptin sensitivity, including changes in expression of leptin receptor 
isoforms or signalling components. Therefore, the expression of components of
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leptin receptor-mediated signal transduction (namely OB-Ra, OB-Rb, STAT3, 
STATS, SOCS-3 and CIS) was examined in the hypothalamus of ob/ob mice, 
which are highly sensitive to the leptin effects on feeding, treated 
intraperitoneally with leptin.
Most of the in vivo studies to date have looked at the expression of 
STATs and SOCS a short period after leptin treatment (Bjorbaek et a l, 1998b; 
Vaisse et a l, 1996). However, a study by Emilsson et a l has investigated 
changes in expression of components of leptin receptor-mediated signalling in 
ob/ob mice treated with leptin for 48 hours (Emilsson et a l, 1999). Leptin 
treatment of lean and ob/ob mice for 48 hours showed no change in leptin 
receptor expression, although there was a 2-fold increase in leptin receptor 
expression (all isoforms) in the hypothalamus of ob/ob mice (Emilsson et a l, 
1999). The increased leptin receptor expression has also been observed in the 
arcuate nucleus in two other studies (Baskin et a l, 1998; Huang et a l, 1997). 
No change in STAT3 or STATS mRNA was observed in the hypothalamus after 
48 hours of leptin treatment (Emilsson et a l, 1999). In the study by Emilsson et 
a l, the 48 hour leptin treatment resulted in a 2-fold increase in CIS, but not 
SOCS-3, mRNA in the hypothalamus of ob/ob mice, but a 5-fold increase in 
both SOCS-3 and CIS in the hypothalamus of lean mice (Emilsson et a l, 1999). 
Furthermore, in comparing lean and ob/ob mice, the expression of SOCS-3 and 
CIS was increased 2-fold in the hypothalamus of ob/ob mice treated with 
vehicle. A 2-fold increase of SOCS-3, but not CIS, mRNA in the hypothalamus
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of ob/ob mice was maximal between 1-3 hours after leptin treatment (Bjorbaek 
e ta l,  1998b).
In this study, I have examined the mRNA expression of leptin receptor- 
mediated signalling components by quantitative TaqMan RT-PCR in the 
hypothalamus of ob/ob mice treated with leptin for 24-hours and 2-weeks. The 
aim was to compare short- and long-term leptin treatment of ob/ob mice to 
changes in expression of components of the leptin receptor-mediated signalling 
pathway that may contribute to leptin sensitivity. Furthermore, changes in 
components of leptin receptor-mediated signalling were compared between lean 
and ob/ob mice. The expression of hypothalamic NPY mRNA expression was 
also examined, since the effect of leptin on food intake and energy balance 
involves altered hypothalamic NPY gene expression.
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5.2 Results
The groups of animals are as described in the table below. Groups B 
and C were sacrificed after 24 hours of vehicle/leptin treatment and the 
remaining groups were sacrificed after 2 weeks from the beginning of the study.
Table 5.1 Group descriptions of leptin-treated C57BL/6 ob/ob mice
Group Description
A C57BL/6 lean (+/?) mice
B C57BL/6 ob/ob mice treated with vehicle for 24 hours
C C57BL/6 ob/ob mice treated with leptin for 24 hours
D C57BL/6 ob/ob mice treated with vehicle for 2 weeks
E C57BL/6 ob/ob mice treated with leptin for 2 weeks
F C57BL/6 ob/ob mice pair-fed for 2 weeks
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5.2.1 Body Weight
The body weight of the mice was measured daily before leptin treatment 
(Figure 5.1). The body weight of the C57B1/6 lean mice changed little during 
the two weeks being 19.6 ± 0.5 g at the beginning and 20.7 ± 0.5 g at the end of 
the study. In the C57B1/6 oh/oh mice treated for 24-hours with vehicle, the 
body weight remained similar at 35.5 ± 0.9 g before vehicle treatment and 35.7 
± 1.0 g after vehicle treatment. After 24-hour leptin treatment (1 mg/kg/day), 
the body weight of C57B1/6 ob/ob mice was reduced from 36.5 ± 0.7 g to 35.1± 
0.7 g but the change was not statistically significant. In the C57B1/6 ob/ob mice 
treated with vehicle for 2-weeks, the body weight steadily increased from 35.8 ±
1.1 g to 40.6 + 1.0 g. However, the body weight of leptin-treated C57B1/6 ob/ob 
mice was significantly reduced over the 2-week period from 37.1 ±0.5 g to 30.8 
± 0.7 g (P<0.01). A comparison of C57B1/6 ob/ob mice treated with leptin for 
2-weeks compared to vehicle-treated mice showed that changes in body weight 
were statistically significant after 4 days of treatment (P<0.01). The body 
weight of the pair-fed group was intermediate between the vehicle and leptin- 
treated groups and after 2-weeks changed from 36.2 ± 2.0 g to 36.3 ± 1.0 g. In 
comparing vehicle-treated ob/oh mice to pair-fed ob/ob mice, the body weight 
of the pair-fed group was significantly reduced from day 9 of leptin treatment 
(P<0.05). A comparison of body weight in the leptin-treated ob/ob mice and 
pair-fed group showed the weight of the pair-fed group was significantly higher 
2 days after the start of the study, then at 4 days and from day 6 onwards of the 
study (P<0.05).
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Figure 5.1 Changes in body weight of leptin-treated C57BL/6 ob/ob mice 
C57BL/6 ob/ob mice (n=8) were treated with leptin (1 mg/kg/day) for a 24- 
hour-period and 2-week-period. The body weight of the mice was measured 
daily and is represented here in g ± SEM.
C57B1/6 lean 2-weeks vehicle — □—
C57BI/6 ob/ob 2-weeks vehicle —O—
C57B1/6 ob/ob 2-weeks leptin —# —
C57B1/6 ob/ob 2-weeks pair-fed - - 0 —
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5.2.2 Plasma Insulin
Insulin levels (see Figure 5.2) were significantly increased from 1 ng/ml 
in C57B1/6 lean mice to 75 ± 6 ng/ml (P<0.01) in C57B1/6 ob/ob 24-hour 
vehicle-treated mice and 33 + 5 ng/ml (P<0.01) in C57B1/6 ob/ob 2-week 
vehicle-treated mice. There was a significant decrease in insulin levels after 24- 
hours of leptin treatment from 75 + 6 ng/ml in vehicle-treated ob/ob mice 
compared to 33 + 7 ng/ml in leptin-treated ob/ob mice. In comparison to 
C57B1/6 ob/ob 24-hour vehicle-treated mice, insulin in C57B1/6 ob/ob 2-week 
vehicle-treated mice was significantly decreased by 2.6-fold from 75 + 6 ng/ml 
to 33 + 5 ng/ml (P<0.01). Insulin levels in C57B1/6 ob/ob mice treated with 
leptin for 2-weeks were significantly reduced compared to 2-week vehicle- 
treated ob/ob mice by 15-fold from 3 3 + 5  ng/ml to 5 ± 1 ng/ml (P<0.01). 
However, compared to 2-week vehicle-treated ob/ob mice, insulin levels were 
not significantly reduced in the pair-fed group (44 + 7 ng/ml in pair-fed group 
compared to 33 ± 5 ng/ml in 2-week vehicle-treated group). Insulin levels were, 
however, significantly reduced in 2-week leptin-treated ob/ob mice compared to 
pair-fed ob/ob mice (5 + 1 ng/ml compared to 44 + 7 ng/ml; P<0.01).
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Figure 5.2 Plasma insulin concentrations in leptin-treated C57BI/6 oh/ob 
mice
Plasma insulin levels in C57B1/6 ob/ob mice (n=8) treated with vehicle or leptin 
for either a 24-hour or a 2-week period or pair-fed for 2 weeks as described in 
section 2.3.1. Plasma insulin levels were measured in ng/ml ± SEM. The 
groups comparisons are listed below and the bars above the graph show 
significant changes between the groups (P<0.05).
A vs B lean vs ob/ob 24-hour vehicle
A vs D lean vs ob/ob 2-week vehicle
B vs C ob/ob 24-hour vehicle vs ob/ob 24-hour leptin
B vs D ob/ob 24-hour vehicle vs ob/ob 2-week vehicle
D vs E ob/ob 2-week vehicle vs ob/ob 2-week leptin
D vs F ob/ob 2-week vehicle vs ob/ob 2-week pair-fed
E vs F ob/ob 2-week leptin vs ob/ob 2-week pair-fed
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5.2.3 Gene Expression
The quantitative expression of components of the leptin receptor- 
mediated signalling pathway was examined by TaqMan RT-PCR in vehicle- and 
leptin-treated ob/ob mice. In this study, a number of housekeeping genes were 
analysed to determine which would be best to use as a covariate in ANCOVA 
analysis. The genes examined were glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), cyclophilin, 36B4 and HPRT. Of these genes, 36B4 was the most 
consistent and suitable to be used as a covariate (see appendix 1).
5.2.3.1 OB-Ra and OB-Rb
The changes in expression of OB-Ra and OB-Rb in the hypothalamus of 
leptin-treated ob/ob mice are shown in Figure 5.3. The expression of OB-Ra 
mRNA was unchanged in any of the treatment groups. There was a non­
significant increase of 17% in OB-Rb mRNA expression in the hypothalamus of 
lean mice compared to 24-hour vehicle-treated ob/ob mice (A vs B). However, 
there was a significant increase in the expression of OB-Rb mRNA in 2-week 
vehicle-treated (A vs D), leptin-treated (A vs E) and pair-fed (A vs F) ob/ob 
mice compared to leans by 31% (P<0.01), 23% (P<0.05) and 39% (P<0.01), 
respectively. There was no significant change in OB-Rb mRNA expression in 
the remaining group comparisons of the study, namely, after leptin treatment of 
ob/ob mice for 24-hours compared to vehicle-treated ob/ob mice; in 24-hour vs 
2-week vehicle-treated ob/ob mice; in 2-week leptin-treated compared to 
vehicle-treated ob/ob mice; in pair-fed ob/ob mice vs the 2-week vehicle-treated
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ob/ob mice and in the 2-week leptin-treated ob/ob mice vs the 2-week pair-fed 
ob/ob mice. In summary, the expression of OB-Rb, but not OB-Ra, is higher in 
the hypothalamus of ob/ob mice compared to leans. Furthermore, there is no 
effect on hypothalamic leptin receptor expression after ob/ob mice have been 
treated with leptin for either 24-hours or 2-weeks.
5.2.3.2 STAT3 and STATS
The changes in expression of the STATS and STAT5 genes in the 
hypothalamus of leptin-treated ob/ob mice are shown in Figure 5.4. In 
comparing lean mice and 24-hour vehicle-treated ob/ob mice (A vs B), STATS 
and STAT5 mRNA expression were increased in ob/ob mice by 32% (P<0.01) 
and 23% (P<0.05), respectively. Similarly, the expression of STATS and 
STAT5 mRNA was increased in 2-week vehicle-treated ob/ob mice compared 
to lean mice (A vs D) by 47% and 49% (P<0.01), respectively. The expression 
of both STAT3 and ST AT5 was increased in 2-week leptin-treated ob/ob mice 
compared to leans (A vs E) by 43% and 50% (P<0.01), respectively. Whereas, 
STATS was increased by 20% (P<0.01) in 2-week pair-fed ob/ob mice 
compared to leans (A vs F), however ST AT 5 remained unchanged. There was 
no significant change in STATS or STAT5 in ob/ob mice treated with leptin 
compared to vehicle for 24-hours (B vs C). The expression of STATS and 
STAT5 was unchanged in ob/ob mice treated with leptin for 2-weeks compared 
to vehicle-treated ob/ob mice (D vs E), but both STATS and ST AT5 were 
significantly reduced by 19% and 27% (P<0.01), respectively, in the pair-fed
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group when compared to vehicle-treated ob/ob mice (D vs F). However, a 
comparison of 24-hour and 2-week vehicle-treated ob/ob mice (B vs D) showed 
STAT5 mRNA was significantly increased by 20% (P<0.05) and STATS was 
increased by 11%, but not statistically significant, in 2-week vehicle-treated 
ob/ob mice. Reduced STATS and STATS mRNA (16% and 28%, respectively; 
P<0.01) was also observed in the pair-fed ob/ob mice in comparison to the 2- 
week leptin-treated ob/ob mice (E vs F). In summary, the expression of STATS 
and STATS was higher in ob/ob mice compared to leans. Furthermore, the 
expression of STATS and STATS was lower in pair-fed ob/ob mice compared to 
ob/ob mice treated with vehicle or leptin for 2-weeks. Although leptin 
treatment did not change STATS or STATS mRNA expression in ob/ob mice, 
pair-feeding did reduce STATS and STATS mRNA expression.
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Figure 5.3 Changes in OB-Ra and OB-Rb mRNA expression in the 
hypothalamus of C57B1/6 ob/oh mice treated with leptin for a 24-hour and 
2-week period
The mRNA levels for the reference group (e.g. A in A vs B) has been ascribed a 
value of 1 and the symbols indicate relative changes from this baseline. 
Comparisons are shown of (a) OB-Ra and (b) OB-Rb mRNA expression in the 
hypothalamus of:
A vs B lean vs ob/ob 24-hour vehicle
A vs D lean vs ob/ob 2-week vehicle
A vs E lean vs ob/ob 2-week leptin
A vs F lean vs ob/ob 2-week pair-fed
B vs C ob/ob 24-hour vehicle vs ob/ob 24-hour leptin
B vs D ob/ob 24-hour vehicle vs ob/ob 2-week vehicle
D vs E ob/ob 2-week vehicle vs ob/ob 2-week leptin
D vs F ob/ob 2-week vehicle vs ob/ob 2-week pair-fed
E vs F ob/ob 2-week leptin vs ob/ob 2-week pair-fed
Error bars indicate 95% confidence intervals and changes are shown as
significant where * P<0.05 and ** P<0.01.
■  OB-Ra mRNA 
•  OB-Rb mRNA
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Figure 5.4 Changes in STAT3 and STAT5 mRNA expression in the 
hypothalamus of C57B1/6 oh/oh mice treated with leptin for a 24-hour and 
2-week period
The mRNA levels for the reference group (e.g. A in A vs B) has been ascribed a 
value of 1 and the symbols indicate relative changes from this baseline. 
Comparisons are shown of (a) STATS and (a) STATS mRNA in the 
hypothalamus of:
A vs B lean vs ob/ob 24-hour vehicle
A vs D lean vs ob/ob 2-week vehicle
A vs E lean vs ob/ob 2-week leptin
A vs F lean vs ob/ob 2-week pair-fed
B vs C ob/ob 24-hour vehicle vs ob/ob 24-hour leptin
B vs D ob/ob 24-hour vehicle vs ob/ob 2-week vehicle
D vs E ob/ob 2-week vehicle vs ob/ob 2-week leptin
D vs F ob/ob 2-week vehicle vs ob/ob 2-week pair-fed
E vs F ob/ob 2-week leptin vs ob/ob 2-week pair-fed
Error bars indicate 95% confidence intervals and changes are shown as
significant where * P<0.05 and ** P<0,01.
■ STAT3 mRNA 
•  STATS mRNA
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5.2.3.3 SOCS-3 and CIS
The changes in expression of SOCS-3 and CIS in the hypothalamus of 
leptin-treated ob/ob mice are shown in Figure 5.5. The expression of CIS 
mRNA did not change in any of the group comparisons made. The expression 
of SOCS-3 mRNA in the hypothalamus of 24-hour vehicle-treated ob/ob mice 
compared to lean mice (A vs B) was reduced by 14% but not significantly. 
However, in the hypothalamus of 2-week vehicle-treated ob/ob mice compared 
to lean mice (A vs D), the expression of SOCS-3 was significantly reduced by 
28% (P<0.01). The expression of SOCS-3 mRNA remained unchanged in 2- 
week leptin-treated compared to leans (A vs E), however pair-fed ob/ob mice 
compared to leans (A vs F) showed a reduction of 13% that was not significant. 
After ob/ob mice were treated with leptin for 24-hours (B vs C), SOCS-3 
mRNA expression was reduced by 17% (P<0.05). However, SOCS-3 mRNA 
was reduced by 16% (P<0.05) in the hypothalamus of 2-week vehicle-treated 
ob/ob mice compared to 24-hour vehicle-treated oh/ob mice (B vs D). In 
comparing 2-week leptin-treated ob/ob mice and the pair-fed group to vehicle- 
treated ob/ob mice (D vs E and D vs F), the expression of SOCS-3 was 
increased by 29% (P<0.01) and 20% (P<0.05), respectively. However, when 
the ob/ob mice treated with leptin for 2-weeks were compared with the pair-fed 
group (E vs F), there was no significant change in SOCS-3 mRNA expression. 
In summary, the expression of hypothalamic SOCS-3 mRNA tends to be lower 
in ob/ob mice compared to leans. Although 24-hour leptin treatment reduced 
SOCS-3 mRNA expression, the chronic 2-week leptin treatment increased
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SOCS-3 mRNA expression though pair-feeding had a similar effect. The 
analysis of hypothalamic CIS mRNA expression showed no significant changes 
in ob/ob mice compared to leans, or after leptin treatment for either 24-hours or 
2-weeks.
S.2.3.4 NPY
The changes in hypothalamic NPY expression of leptin-treated ob/ob 
mice are shown in Figure 5.6. The expression of NPY in the hypothalamus of 
vehicle-treated ob/ob mice for 24-hours and 2-weeks compared to lean mice (A 
vs B and A vs D) was significantly increased by 89% and 148% (P<0.01), 
respectively. The expression of NPY was increased in 2-week leptin-treated 
and pair-fed ob/ob mice compared to leans (A vs E and A vs F) by 97% and 
252% (P<0.01), respectively. When ob/ob mice were treated with leptin for 24- 
hours (B vs C), there was a 17% reduction in NPY mRNA expression but this 
was not significant. The expression of NPY was increased by 31% (P<0.05) in 
2-week vehicle-treated ob/ob mice compared to 24-hour vehicle-treated ob/ob 
mice (B vs D). When ob/ob mice were treated with leptin for 2-weeks, NPY 
mRNA expression was reduced by 20% (P<0.05) compared to vehicle (D vs E). 
In comparison to the 2-week vehicle-treated ob/ob mice, the expression of NPY 
in the pair-fed mice (D vs F) was significantly increased by 42% (P<0.01). 
Furthermore, when compared to ob/ob mice treated with leptin for 2-weeks, the 
expression of NPY in the pair-fed mice (E vs F) was significantly increased by 
79% (P<0.01). In summary, the expression of hypothalamic NPY mRNA was
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higher in ob/ob mice compared to leans. Moreover, leptin treatment of ob/ob 
mice reduces hypothalamic NPY mRNA after 2-weeks, whereas diet restriction 
increased hypothalamic NPY mRNA.
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Figure 5.5 Changes in SOCS-3 and CIS mRNA expression in the 
hypothalamus of C57B1/6 oh/ob mice treated with leptin for a 24-hour and 
2-week period
The mRNA levels for the reference group (e.g. A in A vs B) has been ascribed a 
value of 1 and the symbols indicate relative changes from this baseline. 
Comparisons are shown of (a) SOCS-3 and (b) CIS mRNA in the hypothalamus 
of:
A vs B lean vs ob/ob 24-hour vehicle
A vs D lean vs ob/ob 2-week vehicle
A vs E lean vs ob/ob 2-week leptin
A vs F lean vs ob/ob 2-week pair-fed
B vs C ob/ob 24-hour vehicle vs ob/ob 24-hour leptin
B vs D ob/ob 24-hour vehicle vs ob/ob 2-week vehicle
D vs E ob/ob 2-week vehicle vs ob/ob 2-week leptin
D vs F ob/ob 2-week vehicle vs ob/ob 2-week pair-fed
E vs F ob/ob 2-week leptin vs ob/ob 2-week pair-fed
Error bars indicate 95% confidence intervals and changes are shown as
significant where * P<0.05 and ** P<0.01.
■ SOCS-3 mRNA 
•  CIS mRNA
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Figure 5.6 Changes in NPY mRNA expression in the hypothalamus of 
C57BI/6 ob/ob mice treated with leptin for a 24-hour and 2-week period
The iiiRNA levels for the group (e.g. A in A vs B) has been ascribed a value of 
1 and the symbols indicate relative changes from this baseline. Comparisons 
are shown of NPY mRNA in the hypothalamus of:
A vs B lean vs ob/ob 24-hour vehicle
A vs D lean vs ob/ob 2-week vehicle
A vs E lean vs ob/ob 2-week leptin
A vs F lean vs ob/ob 2-week pair-fed
B vs C ob/ob 24-hour vehicle vs ob/ob 24-hour leptin
B vs D ob/ob 24-hour vehicle vs ob/ob 2-week vehicle
D vs E ob/ob 2-week vehicle vs ob/ob 2-week leptin
D vs F ob/ob 2-week vehicle vs ob/ob 2-week pair-fed
E vs F ob/ob 2-week leptin vs ob/ob 2-week pair-fed
Error bars indicate 95% confidence intervals and changes are shown as
significant where * ?<0.05 and ** P<0.01.
■  NPY mRNA
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5.3 Discussion
This set of investigations are similar in design to a previous study by 
Emilsson et a l, who looked at the effect of 48 hours of leptin treatment (1.5 
mg/kg/d ay) on the expression of components of the leptin receptor-mediated 
signalling pathway in a number of tissues in lean and obese (pb/ob) mice by RT- 
PCR (Emilsson et a l, 1999). In this study, the expression of components of the 
leptin receptor-mediated signalling pathway was examined in the hypothalamus 
of oh/ob mice treated with leptin for 24-hours and 2-weeks by quantitative 
TaqMan RT-PCR. The dose of i.p. leptin used was 1.0 mg/kg/day, a sub- 
maximal leptin concentration within the dose response range originally reported 
to inhibit food intake and activation of the JAK7STAT pathway (Morton et al, 
1998; Pelleymounter et a l, 1995; Vaisse et a l, 1996).
Leptin signalling in both peripheral and central tissues (Vaisse et a l, 
1996) is primarily mediated through the OB-Rb receptor isoform by the 
activation of the JAK/STAT pathway. Investigation of leptin receptor 
expression showed a 17% increase of OB-Rb mRNA in the hypothalamus of 24- 
hour vehicle-treated ob/ob mice compared to leans, but the change was not 
significant. However, the expression of OB-Rb mRNA in the hypothalamus of 
2-week vehicle-treated ob/ob compared to lean mice was significantly increased 
by 31% increase and the increase was maintained after leptin treatment or pair- 
feeding. This increase is consistent with previous reports; although the authors 
report a greater (2-fold) increase of OB-R expression in the hypothalamus of
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ob/ob mice compared to leans by in situ hybridisation and RT-PCR (Baskin et 
a l, 1998; Emilsson et a l, 1999; Huang et a l, 1997). Perhaps the lack of 
circulating leptin results in increased hypothalamic OB-R expression. The 
observations in this set of experiments are inconsistent with the study described 
in Chapter 3 (see 3.3.1 Discussion) where no change in OB-Ra or OB-Rb 
mRNA was observed in ob/ob mice compared to leans. Furthermore, there was 
no change in hypothalamic leptin receptor expression after ob/ob mice were 
treated with leptin for 24-hours and 2-weeks, which is in agreement with the 
observations by Emilsson et a l where oh/ob mice were treated with leptin for 
48 hours (Emilsson e ta l,  1999).
The expression of STATS and STAT5 mRNA was increased in the 
hypothalamus of ob/ob mice compared to leans, which contrasts with the results 
by Emilsson et a l where no change was observed (Emilsson et a l, 1999). The 
increase in STATS and STATS mRNA expression is consistent with the 
increased OB-Rb mRNA in ob/ob mice suggesting an increase in the potential 
for leptin signalling in these animals. There was no change in STATS or 
STATS mRNA expression after leptin treatment of ob/ob mice for 24-hours or 
2-weeks compared to vehicle-treated ob/ob mice, which is in agreement with the 
observations by Emilsson et a l after 48 hours of leptin treatment (Emilsson et 
a l, 1999). However, both STATS and STATS mRNA expression were slightly 
increased in 2-week vehicle-treated ob/ob mice compared to 24-hour vehicle- 
treated ob/ob mice, although the STATS mRNA increase was not significant. It 
is not clear why STATS and STATS are increased but it may be related to the
1S4
weight gain that occurs during the 2-week period. In addition, the expression of 
STATS and STATS was reduced by similar levels in pair-fed ob/ob mice 
compared to 2-week vehicle or leptin-treated ob/ob mice. This suggests the 
reduced STATS and STATS expression in pair-fed ob/ob mice may be due to 
the effects of reduced food intake, and suggests that the lack of effect of leptin 
on STATs involves the interplay of other factors. Although the expression of 
STATS and STATS was reduced in 2-week pair-fed compared to vehicle-treated 
and leptin-treated ob/ob mice, there was still a significant elevation in 
expression compared to leans.
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Table 5.2 Summary of gene expression changes involved in leptin receptor- 
mediated signalling in the hypothalamus
OB-Ra OB-Rb STATS STATS SOCS-3 CIS NPY
A vs B NC T 17% t T 32% * T 23% * i  14% t NC t  89% **
A vs D NC t  31% ** t  47% ** t  49% ** 28% ** NC T 148% **
A vs E NC t  23% * t  43% ** t  50% ** NC NC t  97% **
A vs F NC Î  39% ** T 20% NC 13% t NC T 252% **
B vs C NC NC NC NC 4- 17% * NC 4- 17% t
B vs D NC NC t  11% t T 20% * 1 16% * NC t  31% *
D vs E NC NC NC NC t  29% ** NC 4- 20% *
D vs F NC NC i  19% ** 4- 27% ** T 20% * NC t  42% **
E vs F NC NC 16% ** 'j.28% ** NC NC t  79% **
Key: NC -  no change, f  - non-significant change, * P<0.05, ** P <0.01
There was a trend towards reduced SOCS-3 mRNA expression in 24- 
hour vehicle-treated ob/ob mice and a significant reduction in 2-week vehicle- 
treated ob/ob mice when compared to lean mice. Emilsson et al. have observed 
a 2-fold increase in hypothalamic SOCS-3 mRNA expression in ob/ob 
compared to lean mice (Emilsson et a l, 1999), the effects of which they propose 
could be counteracted by the observed 2-fold increase in OB-R mRNA in the 
hypothalamus of ob/ob mice. Since ob/ob mice are more sensitive to the effects 
of leptin on feeding than lean mice, the reduced expression of SOCS-3 mRNA 
in leptin deficient ob/ob mice observed here is consistent with its role as a
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negative regulator of leptin signalling. Interestingly, SOCS-3 mRNA 
expression was reduced after 24-hours of leptin treatment but increased after 2- 
weeks of leptin treatment compared to vehicle-treated oh/oh mice. Whilst there 
have been reports of increased SOCS-3 mRNA expression after leptin treatment 
implying initiation of a negative feedback loop, the expression has been 
measured from between 0.5-2 hours after leptin treatment. In a study by 
Emilsson et a l, there was no change in SOCS-3 mRNA expression after 48 
hours of leptin treatment at 1.5 mg/kg/day (Emilsson et a l, 1999). Surprisingly 
therefore, in our study, SOCS-3 mRNA was significantly reduced by 17% after 
24-hours of leptin treatment of ob/ob mice, which is inconsistent with previous 
in vitro and in vivo studies and its role as a suppressor of leptin signalling. The 
differences in SOCS-3 mRNA expression after 24-hours and 2-weeks of leptin 
treatment suggest that leptin may have different acute and chronic effects. The 
increased expression of SOCS-3 mRNA in 2-week leptin-treated and pair-fed 
ob/ob mice compared to vehicle could be explained by the reduced levels of 
SOCS-3 mRNA in 2-week vehicle-treated ob/ob mice compared to 24-hour 
vehicle-treated ob/ob mice or due to reduced food intake rather than leptin per 
se. Emilsson et a l observed a 2-fold increase in hypothalamic CIS mRNA 
expression in ob/ob mice compared to leans and after 48 hours of leptin 
treatment (Emilsson et a l, 1999). However, no change in hypothalamic CIS 
mRNA was observed in this study in comparing ob/ob mice to leans or after 
leptin treatment for 24-hours or 2-weeks (Emilsson et a l, 1999). An in vitro
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study in CHO cells expressing OB-Rb, showed no change in CIS mRNA 
expression up to 4 hours after leptin treatment (Bjorbaek et a l, 1999).
Hypothalamic NPY expression was increased in 24-hour and 2-week 
vehicle-treated ob/ob mice compared to lean mice by 89% and 148%, 
respectively. This is consistent with previous observations, where it has been 
observed that NPY is expressed at high levels in the hypothalamus of ob/ob 
mice compared to leans. After 24-hours leptin treatment, there was a small 
reduction, though not significant, in hypothalamic NPY mRNA expression in 
ob/ob mice. There may be a number of factors why NPY levels are higher in 2- 
week compared to 24-hour vehicle-treated ob/ob mice, such as the reduced 
insulin levels in 2-week vehicle ob/ob mice (Davies & Marks, 1994). After 2- 
weeks of leptin treatment there was a significant reduction in NPY mRNA 
expression compared to vehicle-treated ob/ob mice. Furthermore, NPY mRNA 
was increased in the pair-fed group compared to both the 2-week vehicle-treated 
ob/ob mice and the 2-week leptin-treated ob/ob mice, which is consistent with 
the effect of leptin on NPY gene expression in food-deprived mice. These 
observations are consistent with increased leptin resulting in reduced 
hypothalamic NPY expression and the leptin deficiency in ob/ob mice resulting 
in increased hypothalamic NPY mRNA expression compared to leans.
In summary, there are some significant changes in components of the 
leptin receptor-mediated signalling pathway after leptin treatment; however 
some of the changes have not been consistent in magnitude or direction to 
previous studies. It should be noted that there are other signals capable of
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activating the JAK-STAT pathway that may affect the expression of STATs and 
SOCS genes in the hypothalamus. Moreover, components involved in leptin 
receptor-mediated signalling are highly expressed in particular areas of the 
hypothalamus; therefore by examining the gene expression in the hypothalamic 
block the changes may not be a true reflection of the changes that occur. Of the 
genes examined, the expression of SOCS-3 mRNA in ob/ob mice was the only 
one that changed after 24-hours or 2-weeks of leptin treatment, but there were 
significant changes in OB-Rb, STAT3, STAT5 and SOCS-3 in vehicle-treated 
ob/ob mice compared to leans. This suggests regulation of the components of 
the leptin receptor-mediated signalling pathway may be involved in leptin 
sensitivity but their role remains unclear. Finally, in discussing the relevance of 
changes in mRNA, it must be remembered that this may not equate to changes 
in protein expression whilst the biological effect, if any, of small changes in 
mRNA expression remains to be determined.
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Chapter 6
Quantitative Leptin Receptor Expression in 
the Hypothalamus of ZDF rats
160
The animal study described in this chapter was performed by 
Mohammad Tadayyon and Carolyn Lister at GlaxoSmithKline. mRNA was 
made available from the hypothalami of ZDF +/? and fa/fa  rats to investigate 
leptin receptor expression by TaqMan analysis.
6.1 Introduction
In humans, the consumption of excess food can result in obesity, which 
over a long period of time can lead to insulin resistance, p-cell failure and to 
type II diabetes. The diabetes is preceded by an extended period of insulin 
resistance, due to an increased proportion of adiposity, during which 
compensatory increased insulin production maintains normal glucose levels 
(Unger1995). Hyperglycaemia manifests when insulin production fails to keep 
pace with progressively increasing insulin resistance and type II diabetes 
ensues. The Zucker Diabetic Fatty (ZDF) rats provide a useful model of 
adipogénie type II diabetes because they exhibit a similar pattern of increased 
obesity, insulin resistance followed by p-cell failure (Peterson et a l, 1990) to 
that observed in obese humans.
In ZDF rats there is a marked increase in the triglyceride content in 
pancreatic islets during the development of the p-cell defects of adipogénie 
diabetes which leads to increased {3-cell death, so-called "lipotoxicity". 
(Unger1995). Lipotoxicity is observed in several peripheral tissues and is 
attributed to products of excessive non-p-oxidative metabolism of fatty acid 
excess in skeletal muscle, pancreatic islets, and myocardium (Lee et a l, 1997;
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Shimabukuro et a l, 1998b; Shimabukuro et a l, 1998c). Furthermore, 
lipoapoptosis of p-cells in obese ZDF fa/fa  rats is thought to be mediated by 
overproduction of ceramide, and is induced by high levels of long chain fatty 
acids (Shimabukuro et a l, 1998b). Ceramide increases the expression of 
inducible nitric oxide synthase (iNOS) through activation of nuclear factor kB  
(Katsuyama et a l, 1998), and thereby augments the production of nitric oxide 
(NO) (Shimabukuro et a l, 1997a). NO forms potent oxidants, such as 
peroxynitrite (Ghafourifar et a l, 1999; Lin et a l, 1995), that cause apoptosis. 
Therefore it is possible that the pathogenesis of p-cell failure is entirely 
secondary to the overabundance of triglycerides in the pancreatic islets. 
Experiments to reduce the islet triglyceride content by caloric restriction and 
administration of inhibitors of inducible iNOS in prediabetic ZDF rats reduce p- 
cell abnormalities and apoptosis (Ohneda et a l, 1995; Unger1995), raising the 
possibility of a causal relationship between the fat overload in islets and the P- 
cell dysfunction. It is believed that high levels of these metabolic products may 
be responsible for the complications of obesity, insulin resistance, 
cardiovascular disease and diabetes by disrupting cell function and ultimately by 
promoting programmed cell death (also known as "lipoapoptosis") 
(Shimabukuro et a l, 1998c; Unger1995).
In the Zucker fa/fa  and ZDF rat, there is a single A -> C amino acid 
substitution at nucleotide 880 in the extracellular domain of the leptin receptor 
(OB-R(/a)), resulting in a glutamine^^^ (Gln^^^) to proline^ *^  ^ (Pro^^^) amino acid 
substitution (lida et a l, 1996; Phillips et a l, 1996). The resulting phenotype of
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the Zucker fa/fa  rat is obesity, hyperphagia, sterility, hypercholesterolemia, and 
hyperlipidemia (Zucker & Zucker, 1961; Zucker & Zucker, 1962; Zucker & 
Zucker, 1963). The Zucker fa/fa  rat, like the ZDF fa/fa  rat, is also 
hyperinsulinaemic and insulin resistant, but does not display fasting 
hyperglycaemia and is only mildly glucose intolerant. In human terms 
therefore, the Zucker fa/fa  rat is probably representative of the obese, pre­
diabetic subject. The ZDF rat is similar to, and was derived from, the Zucker 
fa/fa  rat, with the exception that the males are hyperglycaemic by the age of 
about 10 weeks (Clark & Palmerl982; Janssen et a i, 1999). Whilst plasma 
insulin is elevated during the development of diabetes, it drops to below the 
level of lean controls as the p-cell start to fail and the diabetic state develops 
(Janssen et a l, 1999). The body weight of ZDF rats increases during the 
development of diabetes, but is reduced as the diabetic state develops (Janssen 
et a l, 1999). The ZDF model is therefore useful for the study of adult onset 
diabetes.
In vitro experiments have shown reduced OB-R (fd) expression 
compared to wild type OB-R in transfected COS-7 cells (Chua et a l, 1996b; 
Rosenblum et a l, 1996; White et a l,  1997b). Furthermore, the fatty mutation in 
short OB-R isoforms results in a 6 to 8-fold reduction in cell surface expression 
relative to its wild-type (wt) counterpart, whereas OB-Rb (fd) exhibits only a 2 
to 3-fold reduction in cell surface expression compared with OB-Rb (wt) (White 
et a l, 1997b). In COS-1 cells, overexpression of OB-Rb (wt) activates 
endogenous STATl and -3, or coexpressed STATl, -3 and -5B upon leptin
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binding. In contrast, OB-Rb (fd) constitutively activates both endogenous 
STATl and -3, and coexpressed STATl and -3, and activation of these STATs 
was further increased by the addition of leptin (White et a l, 1997b). The OB- 
Rb (fd) has a reduced level of STATl and -3 activation due to the reduced cell 
surface expression of this receptor compared with OB-Rb (wt) and a reduced 
intrinsic ability of OB-Rb (fd) to activate STATl and -3 compared with OB-Rb 
(wt) (Rosenblum et a l, 1996; White et a l, 1997b). Furthermore, OB-Rb (fd) is 
unable to constitutively activate cotransfected STAT5B and exhibits attenuated 
leptin activation of STAT5B compared with OB-Rb (wt) (White et a l, 1997b). 
The excessive fat accumulation in islets of ZDF rats is the consequence of this 
amino acid substitution in all isoforms of the leptin receptor, which abolishes 
the direct lipopenic action (i.e. increase fatty acid oxidation and the expression 
of genes for fatty acid oxidation) of leptin on the p-cell because of impaired 
leptin signalling (Shimabukuro et a l, 1997b). However, the overexpression of 
wild-type OB-R in ZDF rats using adenovirus can restore the lipopenic action of 
leptin, reduce exaggerated iNOS expression by islets and enable FF As to up- 
regulate proinsulin gene expression (Wang et a l, 1998b).
The aim of this chapter was to investigate whether the mutation in the 
leptin receptor of ZDF rats changes the expression of OB-Ra and OB-Rb 
mRNA in the hypothalamus when compared to that of controls (+/?).
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6,2 Results
The body weight, blood glucose and plasma insulin levels of ZDF +/? 
and ZDF fa/fa  rats were measured between the ages of 7 and 24 weeks, and the 
plasma leptin levels and pancreatic insulin content was determined at the end of 
the study. The body weight of ZDF +/? rats and ZDF fa/fa  rats are shown in 
Figure 6.1. At the age of 7 weeks, body weights of ZDF fa/fa  rats were 
significantly higher than that of ZDF 4-/? rats (193 ± 5 g versus 147 ± 7.5 g; 
P<0.01). Body weights of the ZDF fa/fa  rats increased significantly from 193 ± 
5 g at 7 weeks of age to 398 ± 13.4 g at 16 weeks of age (P<0.05). Thereafter, 
the body weights of ZDF fa/fa  rats did not significantly alter whereas ZDF +/? 
rats showed a small but steady increase in body weight. The body weight of 
ZDF fa/fa  rats was the same as ZDF +/? rats at 23 weeks of age, but by the 
following week, the body weight of the ZDF fa/fa  rats was lower but not 
significantly at 409 ± 20.5 g compared to 423 ± 12.3 g for ZDF +/? rats.
The blood glucose concentration of ZDF +/? rats did not increase with 
age and remained steady during the study period, on average at about 5 mmol/1 
(Figure 6.2). At the age of 8 weeks, there was no significant difference in blood 
glucose concentrations of ZDF fa/fa  rats compared to ZDF +/? rats (7.5 ± 0.6 
mmol/1 versus 6.2 ± 0.3 mmol/1). However, there was a significant increase in 
blood glucose levels in ZDF fa/fa  rats compared to lean controls at the age of 10 
weeks (12.9 ± 1.6 mmol/1 versus 4.65 ±0.1 mmol/1; P<0.01). Thereafter, blood 
glucose levels further increased significantly in ZDF fa/fa  rats compared to ZDF 
+/? rats to 27 mmol/1 (P<0.01) at 25 weeks.
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Figure 6.1 Changes in body weight of ZDF +/? and fa/fa  rats
Changes in body weight of ZDF +/? and fa/fa  rats fed a chow diet between the 
ages of 7 and 24 weeks. Values are represented as grams ± SEM and * P<0.05. 
□  ZDF +/? rats 
■  ZDF fa/fa  rats
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Figure 6.2 Changes in blood glucose concentrations of ZDF +/? and fa/fa  
rats
Blood samples were taken from ZDF rats during the course of the study to 
measure the blood glucose concentration. The blood glucose concentrations 
(mmoFl) of ZDF ±/? and fa/fa  rats were measured between the ages of 8 and 23 
weeks. Values are represented as mmol/1 ± SEM and ** P<0.01.
□  ZDF +/?
■  ZDF fa/fa
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There was little change In plasma insulin levels of ZDF +/? rats between 
the ages of 10 and 24 weeks, with levels ranging between 2.2 ± 0.3 ng/ml and 
1.3 ±0.1 ng/ml (Figure 6.3). However, insulin levels of ZDF fa/fa  rats at the 
age of 10 weeks were significantly higher than ZDF +/? rats (20.3 ± 2.2 ng/ml 
versus 1.9 ± 0.2 ng/ml; P<0.01). Although plasma insulin levels of ZDF fa/fa  
rats decreased with age, the insulin levels remained significantly higher than 
ZDF +/? rats until the age of 21 weeks (7.8 ± 2.5 ng/ml versus 1.8 ± 0.2 ng/ml; 
P<0.05).
In this study, plasma leptin levels were measured only from terminal 
blood samples of ZDF ±/? and ZDF fa/fa  rats (Table 6.1). At the age of 24 
weeks, leptin levels in ZDF fa/fa  rats were significantly higher than ZDF +/? 
rats by 3.5-fold. Pancreatic insulin levels showed almost a 6.75-fold reduction 
in ZT>V fa/fa  rats compared to ZDF +/? rats.
Table 6.1 Leptin and pancreatic insulin levels in terminal blood samples of 
ZDF +/? and fa /fa  rats
Group Leptin
(ng/ml)
Pancreatic Insulin 
(ng insulin /mg tissue)
ZDF +/? 3.6 ± 0.4 1836 ± 329
fa/fa 12.6 ±2.1** 272 ± 94**
** P<0.01
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Figure 6.3 Changes in plasma insulin concentration of ZDF +/? and fa/fa  
rats
Plasma insulin concentrations (ng/ml) were measured from blood samples of 
ZDF +/? and fa/fa  rats between the ages of 10 to 24 weeks. Values are 
represented as mmol/1 + SEM, * P<0.05 and ** P<0.01.
□  ZDF +/? rats 
■  ZDF fa/fa  rats
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OB-Ra and OB-Rb mRNA expression was investigated in the 
hypothalamus of ZDF fa/fa  rats and ZDF +/? rats using (3-actin, GAPDH, 
cylophilin and HPRT as housekeeping genes. The results shown in Figure 6.6 
are a pool of the TaqMan runs described above. None of the housekeeping 
genes were used as a co-variate for ANCOVA analysis because either they were 
not suitable due to variation in the data or they did not improve the analysis. In 
the hypothalamus, the mRNA expression of OB-Ra and OB-Rb in ZDF fa/fa  
rats compared to ZDF +/? rats was increased by 86% and 92% (P<0.05), 
respectively (Figure 6.4).
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Figure 6.4 OB-Ra and OB-Rb expression in the hypothalamus of ZDF +/? 
and fa/fa  rats
The mRNA expression of OB-Ra and OB-Rb in ZDF +/? rats have been 
ascribed a value of 1 and the symbols indicate fold changes from this baseline 
(as described in Appendix 1). Comparisons are shown of OB-Ra and OB-Rb 
mRNA in the hypothalamus of ZDF +/? and ZDF fa/fa  rats at the age of 24 
weeks. Error bars indicate 95% confidence intervals and changes are shown as 
significant where * P<0.05.
□ OB-Ra 
■  OB-Rb
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6.3 Discussion
The aim of this study was to investigate if there are any changes in 
hypothalamic leptin receptor expression in ZDF fa/fa rats compared to ZDF +/? 
rats. This study shows that leptin levels were clearly elevated by 3.5-fold in 
ZDF fa/fa  rats compared to ZDF +/? rats at the age of 24 weeks. This can be 
explained by the fact that ZDF fa/fa  rats have more fat resulting from their 
reduced leptin sensitivity. In young ZDF fa/fa  rats, plasma insulin levels were 
highly elevated compared to young ZDF +/? rats due to their high glucose 
levels. However, as (3-cells of ZDF fa/fa  rats start to deteriorate plasma insulin 
levels in ZDF fa/fa  rats were reduced with age whereas plasma insulin remained 
similar in ZDF +/? rats during the 24 week period. At the age of 24 weeks, 
there was no significant difference in plasma insulin levels between ZDF fa/fa  
rats and ZDF +/? rats. The reduction in ZDF fa/fa  insulin levels is caused by the 
failure of P-cells to compensate for the insulin resistant state of the rats due to 
lipotoxicity.
The changes in body weight, blood glucose, plasma insulin and plasma 
leptin levels measured in ZDF fa/fa  rats and ZDF +/? rats are similar to changes 
observed in a recent study by Janssen et a l of animals between 10 and 25 weeks 
of age (Janssen et a l, 1999). In the study by Janssen et a l, plasma leptin levels 
were measured for the duration of the study and correlated with plasma insulin 
rather than with body weight in ZDF fa/fa  rats (Janssen et a l, 1999). This 
suggests an important role for insulin in the modulation of leptin secretion 
which is in accordance with previous studies (Patel et a l, 1998; Saladin et a l.
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1995). Saladin et a l showed that insulin administration of fasted rats increased 
leptin mRNA to the level of fed controls, and Patel et a l showed that increased 
plasma leptin and leptin mRNA following food intake is dependent on plasma 
insulin levels in rats (Patel et a l, 1998; Saladin et a l, 1995). In human adipose 
tissue, insulin appears to induce an early inhibition of leptin secretion by the 
adipose cell whereas prolonged exposure to insulin increases plasma leptin 
concentrations (Casabiell et a l, 2000). As a feedback mechanism leptin has 
been shown to modulate insulin secretion. Leptin inhibits the secretion of 
insulin in isolated islets of ob/ob mice (Kieffer et a l, 1997) and in the perfused 
pancreas of ob/ob mice (Emilsson et a l, 1997).
The differential expression of the OB-Rb transcript in human 
hypothalamus may be caused by endogenous factors such as insulin and leptin 
(Hikita et a l, 2000). There is growing evidence that insulin functions as an 
afferent metabolic signal in the CNS (Inui, 1999; Porte et a l, 1998; Woods et 
a l, 1998). For example, insulin reduces food intake and body weight in a dose- 
dependent manner when administered directly into the CNS (Woods et a l, 
1998). Furthermore, in growth hormone releasing hormone (GHRH) transgenic 
mice, growth hormone (GH) and/or GHRH as well as leptin and insulin may 
contribute to changes in OB-Rb mRNA expression in the anterior pituitary and 
hypothalamus (Cai & Hyde, 1999). It is possible that insulin-mediated 
intracellular signalling may regulate OB-Rb expression levels in hypothalamic 
neurons. Porte et a l have proposed the hypothesis that intact leptin signalling is 
required for CNS responses to insulin, and that leptin resistance, therefore,
173
would lead to a condition in which insulin is less effective as a satiety signal 
(Porte et a l, 1998). Therefore, it is likely that insulin might perform its satiety 
function in part by regulating leptin signalling in neurons. In the process of 
such a regulatory mechanism, the differential regulation of OB-Rb by insulin 
and leptin might play a role in maintaining body weight mass. A previous 
observation (lida et a l, 1996) that OB-R mRNA expression is increased in the 
hypothalamus of Zucker fa/fa  rats by 3.5-fold, is consistent with increased OB- 
Ra and OB-Rb mRNA expression in the hypothalamus of ZDF fa/fa  rats. The 
elevated levels of leptin present in this animal model might be expected to result 
in reduced hypothalamic leptin receptor expression, however compromised 
leptin receptor signalling and high insulin levels may be involved in the 
upregulation of receptor expression. The feedback mechanism could involve 
another hormone or a downstream signalling factor, such as SOCS-3.
In situ binding experiments using ^^S-leptin on brain slices from fa/fa  
rats indicate that th e /a /^  OB-R is capable of binding leptin (Phillips et a l, 
1996). Therefore, the Gin to Pro mutation does not render a null state for leptin 
binding, suggesting that the mutation may have its predominant effect on OB-R 
expression or dimer formation, a requisite for signalling with this class of 
receptors (Kishimoto et a l, 1994). Rosenblum et a l have observed that the 
mutated fa  OB-R is functional but there is reduced activation of STATs 1 and 3 
(Rosenblum et a l, 1996). In addition the efficiency of fa  OB-R expression is 
greatly reduced when transfected into either GTl-7 and COS-7 cells and 
compared to the wild-type OB-R (Rosenblum et a l, 1996). The decreased
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response to leptin in cells expressing fa  rat OB-R suggests that the Gln^^  ^ —> 
Pro^^  ^ mutation plays a role in the cell-surface expression of OB-R and which 
may be one cause of the leptin resistant phenotype. Therefore, the amount of 
OB-R present on a cell surface in addition to attenuated signalling capacity may 
be critical for regulation of body weight. Interestingly, there are examples of 
missense mutations in the human insulin receptor which cause impaired receptor 
transport to the cell surface and are partially, if not completely, responsible for 
insulin resistance (Kadowaki et a l, 1990; Kadowaki et a l, 1991; Maassen et a l, 
1991). In addition to the elevated insulin levels and impaired leptin receptor 
signalling, the increased OB-Ra and OB-Rb mRNA expression may be a 
compensatory mechanism for reduced cell surface expression.
There are a number of studies that illustrate reduced OB-R cell surface 
expression and signalling in the Zucker fa  rat (Crouse et a l, 1998; Rosenblum 
et a l, 1996; White et a l, 1997b; Yamashita et a l, 1997). White et a l have 
suggested the mutation in OB-Rb (fa) induces an incomplete conformational 
change that partially mimics the ligand bound state, resulting in partial 
constitutive receptor activation. The OB-Rb (fa) may adopt a conformation that 
prevents efficient interaction with downstream signalling components resulting 
in constitutively activate STAT5B and impaired for leptin-induced STAT5B 
activation.
In summary, the mRNA expression of OB-Ra and OB-Rb are increased 
in the hypothalamus oîZDV fa/fa  rats, perhaps in an attempt to compensate for 
reduced OB-R surface expression and leptin signalling. Although it has been
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suggested that the reduced OB-R surface expression may result in reduced 
leptin transport to the CNS, the concentration of cerebral spinal fluid leptin in 
ZDF fa/fa  rats is equal to that in non-obese controls (Wu-Peng et a l, 1997). 
Consistent with reduced leptin signalling, this suggests the fatty rat is obese due 
to diminished leptin responsiveness in hypothalamic neurons. Furthermore, 
fatty rats respond to i.c.v. leptin injections only at greatly increased doses 
relative to lean controls (A1 Barazanji et a l, 1997; Cusin et a l, 1996). 
Moreover, the phenotype of ZDF fa/fa  may be a result of constitutive OB-Rb 
(fa) signalling, which is not inconsistent with the recessive nature of the fatty 
mutation since the coexpression with OB-Rb (wt) results in suppression of 
constitutive OB-Rb (fa) signalling (White et a l, 1997b). Although the increase 
in hypothalamic OB-Ra and OB-Rb mRNA expression is small, it is not known 
what the effects at the protein level will be. Therefore, the resulting phenotype 
of ZDF fa/fa  rats may be due to both reduced receptor levels on the cell surface 
and reduced signalling of the leptin receptor.
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Chapter 7 
General Discussion
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The aim of this research was to investigate whether changes in mRNA 
expression of genes involved in leptin receptor-mediated signalling plays a role 
in leptin sensitivity. These studies primarily used leptin-insensitive dietary 
obese and leptin-sensitive genetically obese mice as model systems. Leptin 
insensitivity may be a result of one or more defects; the transport of leptin to the 
hypothalamic nuclei, the expression of leptin receptor isoforms in central and 
peripheral tissues and/or the expression of signalling components downstream 
of the leptin receptor. This series of experiments was designed to focus on the 
latter two possibilities. The expression of six genes that have reportedly been 
involved in leptin receptor-mediated signalling: OB-Ra, OB-Rb, STAT3, 
STAT5 SOCS-3 and CIS was examined. Initially, a study was set up to 
compare the gene expression of components of leptin receptor-mediated 
signalling in the hypothalamus of leptin-insensitive dietary obese and leptin- 
sensitive genetically obese (ob/ob) mice (Chapter 3). This also raised the 
opportunity to investigate gene expression in other tissues in which there were 
increasing number of reports of leptin receptor expression and function. The 
other tissues examined were the pituitary, pancreas, WAT, BAT and small 
intestine (Chapter 4).
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7.1 AKR/J mice fed a palatable diet compared to chow
7.1.1 Hypothalamus and pituitai*y
In AKR/J mice fed a palatable diet compared to those fed on chow, 
hypothalamus and pituitary showed changes in components of leptin receptor- 
mediated signalling. The expression of OB-Ra and STATS mRNA was reduced 
in the hypothalamus; OB-Ra mRNA was reduced in the pituitary. The reduced 
expression of OB-Ra mRNA in the hypothalamus and pituitary may implicate 
reduced leptin access in these tissues and/or reduced OB-Ra-mediated signalling 
i.e. JAK2 and MARK activation. Leptin, through OB-Rb, can activate STATS, 
but not STATS, in the hypothalamus of lean and ob/ob mice (Vaisse et a l,
1996), suggesting the reduced STATS mRNA in dietary obese AKR/J mice may 
be due to obesity-related factors other than leptin. No significant change was 
observed in SOCS-3 mRNA in the hypothalamus of AKR/J mice fed a palatable 
diet compared to those fed on a chow diet, although expression tended to 
increase and is consistent with leptin insensitivity in dietary obese mice. 
However, a recent study on the development of dietary obesity in C57BL/6J 
mice showed reduced central leptin sensitivity after 19 weeks on a high-fat diet 
(Lin et a l, 2000). Perhaps in this 14-week study, the mice are still sensitive to 
the effects of leptin and the effect is more pronounced on the expression of 
SOCS-3 mRNA than on OB-Rb or STAT3 mRNA. A further explanation may 
be that there are a number of signals involved in obesity that can activate SOCS- 
3 mRNA in the hypothalamus, such as NPY and POMC (Elias et a l, 1999).
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7.1.2 Peripheral tissues
The reduced CIS mRNA in the pancreas of AKR/J mice fed a palatable 
diet compared to those on chow, albeit not significant, may indicate the 
pancreas has increased leptin sensitivity. In WAT of AKR/J mice fed a 
palatable diet compared to chow, the expression of OB-Ra, OB-Rb, STATS and 
CIS mRNA was increased, but SOCS-3 mRNA was reduced. The increased 
expression of OB-Ra and OB-Rb mRNA was not significant; however, the 
general increase in components of leptin receptor-mediated signalling suggests 
this tissue is sensitive to leptin but the increased CIS mRNA may compensate. 
In BAT of AKR/J mice fed a palatable diet compared to chow, the expression of 
OB-Rb mRNA was reduced but STAT3 and STATS mRNA was increased. 
Whilst these changes were not significant, they show that although OB-Rb 
mRNA is reduced consistent with low leptin sensitivity, the expression of 
STAT3 and STATS mRNA is increased. Perhaps in compensation these 
changes suggest the interplay of other obesity-related factors as well as tissue- 
specific changes, which are most likely related to the biological function of 
leptin in these tissues. In contrast to WAT, all of the components of the leptin 
receptor-mediated signalling pathway examined, except CIS, were significantly 
reduced in the small intestine of AKR/J mice fed a palatable diet compared to 
chow. This suggests that the small intestine has low leptin sensitivity and may 
have reduced leptin signalling.
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7.2 oh/oh compared to lean mice
7.2.1 Hypothalamus and pituitaiy
In ob/ob compared to lean mice in this study, the expression of 
components of the leptin receptor-mediated signalling pathway may be expected 
to increase due to the lack of circulating leptin; however they were generally 
increased in some tissues and reduced in others. In the hypothalamus of ob/ob 
mice, only STATS and SOCS-3 mRNA was reduced. These changes contrast to 
those observed in the study of leptin-treated ob/ob mice where OB-Rb, STATS, 
STATS and NPY mRNA were increased in ob/ob mice compared to leans. An 
increase in expression of components of leptin receptor-mediated signalling is 
expected since the ob/ob mice are leptin-hypersensitive. It is possible that the 
reduced SOCS-3 mRNA in ob/ob compared to lean mice may compensate for 
the increased STATS mRNA, where the change in STATS mRNA may involve 
other obesity-related factors. There was no significant increase in the 
expression of hypothalamic NPY mRNA, which is expected due to the lack of 
circulating leptin, although there was tendency towards an increase. In the 
pituitary of ob/ob mice compared to leans, the expression of OB-Rb, STATS, 
ST AT 5 and SOCS-3 mRNA was reduced, which may be due to leptin 
deficiency. Furthermore, CIS mRNA was reduced in the pituitary of ob/ob 
mice, but not significantly, and may also be due to leptin deficiency.
181
7.2.2 Peripheral tissues
In the pancreas, the expression of STATS, STAT5 and SOCS-3 mRNA 
was increased, perhaps due to high leptin sensitivity and/or increased insulin 
signalling in the pancreas, which can activate these components. As expected, 
insulin and PDX-1 mRNA expression was increased in the pancreas of ob/ob 
mice compared to leans, which is consistent with the elevated pancreatic insulin 
levels. Furthermore, the reduced GLUT2 mRNA in the pancreas may be 
associated with the reduced glucose tolerance of ob/ob mice. In BAT of ob/ob 
mice compared to leans, the increased OB-Ra, OB-Rb and STAT3 mRNA 
expression and reduced CIS mRNA expression is consistent with elevated leptin 
sensitivity in this tissue. However, the increased expression of SOCS-3 mRNA 
may be due to other obesity-related factors. In the small intestine of ob/ob mice 
compared to leans, the expression of OB-Rb and CIS mRNA was reduced and 
STAT3 mRNA was increased. The changes of these genes in different tissues 
do not follow any particular pattern and may be due to the effect of other 
obesity-related factors. It is difficult to distinguish effects of no leptin, tissue- 
specific effects and other obesity-related factors.
7.3 AKR/J comapared to C57BL/6 lean mice
In comparing obesity-prone AKR/J lean mice to C57BL/6 lean mice, the 
expression of leptin receptor-mediated signalling components was generally 
increased in all tissues of AKR/J mice examined (except WAT where there was 
no comparison made). In the hypothalamus, only OB-Ra mRNA was increased
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significantly but the expression of CIS mRNA also showed a trend towards an 
increase. In the pituitary, the expression of OB-Ra, OB-Rb, ST AT5 and SOCS- 
3 mRNA was increased significantly while STAT3 mRNA expression tended to 
increase. In the pancreas, STAT3, ST AT 5 and SOCS-3 mRNA was increased 
while in BAT, the expression of OB-Ra, OB-Rb and CIS mRNA was increased. 
In the small intestine, there was a significant increase in OB-Rb and STAT3 
mRNA, however the increases in OB-Ra, STATS, and SOCS-3 mRNA were 
close to significance. Interestingly, in all of these tissues, the expression of OB- 
Ra mRNA was increased, whilst OB-Rb mRNA was increased in all of the 
tissues except the hypothalamus. Therefore, the increased expression in 
components of leptin receptor-mediated signalling is tissue-specific, which may 
be related to the function of the leptin in these tissues and contribute to their 
phenotype.
7.4 Leptin treatment of oh/ob mice
A recent paper by Emilsson et al. (1999) had looked at the gene 
expression of components of leptin receptor-mediated signalling in central and 
peripheral tissues after 48-hr intraperitoneal leptin treatment of lean and ob/ob 
mice and observed increased expression of SOCS-3 and CIS mRNA in leptin- 
treated lean mice in the hypothalamus, liver and small intestine. Furthermore, a 
study by Bjorbaek et a l showed increased SOCS-3 mRNA expression in the 
hypothalamus of ob/ob mice after peripheral leptin administration but no change 
in CIS mRNA (Bjorbaek et a l, 1998). In order to expand our understanding of
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the regulation of leptin sensitivity, the study presented in chapter 5 was 
designed to examine the expression of components of leptin receptor-mediated 
signalling after short and long-term leptin treatment in ob/ob mice and attempt 
to reduce the body weight of ob/ob mice considerably to see if any changes in 
the genes of interest were reversed.
In the study of ob/ob mice treated with leptin for 24 hours and 2 weeks, 
an increase of OB-Rb, STATS, STAT5 and NPY mRNA was observed in the 
hypothalamus of vehicle-treated ob/ob mice compared to leans. However, the 
hypothalamic expression of SOCS-3 mRNA was reduced in ob/ob mice 
compared to leans. The treatment of ob/ob mice with leptin for 24 hours 
showed a significant reduction of SOCS-3 mRNA, whilst the expression of both 
OB-Ra and NPY mRNA showed a non-significant trend towards a reduction. 
However, after ob/oh mice were treated with leptin for 2 weeks, the expression 
of SOCS-3 mRNA was increased and NPY mRNA was decreased, and STAT3 
and STAT5 mRNA expression was unchanged. Furthermore, food restriction of 
ob/ob mice for 2 weeks showed an increased expression of STATS and ST AT5 
mRNA, whilst SOCS-3 and NPY mRNA was increased. This implies that 
increased SOCS-3 mRNA after 2 weeks of leptin treatment is due to reduced 
food intake rather than leptin effects. Previously, it was shown that SOCS-3 
mRNA was increased between 1-3 hours after leptin treatment of ob/ob mice 
(Bjorbaek et a l, 1998), but a subsequent study in CHO cells showed a 
continued increase up to 20 hours after treatment (Bjorbaek et a l, 1999). It is
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not clear why expression of SOCS-3 mRNA was reduced after 24 hours of 
leptin treatment.
7.5 fa /fa  compared to +/? rats
An opportunity arose to examine the expression of leptin receptor 
isoforms OB-Ra and OB-Rb in the hypothalamus of ZDF fa/fa  rats, a rat model 
of diabetes that has a mutation in the leptin receptor. Results from this study are 
presented in Chapter 6. In the hypothalamus of ZDF +/? rats compared to ZDF 
fa/fa  rats, the expression of OB-Ra and OB-Rb mRNA was increased by almost 
2-fold. This may be due to reduced leptin receptor-mediated signalling and cell 
surface receptor expression, as observed in the fatty  rat, and as a result there is a 
compensatory increase in the expression of leptin receptor isoforms.
7.6 Future Work
In the dietary and genetically obese mice, there were a number of tissues 
yet to be examined, such as the liver, kidney, soleus muscle and adrenals. In 
addition to examining other tissues, there is much scope to determine changes in 
expression of other relevant genes. For example, in the hypothalamus there are 
a number of genes involved in energy balance that would be interesting to 
examine, such as melanin-concentrating hormone (MCH), orexins, CART, 
CRH, the melanocortin system i.e. POMC, ACTH, a-melanocyte stimulating 
hormone (a-MSH), melanocortin-4 (MC-4) receptor and AGRP. The analysis 
of these genes and more may provide further insight in the genes that are
185
involved in leptin sensitivity. In the pituitary, it would be interesting to analyse 
the genes expressed by gonadotropes, somatotropes and corticotropes that may 
be involved in leptin effects, such as adrenocorticotropin hormone (ACTH), 
follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid 
stimulating hormone (TSH) and GH. Furthermore, it would have been useful to 
analyse the expression of components of the leptin receptor-mediated signalling 
pathway in the islets of the pancreas, where most of the leptin receptor isoform 
expression is concentrated and there is cross-talk of leptin and insulin signalling 
pathways. In adipose tissue, leptin is believed to increase the expression of 
UCP mRNA and shift fuel consumption to fat oxidation. Therefore, it would be 
interesting to analyse the expression of UCP mRNA as well as genes that may 
be involved in fatty acid metabolism.
In the study described in Chapter 5 of ob/ob mice treated with leptin, the 
expression of components of leptin receptor-mediated signalling pathway in the 
hypothalamus could have been followed up by the analysis of the genes 
involved in energy balance described above. Furthermore, the pancreas and 
adipose tissue were also extracted from the mice but the tissues remain to be 
analysed. The expression of OB-Ra and OB-Rb mRNA was analysed in the 
hypothalamus of ZDF +/? and fa/fa  rats, however there were no other genes 
analysed. It would be interesting to see the effects on expression of components 
of the leptin receptor mediated signalling pathway in ZDF fa/fa  rats given that 
the fatty  rat performs reduced signal transduction and compare results to those 
in other animal models.
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Most of the studies to date that examined leptin sensitivity in obesity 
have investigated the effects of leptin on feeding, however few studies have 
examined leptin sensitivity at a functional or physiological level with respect to 
factors other than feeding. The changes in leptin sensitivity may not be 
restricted to the hypothalamus alone, but perhaps some of the peripheral tissues 
also exhibit changes in leptin sensitivity. Therefore, leptin access to the brain 
may not be the only factor involved in leptin sensitivity, but the reduced effects 
of leptin in peripheral tissues may affect metabolic functions as observed in 
obesity. For example, a reduced effect of leptin in adipose tissue may have an 
effect on UCP genes and reduce energy expenditure, and in pancreatic islets, a 
reduced effect of leptin may result in increased insulin secretion and an increase 
in fatty acids due to reduced fatty acid oxidation. The importance of the 
changes in gene expression involved in leptin receptor-mediated signalling in 
some tissues may be better understood knowing the effects of leptin 
insensitivity on other metabolic effects in obesity.
Whilst I have only looked at the mRNA expression of leptin receptor- 
mediated signalling components in the tissues of these obese models, it would 
be interesting and very informative to investigate the changes in protein 
expression. It goes without saying that changes of mRNA do not necessarily 
reflect changes in protein expression nor activity of the gene expression.
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7.7 Concluding Remarks
I have presented data suggesting the changes in expression of 
components of the leptin receptor-mediated signalling pathway may contribute 
to how cells respond to leptin in a tissue- and strain-specific manner. 
Furthermore, analysis of tissues taken from dietary obese and genetically obese 
mice suggests some tissues may be more sensitive to the effects of leptin 
compared to others. Some strains of mice are more prone to diet-induced 
obesity compared to others, which may be reflected by the increased expression 
of components of the leptin receptor-mediated signalling pathway in certain 
tissues. The specific pattern of gene expression changes were different 
dependent on the strain and conditions of the experiment. In many cases, 
changes due to leptin sensitivity could not be definitively distinguished from 
those due to other obesity-related factors.
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Appendix 1
The level of mRNA expressed for a particular transcript has a common 
element or component of variation which may be due to sample specific 
differences such as sample or tissue quality. Housekeeping or endogenous 
control genes are measured in parallel to test genes to quantify such a 
component. They are used in a number of ways, with the intention of removing 
such differences, leaving a better estimate of the treatment effect. A log-log 
plot of the gene of interest against housekeeping gene would expect to result in 
a strong correlation between the two genes. However, if the housekeeping gene 
is also affected by treatment, subsequent use of the housekeeper could remove 
"real" treatment effects in the test gene or even introduce "false" effects.
The calculation of ratios (test/housekeeper cDNA quantity) is the most 
common way of adjusting for sample specific differences. An improvement on 
the ratio analysis is the Analysis of Covariance (ANOCOVA), as this takes into 
account different types of relationships between test and reference genes. 
ANOCOVA still runs the risk of introducing false positive and negative results 
due to the use of a housekeeping gene that is affected by treatment. However, 
covariate efficiency factors (c.e.f.) can help to assess housekeeping genes not 
only by quantifying the degree to which a housekeeping gene is affected by 
treatment (c.e.f. (Tit)), but also whether they have been successful in adjusting 
for variation caused by sample specific differences such as sample or tissue 
quality (c.e.f. (Res)). The c.e.f. (Tit) value ranges between zero and one, where
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a value of one indicates the housekeeping gene is independent of treatment and 
zero indicates the housekeeping gene is affected by the treatment. The c.e.f. 
(Res) ranges from zero to infinity, where values greater than one improve the 
precision of the analysis and the larger the value the greater the improvement. 
The gain in reducing variation by using a housekeeping gene can be offset by 
the inefficiency of a housekeeper with respect to the treatment. An overall 
assessment of the usefulness of housekeeping genes can be performed by 
comparing the product of the two efficiency factors (c.e.f. (Product)) across 
analyses using different housekeeping genes.
The ANOCOVA analysis was performed for each test gene without 
using a housekeeping gene as a co-variate as well as using each of the 
housekeeping genes (GAPDH, cyclophilin, 36B4 and HPRT) as co-variâtes. 
The most suitable housekeeping gene was selected not only by comparing the 
values of c.e.f. (Product), but also by taking into consideration the c.e.f. (Trt) 
and c.e.f. (Res) values. In the study investigating dietary and genetically obese 
mice, the analysis showed that HPRT was the most suitable housekeeping gene 
in the hypothalamus and small intestine, whereas cyclophilin was the most 
suitable housekeeping gene in the pituitary, pancreas and WAT. There was no 
suitable housekeeping gene in BAT that improved the analysis, therefore the 
changes were reported without using a housekeeping gene as a co-variate. In 
the study of leptin treatment of ob/ob mice, the housekeeping gene used for the 
hypothalamus was 36B4 since it was the most consistent of the housekeeping 
genes, although cyclophilin and HPRT could also have been used. In the
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hypothalamus of +/? and fa/fa  ZDF rats, the two housekeeping genes analysed 
to use as a co-variate were p-actin and GAPDH. However, neither of these 
housekeeping genes were used as a co-variate since they did not improve the 
analysis.
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